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Approximately 50% of all malignant pleural mesotheliomas (MPM) are deficient in 
argininosuccinate synthetase (ASS1), the rate-limiting enzyme in arginine 
biosynthesis, and are sensitive to arginine deprivation. This discovery in MPM has 
been translated into the clinic using the arginine depletor pegylated arginine 
deiminase (ADI-PEG20), which showed a halving in the risk of disease progression 
in a randomised phase II study. However, unstudied to date, stromal resistance to 
ADI-PEG20 may reduce its efficacy. Here, I studied the effect of macrophages, 
abundant in mesothelioma, on the tumour cytotoxicity of ADI-PEG20.  
A distinct pro-inflammatory cytokine gene expression signature involved in 
macrophage recruitment and activation was identified and validated in ADI-PEG20-
treated ASS1 negative MPM cell lines. In vivo induction of pro-inflammatory 
cytokines was also seen in ADI-PEG20-treated patient plasma. Notably, in vitro co-
culture experiments demonstrated a significant increase in ASS1 negative MPM cell 
viability upon co-culture with macrophages in the presence of ADI-PEG20. This was 
accompanied by a significant increase in ASS1 expression in co-cultured 
macrophages, with a corresponding increase in argininosuccinate lyase (ASL) 
expression in co-cultured tumour cells and a doubling in levels of the arginine 
precursor, argininosuccinate, in cell supernatant.  The addition of argininosuccinate 
to tumour cell media rescued ASS1 negative MPM cells from ADI-PEG20 
cytotoxicity, while the macrophage-mediated resistance to ADI-PEG20 was 
abrogated following ASL knockdown in MPM cells. Finally, xenograft studies 
demonstrated a significant reduction in tumour volume in mice treated with ADI-
PEG20 in combination with macrophage depletion, compared with ADI-PEG20 
alone.  
Collectively, the data indicate that as a result of metabolic ‘cross-talk’ between 
macrophages and ASS1 negative MPM cells, macrophages mediate MPM 
resistance to ADI-PEG20 via the provision of argininosuccinate. My studies provide a 
rationale for combining ADI-PEG20 with an inhibitor of macrophage recruitment in 
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Chapter 1. Introduction 
 
1.1 Malignant Pleural Mesothelioma 
 
 
Malignant pleural mesothelioma (MPM) is an aggressive inflammatory malignancy 
arising from the mesothelial surface of the pleural cavity. It is characterised by 
insidious growth, high primary chemoresistance, and a uniformly poor prognosis, 
with median overall survival ranging between 9 and 12 months and a 5-year survival 
of less than 5% (1, 2).  
 





Exposure to the asbestos group of silicate minerals is the principle risk factor for the 
development of MPM. The group of minerals categorized as ‘asbestos’ are divided 
into two basic structural types: amphibole and serpentine. Chrysotile is the only 
serpentine asbestos, and exists as a long, curly, and pliable fiber most suitable for 
making fabrics. Amphibole fibers are short, straight, and stiff, and have been used to 
make pipes and tiles. The major commercial amphiboles are amosite, crocidolite, 
and anthophyllite. Mixtures of chrysotile and amphiboles were used to produce an 
array of roofing, insulation, and fire-proofing materials. The larger amphibole 
minerals are reported as having the greatest carcinogenicity (3).  
 
The first convincing evidence of a link between asbestos and MPM was reported in 
1960 in South Africa. Wagner and his colleagues described asbestos exposure in 33 
cases of MPM in South African mine workers (4). Later, several studies from the 
USA, Europe, Australia and Japan verified asbestos inhalation as the aetiological 
risk factor of MPM (5-8). Despite this, due to its extraordinary fire resistant 
properties, there was widespread use of asbestos around the world, predominantly 
in the shipbuilding and construction industries, until the end of the 1970’s. Industrial 
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use of asbestos was then largely eliminated in developed countries, but it is still 
present today in countless buildings, where it is used as insulation and a fire 
retardant (3).  
 
The mechanism of asbestos-induced MPM is not fully understood but it is generally 
believed that asbestos inhalation leads to the deposition of fibers deep in the lung 
parenchyma, with eventual migration and implantation of these fibers into the lining 
of the pleura. As the fibers are too large to be cleared by pulmonary macrophages, a 
chronic state of inflammation ensues during which the secretion of free radicals 
causes genotoxic damage, facilitating the transformation of normal mesothelial cells 
to malignant cells, a process frequently referred to as ‘frustrated phagocytosis’ (9). It 
was recently discovered that asbestos induces necrotic cell death, causing an 
increase in extracellular high-mobility group protein B1 (HMGB-1). HMGB-1 release 
triggers a chronic inflammatory response, macrophage accumulation and the 
secretion of tumour necrosis factor alpha (TNFα), which in turn activates NF-kB, 
leading to the survival of mesothelial cells that have accumulated asbestos induced 
genetic damage (10). Production of reactive oxygen species (ROS) from the high 
iron content within asbestos fibers and direct damage to DNA by these fibers are 
also accepted pathogenic features of asbestos exposure (11). In addition, MPM has 
a dysfunctional epigenetic background, with a number of epigenetic events having 
been observed which may contribute to MPM carcinogenesis. Importantly, asbestos 
has been shown to influence the epigenetic regulation of a number of critical genes, 
with methylation of p16, CDKN2B and RASSF1 significantly associated with 
asbestos exposure (12). The methylation of MT1A has also been correlated with 
asbestos burden (13), and, furthermore, increased asbestos burden has been 
associated with increased hypermethylation of cell cycle genes such as APC and 
CCND2 (14). A number of methylation profiles have been linked to reduced overall 
survival in MPM (15).  
 
However, it is unknown why the transformation of asbestos-injured cells into MPM 
occurs in only 2% to 10% of individuals exposed to asbestos. Conversely, up to 80% 
of MPM patients have a documented history of asbestos exposure. In addition, there 
does not appear to be a linear dose-response relationship between asbestos 
exposure and MPM, meaning that the amount of exposure does not correlate with 
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increased risk of disease. Instead, some individuals are thought to be more 
susceptible to asbestos (16). This suggests a complex relationship between 
environment, biology and genetics in the pathogenesis of MPM.  
 
1.1.1.2 Endemic Eronite exposure 
 
  
The possibility of a specific gene-environment interaction was raised following the 
observation of high MPM rates in the Cappadocian villages of Turkey (17). This 
region is rich in the highly carcinogenic mineral erionite, which causes MPM in 
animal models and has been detected in the lungs of local people. Pedigree analysis 
in affected families indicates a genetic susceptibility that is inherited in an autosomal 
dominant pattern (18).   
 
1.1.1.3 Ionising radiation 
 
Long-term effects of ionising radiation have also been aetiologically linked to MPM, 
although in a much smaller group of individuals than the asbestos exposed. Indeed, 
the risk of developing MPM was found to be significantly higher in cases previously 
exposed to α-particle-emitting agents, such as the radioactive contrast Thorotrast 
(used in the 1950’s) (19). Moreover, it is well-documented that mesothelioma is more 
common in testicular cancer and Hodgkin's lymphoma survivors who have been 
treated with external radiotherapy (20, 21). However, today, due to better 
understanding of the risks of developing secondary cancers, together with improved 
alternative therapies for these cancers, these treatments are used much less 
frequently. 
 
1.1.1.4 Simian Virus 40 
 
 
Simian Virus 40 (SV40), a rhesus monkey DNA virus likely introduced to humans 
from contaminated Salk polio vaccines produced between 1955 and 1978 (22), has, 
too, been implicated as a cofactor in the causation of MPM (16). SV40 acts as a 
potent oncogenic virus for human and rodent cells by blocking tumour suppressor 
genes (23, 24). It has been reported that up to 60% of human mesotheliomas 
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contain SV40 DNA (25). However, despite a number of studies illustrating the 
malignant transformation potential of this virus in vitro and in animal studies of MPM 
(16, 26-28), the interpretation of the repeated finding of SV40 in human MPM is still 
controversial. 
 
1.1.1.5  Molecular pathogenesis of MPM 
 
1.1.1.5.1 Chromosomal alterations  
 
Studies have shown that mesotheliomas have complex and variable chromosomal 
alterations (29), and only few features are shared between patients. Loss-of-
heterozygosity analyses have demonstrated frequent deletions of specific sites 
within chromosome arms 1p, 3p, 6q, 9p, 13q, 15q and 22q. Three of these regions 
are most commonly altered, the tumour suppressors CDKN2A–ARF at 9p21, NF2 at 
22q12 (30) and BAP1 at 3p21 (31). 
 
1.1.1.5.1.1 Cyclin-dependent kinase inhibitor 2A/alternative reading frame 
(CDKN2A/ARF) inactivation 
 
Homozygous deletion of the 9p21 region is frequently present in mesothelioma cell 
lines and tumour specimens. Loss of 9p21 results in loss of the INK4a/ARF locus, 
which encodes two distinct proteins, p16INK4a and p14ARF, translated from 
alternatively spliced mRNA. p16INK4a inhibits the cyclin-dependent kinase (CDK)-
mediated inactivation of pRb. p14ARF stabilizes p53 through its actions on Mdm2. 
As the INK4a/ARF locus plays an important role in the activity of both the p53 and 
pRb tumour suppressor pathways, a single mutational event may lead to the 
functional loss of both of these two key regulatory pathways (32). 
 
1.1.1.5.1.2.   Neurofibromatosis type 2 (NF2) inactivation 
 
The neurofibromatosis type 2 (NF2) gene encodes a tumour suppressor protein, 
merlin (moesin-ezrin-radixin-like protein). NF2 cancer syndrome is characterized by 
the development of tumours of the nervous system such as bilateral vestibular 
schwannomas at the eighth cranial nerve, spinal schwannomas and meningiomas 
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(33). It has been reported that 40–50% of MPM cases harbour an inactivating NF2 
mutation, typically a separate subset to those with BAP1 loss (34, 35). As NF2 
mutation is frequently detected in MPM, genetically engineered Nf2-knockout mouse 
models have been developed to confirm the significance of NF2 inactivation on MPM 
pathogenesis. Asbestos-exposed Nf2 (+/−) knockout mice exhibited markedly 
accelerated MPM tumour formation compared with asbestos-treated wild-type mice 
(36).  
Merlin regulates multiple signal transduction cascades of the cells, including the 
mTOR pathway and Hippo signaling pathway. Indeed, merlin has been shown to be 
a negative regulator of mTORC1, with integrin-mediated adhesion to fibronectin 
being shown to promote mTORC1 signaling through the inactivation of merlin (37). In 
addition, the Merlin-Hippo signaling pathway, key to the regulation of cell division 
and promoting apoptosis, has been shown to be frequently inactivated in 
mesothelioma cells (38). 
 
1.1.1.5.1.3 BRCA1- associated protein-1 (BAP1) inactivation 
 
The nuclear protein, BAP1, has several proposed functions, including transcriptional 
regulation, chromatin regulation, and forming part of protein complexes that regulate 
cellular differentiation, gluconeogenesis, cell cycle checkpoints, transcription and 
apoptosis (39). The BAP1 gene is located on chromosome 3p21, a region that 
shows loss or deletion in many cancers, including 30–60% of mesotheliomas. In 
families who have the BAP1 mutation, there is a significantly increased incidence of 
a number of cancer-types, often developed at an earlier age than observed in the 
general population (39). A BAP1 cancer syndrome has therefore been proposed, 
including mesothelioma, uveal melanoma and cutaneous melanoma (40). Indeed, 
germ-line BAP1 mutations have been reported in families with unusually high 
incidence of mesothelioma (40) and in 25% of sporadic mesotheliomas (41), 
highlighting the importance of genetic factors in MPM susceptibility. However, its 
association with asbestos-induced carcinogenesis has not been established. BAP1 





1.1.1.5.2 Activation of oncogene cascades 
1.1.1.5.2.1 Receptor tyrosine kinases  
 
Receptor tyrosine kinases (RTKs) are commonly activated in malignant cells. 
Activation of RTKs via interaction with peptide growth factors leads to constitutive 
up-regulation of two major downstream cell signaling cascades, mitogen-activated 
protein (MAP) kinase and phosphoinositide-3 kinase (PI3K)-AKT pathways, which 
are critical for proliferation and/or survival of cells. Activation of several growth 
factors and their receptors has been shown to play an important role in the 
oncogenesis and progression of MPM, including Epidermal Growth Factor (EGF), 
Hepatocyte Growth Factor (HGF), Vascular Endothelial Growth Factor (VEGF), and 






Mesothelioma accounts for less than 1% of all cancers in the UK. However, although 
uncommon, it poses an increasing public health and economic problem. This is 
because incidence is still rising as a result of the widespread use of asbestos in the 
last century and the long latency period from the time of first exposure to 
development of MPM, which ranges from approximately 15 to 60 years (45). Indeed, 
incidence in men has increased 5-fold since 1980. Moreover, recent estimates 
expect more than a quarter of a million deaths caused by MPM in Western Europe 
over the next four decades (3, 46).  
 
It is interesting to note here that Canada, which has one of the highest rates of MPM 
in the world, was a major producer and exporter of chrysotile asbestos. Remarkably, 
despite the universal ban on asbestos as proposed by the World Health Organisation 
and most developed countries, asbestos production in Canada did not cease until 
2012 (47).   
 
In addition, asbestos continues to pose a public health risk throughout the world due 
to its current and increasing use in industrializing nations. Thus, the worldwide 
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epidemic is in its beginning, and in countries that still produce and/or use asbestos, 
such as China, India, Russia, Zambia, Colombia and Kazakhstan, a steep rise in 
incidence is likely (48-50). 
 
 
1.1.3 Clinical Presentation 
 
 
The initial clinical presentation for most patients with MPM is progressive dyspnea 
and/or chest wall pain. There also may be a dry cough, weight loss, fever, fatigue, or 
night sweats. The disease is more frequently found unilaterally (95%), and located 
on the right side (60%). The majority of patients will have a documented history of 
asbestos exposure, with common prior occupational exposures including pipefitters, 
plumbers, carpenters, steamfitters, heavy construction or shipbuilding industry 
workers, and those working aboard ships (1). Due to occupational exposure, it is 
more common in men than in women (5:1) (51) and it is also more frequent in 
advanced age as a result of the long latency period, usually presenting in the 6th 





An accurate diagnosis of MPM is important for optimal clinical management, 
including accessing industrial compensation. 
MPM is divided into three major histological sub-types: sarcomatoid, biphasic and 
epithelioid. Epithelioid is the most common subtype and it is also associated with the 
best prognosis (52). To help distinguish between these subtypes, secondary 
carcinoma and other malignant tumours metastatic to serosal membranes, several 
immunohistochemical panels are available (53), of which calretinin is the most 
commonly used antibody, positive for mesothelioma with a reported sensitivity of 
95% and specificity of 87% (54). Other useful antibodies include thrombomodulin 
and cytokeratin 5/6 (55). For a detailed summary of antibodies used, please see 
Table 1.1.  
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Epithelioid mesothelioma Sarcomatoid mesothelioma Markers differentiating 
mesothelioma vs 
reactive mesothelium1 
 Mesothelial markers Carcinoma markers 
Calretinin CEA Cytokeratin 7 Desmin 
 
Cytokeratin 5/6 TTF-1 Cytokeratin 8/18 EMA 
 
HBME-1 CD15 (Leu-M1) Cytokeratin CAM5.2 p53 
 
Podoplanin (D2-40) BG8  Cytokeratin AE1/AE3 GLUT-1 
WT-1 B72.3 MNF116 IMP3 
 
Thrombomodulin MOC31 Cytokeratin 34BetaE12 
 
 
 Ber-EP4 Vimentin  
 E-cadherin   
 
Table 1.1. Markers frequently used in the diagnosis of mesothelioma. The antibody used 
depends on histological subtype, the differential diagnosis and the gender of the patient.  A panel of 
four markers (two ‘positive’ and two ‘negative’ mesothelial markers), selected based upon availability 
and which ones yield good staining results in a given laboratory is recommended. Because of their 
specificity and sensitivity for mesotheliomas, the best combination appears to be calretinin and 
cytokeratin 5/6 (or WT1) for the positive markers and CEA and MOC-31 (or B72.3, Ber-EP4, or BG-8) 
for the negative markers. 1 FISH for deletion of p16/CDKN2A. Adapted from Ascoli 2015 (56). 
 
 
However, to date no mesothelial marker has shown 100% sensitivity and specificity 
for MPM. This, in addition to the fact that MPM is uncommon, makes diagnosis 
difficult. Nevertheless, the identification of the three key genetic alterations 
CDKN2A/ARF, NF2 and BAP1, described in section 1.1.1.5.1, may help lead to the 









As with all malignancies, accurate staging in MPM is key to rational treatment 
planning. Many staging systems have been proposed but the most widely accepted 
is the TNM-type system of the International Mesothelioma Interest Group (IMIG) 
(55). A summary of the classification is described below: 
 
Stage I includes lymph node-negative patients with minimal tumour confined to the 
parietal pleura (stage Ia) or with minimal visceral pleural involvement (stage Ib). 
 
Stage II includes lymph node-negative patients with confluent superficial tumour on 
all pleural surfaces or involvement of the diaphragmatic muscle or lung parenchyma.  
 
Stage III includes patients with metastasis to hilar (N1) or ipsilateral mediastinal (N2) 
lymph nodes, or those with extension of tumour into the soft tissues of the chest wall, 
the endothoracic fascia, mediastinal fat or pericardium (T3 tumour). 
 
Stage IV includes patients who have locally advanced tumour invading the spine or 
ribs, the chest wall extensively, diaphragmatic spread, or contralateral pleural 
spread. Patients with stage IV disease also may have contralateral or supraclavicular 
lymph node involvement (N3) or distant metastases.  
 
Stage III is the most common presenting stage, which means that, in many cases, 
therapeutic options are limited.  
 
 





Surgical management of MPM falls into three categories. First, diagnostic surgery is 
often required, such as video-assisted thoracoscopy (VATS). Second, palliative 
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surgery can be performed to relieve symptoms, including partial pleurectomy with 
pleurodesis, or thoracoscopy with pleurodesis. Third, potentially curative surgery, 
carried out in specialist centres that employ multimodality approaches, including 
surgical resection, chemotherapy, and radiation, is an option in a few patients. In 
general, most stage I, and some stage II and III patients are considered potentially 
resectable. However, there are exceptions: whether a tumour is resectable is also 
based on subtype (many surgeons do not believe that sarcomatoid mesothelioma is 
helped by resection), the extent of spread into nearby tissues, and, importantly, the 
general fitness of the patient. Two forms of radical surgery have been performed 
since the late 1970s: extrapleural pneumonectomy (EPP), which involves removing 
the pleura, as well as the lung and diaphragm, on one side, and, more recently, a 
lung sparing resection of the pleura, now commonly referred to as pleurectomy 
decortication (P/D) (57). The role of surgery in the treatment of MPM has been the 
subject of much heated debate in the last few years, following the controversial 
Mesothelioma and Radical Surgery (MARS) study. In this randomised feasibility 
study, all 50 patients received chemotherapy and/or radiotherapy, and one group 
underwent EPP. The Hazard Ratio (HR) for overall survival (OS) between EPP and 
no EPP groups after adjustment for sex, histological subtype, stage and age, was 
2.75 (p=0.016). Median survival was 14.4 months in the EPP group and 19.5 months 
in the no EPP group. The authors concluded that radical surgery in the form of EPP 
within trimodal therapy offers no benefit and possibly harms patients (58). 
Conclusions from the study have been contested and these criticisms rebutted since 
its publication in 2011. The debate is ongoing. In the meantime, MARS 2, another 
randomised feasibility study, has been recruiting to evaluate P/D following 
chemotherapy compared with chemotherapy alone.  Results are awaited. The two 
surgical procedures have been directly compared in a retrospective analysis of 3000 
patients. This showed that for stage II and III MPM, survival data is the same for both 
EPP and P/D, with P/D causing less impairment of quality of life. However, this 
analysis also showed that there may be an advantage in using EPP in Stage I 
patients, as in this small subgroup, median survival was 4 years following EPP and 
2.5 years following P/D (59).  
 
Selection bias, the difficulty of the surgery and the perioperative mortality rate 
together make the role of radical surgery controversial. The International 
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Mesothelioma Interest Group (IMIG) advise that surgical cytoreduction is indicated 
only when macroscopic complete resection is deemed achievable and that the type 
of surgery (EPP or P/D) depends on clinical factors and on individual surgical 
judgment and expertise.  
 
As radical treatment is reserved only for a carefully selected subgroup of patients, 






Radiotherapy (RT) has been studied in MPM for many years and overall results have 
been largely disappointing. The biggest limitation to radical radiotherapy is the 
diffuse nature of the tumour covering most of the pleural surfaces as well as the 
interlobular fissures. Indeed, treating the entire pleura requires a large radiation field, 
which significantly increases toxicity risks. Traditionally, adjuvant RT following EPP 
or P/D as part of multi-modality regimens has been given through anterior and 
posterior fields that encompass the entire involved hemithorax. More recently, 
complex intensity-modulated radiation therapy (IMRT) techniques have been 
explored, with early outcomes suggesting acceptable safety in appropriately selected 
patients. Newer methods such as Arc therapy or helical tomotherapy are rotational 
RT techniques that deliver radiation from even more beam angles than IMRT. They 
are ideally suited for spherical or circular targets and are therefore of particular 
interest in MPM (60). However, these have not yet been validated clinically and 
therefore future studies will need to test whether the theoretical advantages of newer 




Despite decades of clinical research, cytotoxic chemotherapy remains one of the few 




1.1.5.3.1 First line Chemotherapy 
 
First line chemotherapy for MPM in routine practice has remained unchanged since 
2003, when the pivotal phase III trial conducted by Vogelzang and colleagues (61) 
showed that the combination of cisplatin and pemetrexed gave a three month 
survival benefit over cisplatin alone, improving median survival from 9.3 to 12.1 
months (p=0.02) in patients with advanced disease (See Figure 1.1). This modest 
survival increase was also associated with improvements in quality of life. A similar 
benefit was seen with the addition of raltitrexed to cisplatin, with survival increasing 
from 8.8 to 11.4 months (p=0.048), although objective radiological response rates 
were lower to this combination than to cisplatin and pemetrexed (62).  
 
 
Figure 1.1 Axial computed tomography (CT) scan. Scan shows pre-treatment disease (A) and a 
partial response to chemotherapy with cisplatin and pemetrexed (B) after four cycles of treatment 
(adapted from Nowak (63)). 
 
1.1.5.3.2 Second Line chemotherapy 
 
 
After first line chemotherapy, patients almost invariably experience disease 
recurrence or progression. Currently, there is no standard second line treatment and 
options are limited. However, a recent retrospective review of second-line 
chemotherapy found that disease control with second-line treatment was better in 
those patients who received pemetrexed, and those with a prolonged time to 
progression (≥12 months) after first-line therapy (64). Furthermore, patients re-
treated with a platinum-pemetrexed combination had a lower risk of death than those 
treated with pemetrexed alone (HR =0.11, p<0.001). This therefore indicates that re-
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treatment with pemetrexed plus a platinum is a rational option for second-line 
therapy in good performance status patients with previous disease control after 
pemetrexed-based treatment.  
A variety of cytotoxic agents have some activity in second-line treatment, but none 
have had the appropriate randomised controlled design to determine which particular 
agent is the best choice. The lack of randomised designs also means that we do not 
know if survival benefits ensue from agents with modest objective radiological 
responses in the second-line setting. Single agent vinorelbine has a response rate 
(RR) of 16% and overall survival of 9.6 months as a second-line therapy (65). 
Combinations of gemcitabine and vinorelbine (RR 10%, OS 10.9 months, PFS 2.8 
months) (66), gemcitabine and epirubicin (RR 13%, OS 9.3 months, PFS 6.3 months 
in a high dose group) (67), irinotecan, cisplatin, and mitomycin (RR 20%, OS 7.3 
months, PFS 7.3 months) (68) and others have also been reported. The tolerability 
and response rate of single agent vinorelbine has meant that this is often the 
treatment of choice in clinical practice.  
 
1.1.5.4 Targeted therapies 
 
 
1.1.5.4.1 Molecular targeted therapy 
 
In contrast to lung cancer, oncogenic driver mutations are absent in MPM. The 
development of targeted therapy therefore relies on the evaluation of pathways 
indirectly activated by the loss of tumour suppressor genes or targets associated 
with the disease phenotype. In line with this, various dysregulated molecular 
pathways have been identified in MPM in the past decade, including cell cycle 
regulation, apoptosis, growth factor pathways and angiogenesis. Subsequently, a 
number of novel agents targeting these pathways, which have shown promising 
activity in other cancers, have been trialled empirically in mesothelioma. Below is a 




1.1.5.4.1.1 Epidermal Growth Factor Receptor  
 
 
Epidermal Growth Factor Receptor (EGFR) is expressed by a variety of epithelial 
malignancies, and activation of the pathway interferes with apoptosis, uncontrolled 
cell proliferation and angiogenesis. EGFR overexpression in mesothelioma has been 
reported by several authors (69, 70). However, results from clinical trials have been 
disappointing: single agent treatment with EGFR tyrosine kinase inhibitors (TKIs) 
gefitinib and erlotinib showed no evidence of activity even as first-line treatment (71, 
72).  
 
1.1.5.4.1.2 Vascular Endothelial Growth Factor  
 
 
Vascular endothelial growth factor (VEGF) is a key stimulator of both angiogenesis 
and neovascularisation of tumours. Agents inhibiting the VEGF receptor, in many 
cases in combination with other targets, have shown some evidence of activity in 
MPM in an unselected population, with response rates around 10% and PFS 
between 3 and 4 months (73-75). However, identifying which patients may benefit 
from these agents has been problematic, with no predictive factors yet identified.  
 
The anti-VEGF monoclonal antibody bevacizumab has also been tested in a number 
of completed and ongoing trials. A randomised phase II trial of untreated 
mesothelioma patients compared cisplatin-gemcitabine alone or with bevacizumab. 
The addition of bevacizumab did not improve response, progression-free survival, or 
overall survival compared with chemotherapy alone. A potential benefit in patients 
with low circulating levels of VEGF was, however, suggested in subgroup analysis 
(76). More recently, a two-armed phase II/III trial compared the standard of care 
cisplatin and pemetrexed combination with or without bevacizumab as first-line 
treatment and maintenance in inoperable mesothelioma patients. Notably, results of 
this study revealed that pemetrexed and cisplatin combination with bevacizumab 
gave a significantly longer OS (median OS 18.8 months vs. 16.1 months without 




1.1.5.4.1.3 Cyclin-dependent kinase inhibitor 2A (CDKN2A) 
 
MPM lacks expression of both CDKN2A encoded proteins p16 and ARF due to gene 
deletion or methylation (reviewed in section 1.1.1.5.1.1). Deletion in CDKN2A leads 
to loss of control of cyclin D-dependent kinases (CDK). Although only a very small 
number of MPM cases present with p53 mutations (42), deletion of CDKN2A leads to 
the hypothesis that these tumours may be dependent on G2 checkpoint and 
therefore vulnerable to a G2 checkpoint inhibition when combined with 
chemotherapy. In line with this hypothesis, the calmodulin-binding peptide (CBP501) 
was clinically tested in combination with cisplatin and pemetrexed in order to 
increase the sensitivity of mesothelioma cells to chemotherapy. In patients receiving 
CBP501 with chemotherapy, PFS of more than 4 months was achieved compared 
with 39% receiving chemotherapy alone (78).  
 
1.1.5.4.1.4 Neurofibromatosis type 2 (NF2) 
 
Loss of the tumour suppressor gene NF2 occurs in around 40% of patients 
(reviewed in section 1.1.1.5.1.2) (79). The resultant merlin loss affects a number of 
key pathways, including the activation of mTORC1 and focal adhesion kinase (FAK) 
pathways. Drugs that target these pathways are therefore being considered as 
potential therapeutic options.  
A phase I trial evaluated the effect of the PI3K/mTOR inhibitor GDC0980 (dual 
PI3K/mTOR inhibitors are used due to the compensatory up-regulation of PI3K seen 
with mTOR inhibition alone). The preliminary result of the phase I extension cohort 
showed two objective responses among 26 patients with mesothelioma (80). A 
phase II trial studying the mTOR inhibitor, everolimus, showed no significant activity 
in unselected MPM patients, concluding that additional studies of everolimus in 
advanced MPM are not warranted (81). 
 The role of FAK inhibitors has also been recently studied (63). The COMMAND 
study, a phase II trial investigating the FAK inhibitor defactinib (VS-6063) in 
mesothelioma (NCT01870609), had been scheduled to complete in 2016; however, 
despite promising early results, the trial closed early due to poor efficacy data. 
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1.1.5.4.2 Therapy targeting cell surface receptors 
 
1.1.5.4.2.1 Anti-mesothelin antibodies 
 
Mesothelin is a cell-surface glycoprotein that is present on normal mesothelial cells 
but overexpressed on the surface of mesothelioma. It is known that mesothelin binds 
to CA-125 and reports suggest that overexpression, which occurs prominently on 
epithelioid tumours but not on sarcomatoid tumours, may affect cell adhesion and/or 
invasion (82). Accordingly, a number of anti-mesothelin targeted therapies have 
been developed.  
The chimeric IgG1 antibody Amataximab has recently been evaluated. Studies 
demonstrate that it blocks the binding of mesothelin to CA-125 (83) and that it is well 
tolerated in patients with MPM (84) Furthermore, a single arm phase II clinical trial in 
combination with pemetrexed and cisplatin reported median OS of 6.1 months and a 
median OS of 14.8 months, with a third of patients alive at the time of analysis (85)  
SS1(dsFV)PE38 (SS1P) is an immunotoxin consisting of an anti-mesothelin antibody 
variable fragment linked to a cytotoxic fragment of Pseudomonas exotoxin A. It has 
been shown to be safe in a phase I trial, but only minor antitumor activity could be 
observed. Additionally, the development of neutralising antibodies was observed in 
24% of patients and this prevented its use for more than one cycle (86). However, in 
a subsequent pilot study using immunosuppressive pretreatment with pentostatin 
and cyclophosphamide to prevent neutralising antibodies and allow delivery of more 
courses of treatment, 3 of 10 assessable patients demonstrated dramatic responses 
with subsequent chemotherapy (87). Another phase 1 trial of SS1P combined with 
chemotherapy (cisplatin and pemetrexed) is closed to recruitment and awaiting data 
analysis. (Clinicaltrials.gov NCT01445392). 
 
1.1.5.4.2 Immune checkpoint inhibitors 
 
 
Tumours have evolved multiple mechanisms to evade immune destruction. One of 
these recognised escape mechanisms is expression of T cell inhibitory ligands such 
as cytotoxic T-lymphocyte antigen 4 (CTLA-4), the programmed death 1 ligand (PD-
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L1) and the programmed death 1 receptor (PD-1). Immune checkpoint inhibitors 
block these T cell inhibitory mechanisms and allow T cells to resume their cytotoxic 
activity on cancer cells.  
 
1.1.5.4.3.1 Cytotoxic T lymphocyte antigen-4 
 
CTLA-4 is crucial for preserving host immune tolerance to established tumours. The 
CTLA-4 receptor sequesters CD80 and CD86 immune co-stimulatory signals 
provided by antigen-presenting cells, and this increases the activation threshold for T 
lymphocytes. The anti-CTLA-4 monoclonal antibody tremelimumab was investigated 
in pretreated patients in a phase II single-arm study: the primary endpoint of 
objective response rate was not met (88). However, responses to immune therapy 
can take appreciably longer to become apparent compared with other therapies. 
Furthermore, disease control was noted in 31% of the patients, and overall survival 
rates were 48% at 1 year and 37% at 2 years. Additionally, there is an ongoing 
randomised phase II trial in which pretreated patients are allocated to either single 
agent tremelimumab or placebo (89). 
 
1.1.5.4.3.2 Programmed death -1 receptor/ligand 
 
The programmed death receptor is found on the surface of T-cells and its stimulation 
leads to T-cell deactivation, therefore permitting escape from the immune system 
surveillance. Activation of this receptor occurs by a programmed death ligand 1 (PD-
L1), which exists within the tumor microenvironment and on the surface of tumour 
cells. Monoclonal antibodies directed at the PD-L1 or PD1 receptors are currently 
being considered (90) . Indeed, preliminary results from the phase II trial of 
pembrolizumab in MPM were presented at ASCO 2015 (Clinicaltrials.gov 
NCT02399371). The authors reported a good safety and tolerability profile and 
revealed a 28% partial response (PR) rate, with 48% demonstrating stable disease 






1.1.5.4.4.1 Dendritic cell vaccines 
 
These are in the early stages of evaluation. In a pilot Phase I study, Hegmans and 
colleagues (91) vaccinated 10 patients with autologous dendritic cells. Each vaccine 
was composed of mature dendritic cells pulsed with autologous tumour lysate 
purified from pleural effusions or biopsy samples. In four patients, dendritic cell 
vaccination induced cytotoxic T cells. It was well tolerated and produced three partial 
responses with overall median survival of 19 months, which is encouraging. Results 
from a trial evaluating dendritic cell-based vaccination in combination with low-dose 
cyclophosphamide are awaited. 
 
1.1.5.4.4.2 CRS-207 vaccine 
CRS-207 is a genetically modified Listeria monocytogenes attenuated vaccine 
expressing mesothelin. Mesothelin acts as an antigen and stimulates activation of T-
cells upon exposure to CRS-207 (92). A phase I trial evaluating this vaccine in 
combination with chemotherapy was presented at ASCO 2014 (Clinicaltrials.gov 
NCT01675765). Authors reported that CRS-207 can be safely combined with 
standard of care chemotherapy and showed encouraging anti-tumour activity with 9 
out of 15 subjects having confirmed durable PR and 4 having SD (93). These results 
are considerably better than those expected with chemotherapy alone and warrant 
further evaluation. 
 
1.1.5.4.5 Gene therapy 
 
 
Gene therapy usually involves administration of engineered viruses into which a 
gene of interest has been inserted, with the aim of inducing long term expression of 
the protein product of the inserted gene in the tissues. Two separate gene therapy 




1.1.5.4.5.1 Suicide gene therapy 
 
This method uses engineered viruses that deliver transgenes encoding enzymes that 
metabolize prodrugs into toxic metabolites capable of destroying tumour cells. 
Multiple viral vectors have been investigated. A clinical trial of intrapleural herpes 
simplex virus thymidine kinase/ganciclovir enrolled 34 patients and reported minimal 
morbidity and a dose-dependent median survival as high as 15 months at the 
highest viral titers. Some patients experienced prolonged survival, suggesting 
induction of anti-tumour immunity in addition to the acute viral-mediated cytotoxicity 
(94). 
 
1.1.5.4.5.2 Cytokine gene therapy 
 
An alternative approach involves the delivery of viral vectors encoding specific 
cytokine genes that may exert a direct cytotoxic effect on tumour cells or may alter 
the immunologic response to the tumour. Although early trials of direct intrapleural 
administration of interleukin-2 (IL-2) demonstrated a response rate of almost 50%, 
with a median survival of 28 months in responders (95), subsequent interest has 
focused on gene therapy with interferon (IFN), which plays a critical role in activation 
of the immune system and can also have direct anti-tumour cytotoxic/cytostatic 
effects. Several clinical trials have evaluated adenoviral-mediated IFN (α and β) 
therapy in patients with MPM (96, 97). Survival ranged from 1–22 months with some 
long-term survival, but neutralising antibodies limited the ability to administer 
repeated treatments. 
 
1.1.5.5   Summary 
 
Despite on-going research providing an increasing list of potential new therapies, 
progress has been slow. Consequently, MPM continues to impart a dismal prognosis 
to those diagnosed with the disease.  With the incidence of MPM on the rise and the 
global burden of this devastating disease continuing to increase, novel therapeutic 








A recently re-discovered biological ‘hallmark’ of cancer is energy re-programming, by 
which tumour cells adjust their metabolic and bioenergetic pathways for cell 
proliferation (98). In this way, tumour cells acquire distinct metabolic characteristics 
from normal cells, driven by a combination of genetic lesions and non-genetic factors 
such as the tumour microenvironment. Interest in tumour cell metabolism originated 
over 80 years ago, with Otto Warburg’s seminal discovery that cancer cells display 
higher rates of glycolysis than their non-malignant counterparts, even in the 
presence of sufficient oxygen supply (99), despite this process being far less efficient 
in terms of net ATP production per molecule of glucose (100). This seemingly 
paradoxical phenomenon, termed the ‘Warburg effect’ or aerobic glycolysis, has 
subsequently been observed across many tumour types and often occurs in parallel 
with a significant increase in glucose uptake and consumption, a trend which forms 
the basis of 18F-deoxyglucose-positron emission tomography (18-FDG-PET) in 
cancer imaging today (101). The catabolism of glucose via aerobic glycolysis has in 
many ways become the ‘re-programmed’ pathway that defines the altered cancer 
metabolism hallmark; however, there are many other metabolic pathways that may 
modulate tumour cell growth (102, 103). Understanding these changes and the 
advantage this gives the tumour in terms of development and maintenance remains 
an area of intense research and has significant clinical implications. Indeed, testing 
for metabolic genetic drivers such as mutations in Kreb’s cycle genes (i.e., fumarate 
hydratase (FH), succinate dehydrogenase (SDH), isocitrate dehydrogenase-1/2 (IDH 
1/2)) is already available, and antimetabolites, such as antifolates and pyrimidine 
analogues, are being effectively used in the oncology clinic (104). Furthermore, new 
PET tracers and antimetabolites are being devised that aim to exploit the differential 
biochemistry of sugars, lipids and amino acids in normal and malignant cells (105). 
Here, the focus is on the amino acid arginine, which has gained much clinical 
interest in recent years as an exciting cancer target, driven by the emergence of 











The rationale for targeting amino acids in cancer therapy was pioneered with the 
introduction of asparaginase in childhood leukemia over fifty years ago. In contrast to 
normal cells, leukemic cells are critically dependent on exogenous asparagine for 
growth (known as ‘auxotrophy’), due to lack of the biosynthetic enzyme asparagine 
synthetase (106). As a monotherapy, deamidation of asparagine to aspartate and 
ammonia by asparaginase, led to responses of up to 50% in early studies of patients 
with chemo-refractory leukemia (107). However, it was not until the advent of 
multimodality chemotherapy regimens containing asparaginase that the cure rate of 
acute lymphoblastic leukemia increased from 5% in the 1950's to the present 90%. 
Since its incorporation into treatment protocols in the 1970’s, asparaginase has 
remained a consistent component of paediatric acute lymphoblastic leukaemia (ALL) 




Similarly, observations that various tumour cells are susceptible to arginine 
deprivation were made over 70 years ago (109). However, delay in the development 
of appropriate therapeutic methods has meant that the use of arginine depletion as a 
therapeutic strategy in the clinical setting has been more recent.  
Arginine is a dibasic α amino acid first discovered over 100 years ago from lupin 
seedlings (110). Like asparagine, it is one of the 20 most common natural amino 
acids and is regarded as highly versatile. In addition to protein synthesis, it is 
involved in many diverse aspects of tumour metabolism, including the synthesis of 
nitric oxide (NO), polyamines (putrescine, spermine, spermidine), nucleotides, 
proline and glutamate (111, 112) (Figure 1.2). Arginine and a number of these 
‘downstream’ molecules have been implicated in tumour development, with animal 
studies confirming a modulatory effect of arginine on tumourigenesis. Hence, mice 
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that either had transplantable tumours, or were genetically programmed to develop 
cancer, displayed enhanced tumour growth when fed an arginine rich diet (113, 114). 
In contrast, depletion of dietary arginine inhibited tumour growth (115). 
 
1.3.2.1 Sources and availability of arginine 
 
On an organismal level, diet and protein degradation are the main sources of plasma 
arginine, with only 5-15% (up to 30% in newborns) derived from de novo 
biosynthesis. Because normal cells are able to endogenously synthesise arginine in 
addition to utilising extracellular supplies, it is not classed as an essential dietary 
amino acid. However, in cases of catabolic stress (e.g. inflammation or infection) or 
conditions involving dysfunction of the kidneys or small intestine, levels of arginine 
may not suffice to meet metabolic demands. Accordingly, arginine is classified as a 
semi-essential or conditionally essential amino acid (110). 
 
1.3.2.1.1 Arginine transport systems 
 
In most mammalian cells, arginine requirements are met primarily by uptake of 
extracellular arginine via specific transporters, with system y+, a high-affinity, Na+-
independent transporter of arginine, postulated to be the main route of entry in the 
majority of cell types. Transporters in this system include those of the high affinity 
cationic amino acid transporter (CAT) family (part of the larger SLC7 gene family) 
(116). CAT1 is constitutively expressed and involved in uptake of arginine for basic 
metabolism. CAT2 is recognised as an inducible form, which includes the 
alternatively spliced isoform CAT2B, a high-affinity arginine transporter known to be 
abundant in macrophages. CAT3 and CAT4 have also been described: CAT3 is 








1.3.2.1.2 De novo arginine biosynthesis 
 
Alternatively, endogenous synthesis of arginine in adults occurs via the intestinal-
renal axis. Namely, citrulline is synthesised from glutamine, glutamate and proline in 
the mitochondria of enterocytes via a series of enzymatic reactions, released from 
the small intestine into the circulation, and taken up primarily by the proximal tubular 
cells of the kidney for arginine production. Besides the kidney, however, citrulline is 
also readily converted into arginine in nearly all cell types, including adipocytes, 
endothelial cells, enterocytes, macrophages, neurons, and myocytes (111). Under 
physiological conditions, the arginine biosynthetic pathway is organised according to 
tissue function: for example, as the urea cycle in the liver for elimination of 
nitrogenous waste, and as the nitric oxide (NO)-citrulline cycle in endothelial cells to 
generate NO, with arginine acting as an intermediary molecule (117). 
Arginine is synthesised by two sequential enzymatic reactions in the urea cycle: 
argininosuccinate synthetase-1 (ASS1), which catalyses the condensation reaction 
of citrulline and aspartic acid to argininosuccinate, and argininosuccinate lyase 
(ASL), which catalyses the conversion of argininosuccinate to arginine with the 










Figure 1.2.  Arginine utilisation within the tumour cell. Arginine is a substrate for multiple 
metabolic and inflammatory pathways in health and disease (see text). Arginine may be sourced from 
the extracellular environment via the cationic amino acid transporter, or endogenously synthesised via 
ASS1. The subcellular locations of key enzymes are shown and enumerated in the figure as follows: 
1, arginase; 2, ornithine transcarbamylase (OTC); 3, argininosuccinate synthetase (ASS1); 4, 
argininosuccinate lyase (ASL); 5; nitric oxide synthase; 6, ornithine decarboxylase; 7, pyrroline-5-
carboxylate reductase; 8, pyrroline-5-carboxylate dehydrogenase; 9, proline oxidase 
(dehydrogenase); 10, ornithine aminotransferase; 11, pyrroline-5-carboxylate synthase; 12, arginine 










The human ASS1 gene is located on chromosome 9, has 16 exons and a 1236 
base-pair segment of open reading frame (ORF).  The protein has 412 amino acids 
in total. It is a ubiquitous enzyme, expressed differentially and regulated according to 
cell type, differentiation status and function. For example, in the adult kidney, ASS1 
is located in the cytosol of proximal tubules and is geared to arginine production, 
especially during starvation. Similarly, in the adult liver ASS1 expression is 
predominantly cytosolic, whereas in the endothelial cell it has been identified in 
caveolae, forming invaginations in the plasma membrane (117). Under physiologic 
conditions, hepatic ASS1 is hormonally regulated (e.g. cortisol, insulin, growth 
hormone, and glucagon). In contrast, expression of endothelial and inflammatory cell 
ASS1 is principally under the control of cytokines (IL-1, TNF-α, TGF-β) (112). 
 
Much attention has been focused on ASS1 in recent years, as it is the rate-limiting 
enzyme in arginine biosynthesis. Indeed, several experimental models support a 
rate-limiting role for ASS1 in NO production. Xie and Gross overexpressed ASS1 in 
rat vascular smooth muscle cells and, following treatment with LPS/IFN-γ, noted a 3–
4 fold increase in NO production, despite saturating levels of extracellular arginine 
(118). The reverse experiment using ASS1 RNAi, confirmed that not only was NO 
production in endothelial cells critically dependent on intact citrulline recycling, but 
also that abrogation of ASS1 resulted in apoptotic cell death.  
 
1.3.2.1.3.1 ASS1 deficiency and urea cycle disorders  
 
ASS1 is one of five catalytic enzymes of the urea cycle, which also includes 
carbamoylphosphate synthetase I (CPS1), ornithine transcarbamylase (OTC), 
argininosuccinic acid lyase (ASL) and arginase (ARG). As the urea cycle is the sole 
source of endogenous arginine, ornithine and citrulline and the principal mechanism 
for the clearance of waste nitrogen resulting from protein turnover, urea cycle 
disorders that result from inherited deficiencies in the enzymes of the urea cycle 
pathway are life-threatening. In ASS1 deficiency, the specific urea cycle disorder is 
Citrullinaemia Type 1. This is inherited in an autosomal recessive manner and the 
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estimated incidence is 1:250,000 (119). Severe deficiency or total absence of activity 
of ASS1 results in the accumulation of ammonia and other precursor metabolites 
during the first few days of life. Infants with a severe urea cycle disorder are normal 
at birth but rapidly develop cerebral oedema and the related signs of lethargy, 
anorexia, hyper- or hypoventilation, hypothermia, seizures, neurologic posturing, and 
coma. In milder (or partial) deficiencies, ammonia accumulation may be triggered by 
illness or stress at almost any time of life (120, 121). Early recognition and treatment 
of a urea cycle disorder is essential to prevent severe brain damage.  
 
1.3.2.1.3.2 ASS1 dysregulation in human cancers 
 
 
ASS1 was first cloned from a carcinoma cell line in 1981(122). Since then, various 
independent studies have revealed differential expression across a wide range of 
tumour tissues compared with corresponding normal epithelia, implying a key role for 
ASS1 in malignant disease (see Table 1.2 for details). Specifically, high levels of 
ASS1 mRNA and protein have been noted in malignant ovarian, gastric and colonic 
epithelium. In contrast, tumours often characterised by chemoresistance and poor 
clinical outcome, including melanoma, hepatocellular carcinoma (HCC), 
mesothelioma, renal cell carcinoma, and prostate cancer, exhibit loss of ASS1 
expression (123-127) . Importantly, loss of this rate-limiting enzyme leads to a critical 
dependence on exogenous arginine for growth.  
 
Epigenetic silencing, via methylation of the CpG islands within the ASS1 promoter, 
accounts for loss of ASS1 expression in some tumours studied to date, including 
mesothelioma (128). Other mechanisms identified include repression of the ASS1 
promoter by hypoxia-inducible factor-1alpha (HIF1α), detected in melanoma cells 
(129). Further work is required to ascertain additional mechanisms of loss. 
 
The reason for down-regulation of tumoural ASS1 expression remains unclear and is 
an area of ongoing research. However, as a rate-limiting enzyme involved in 
providing arginine for various key metabolic pathways, it suggests that such loss 
provides a fundamental biological advantage for these tumours. Although ASS1 
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primarily functions as an enzyme, its non- enzymatic functions, such as tumour 
suppression, have recently been evaluated. It appears from several studies that the 
reprogramming of tumour arginine metabolism by switching off ASS1 supports a 
more aggressive phenotype driven by exogenous arginine. To illustrate this, reduced 
ASS1 expression was significantly correlated with the development of pulmonary 
metastasis after surgery and poor prognosis in patients with osteosarcoma, while 
over-expression of ASS1 inhibited tumour growth in vitro (130). Furthermore, ASS1 
deficiency was identified in half of patients with nasopharyngeal carcinomas (NPC), 
and it was associated with advanced tumour stage, high local recurrence rate and 
poor disease- free survival (131). Likewise, in ovarian cancer, ASS1 methylation was 
associated with significantly reduced overall survival and relapse-free survival and 
contributed to treatment failure (132), and, recently, it was reported that 40% of 
bladder tumours exhibited ASS1 deficiency, which was associated with worse 
disease-free and metastasis-free survival. Here, epigenetic silencing of ASS1 was 
shown to consistently enhance tumour proliferation and invasion (133), further 
indicating that ASS1 might be a novel metabolic tumour suppressor. 
Several recent examples taken from the Kreb's cycle illustrate how loss of key 
metabolic enzymes promotes tumourigenesis: mutations of fumarate hydratase (FH) 
predisposing to leiomyosarcomas and papillary renal cell carcinomas; mutations of 
succinate dehydrogenase (SDH) leading to paragangliomas, phaechromocytomas 
and renal cell carcinomas; and isocitrate dehydrogenase (IDH) mutations described 
in more than 70% of low grade glioblastoma (IDH 1 and 2) and 10% of glioblastoma 
multiforme (IDH1) tumours (134). Recessive mutations have not been identified in 
tumoural ASS1. Nevertheless, as evident with the loss of FH and SDH, inactivation 
of ASS1 may be involved in sustaining the bioenergetic and biosynthetic needs of 
the tumour cell via diversion of critical intermediates. Pharmacological studies from 
our laboratory support the hypothesis that exogenous arginine is sparing for 
glutamine in the synthesis of pyrimidines, specifically in ASS1-negative tumour cells. 
Here, arginine depletion in ASS1-negative cells led to a distinct increase in 
intracellular glutamine whilst thymidine levels dropped secondary to inhibition of 
thymidylate synthase (TS) and dihydrofolate reductase (DHFR), emphasising the 
interdependence between exogenous arginine and glutamine for nucleotide 
synthesis. (133). Furthermore, a key study by Rabinovich et al recently 
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demonstrated that the decreased activity of ASS1 in various cancers supports 
proliferation of cells by facilitating pyrimidine synthesis via CAD (carbamoyl-
phosphate synthase 2, aspartate transcarbamylase, and dihydroorotase complex) 
activation. They found that ASS1 deficiency in cancer increases cytosolic aspartate 
levels, which increases CAD activation by upregulating its substrate availability and 
by increasing its phosphorylation by S6K1 through the mTOR pathway, concluding 
that this novel mechanism provides a metabolic link between the urea cycle 
enzymes and pyrimidine synthesis (135) 
Interestingly, it has also been reported that high ASS1 expression is associated with 
unfavourable disease-free survival in head and neck carcinoma (136). Taken 
together, results presented in this section all highlight the importance of dysregulated 





Less is known about the tumoural role of ASL, which is immediately downstream of 
ASS1 and catalyses the final step in arginine biosynthesis. It is apparent from inborn 
errors of metabolism that ASL is critical in synthesising arginine for NO production, 
with NO donors reversing the clinical picture of hypertension in children with ASL 
deficiency (137). More recently, ASL has been explored in cancer; up-regulation was 
noted in hepatocellular carcinoma, linked to increased aggressiveness mediated by 
NO and cyclin A2 signaling (138). There is also evidence that methylated ASL 
contributes to the arginine auxotrophy of glioblastoma multiforme, with loss of ASS1 
and ASL conferring greater sensitivity to arginine depletion (139). In FH deficient 
renal cell cancer (RCC), where ASL is intact, the enzyme’s activity is reversed 
producing high levels of argininosuccinate from arginine and fumarate. As 
argininosuccinate levels correlate with reversed ASL activity here, this has been 
suggested as a potential biomarker in FH null RCC and other tumours (140, 141). 
Although there is much less available data, the role of ASL in human cancer also 
appears to be dependent on tumour type. Further work is required to understand the 







ASS1 deficiency a  
Bladder Cancer (133) 45% 
Breast Carcinoma (125, 142) 9% 
63.8% 
Colorectal carcinoma (125) 2% 
Glioblastoma (139) 36% 
Head and Neck Carcinoma (136) 56% 
Hepatocellular Carcinoma (125) 100% 
Hodgkins Lymphoma (112) 97% 
Kidney carcinoma (125, 126) 29% 
100% 




Malignant melanoma (125, 144) 100% 
62.9% 
Mixofibrosarcoma (145) 44% 
Non-hodgkins lymphoma (146) 95% 
Nasopharyngeal carcinoma (131) 52% 
Oesophageal carcinoma (147) 19% 
Osteosarcoma (130) 63% 
Ovarian cancer (125) 4% 
Pancreatic carcinoma (148) 87% 
Prostate carcinoma (127) 100% 
Retinoblastoma (149) 0% 
Sarcoma (125) 22% 
Seminoma (125) 17% 
Small cell lung carcinoma (150) 44% 
Squamous cell lung cancer (125) 12% 
Stomach carcinoma (125) 0% 
 
 
Table 1.2. Summary of ASS1 expression in tumours 
a ASS1 deficiency indicates the ratio of patients with absent/low expression of ASS1 at protein, mRNA 
and DNA levels, as determined by immunohistochemical staining, RT-PCR or methylation-specific 
PCR respectively, to all the patients enrolled. Adapted from Qiu et al (151) 
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1.3.3 Strategies for arginine depletion 
 
 
Loss of ASS1 and the resulting arginine auxotrophy evident in various tumour types 
has been exploited as an ‘Achilles’ heel’ in recent years. Based on the asparaginase 
treatment paradigm, several arginine- catabolising enzymes have been evaluated for 
use in cancer therapy. In theory, a number of enzymes such as arginine deiminase 
(ADI), arginase, arginine decarboxylase (ADC) and the nitric oxide synthases (NOS) 
are potentially suitable for use as arginine depletors (152). However, various issues, 
including substrate specification, optimal pH and stability of individual enzymes for in 
vivo use, have meant that ADI and, to a lesser extent, arginase have come furthest 
along the path of clinical development. 
 
 
1.3.3.1 Arginine deiminase (ADI) 
 
 
ADI, an enzyme derived from Mycoplasma, degrades arginine into citrulline and 
ammonia. This is important as it allows cells with a functional ASS1 to re-cycle the 
citrulline back to arginine, thereby leaving ‘normal’ cells unaffected by arginine 
depletion whilst targeting ASS1 negative tumour cells. Currently, the commonly used 
ADI protein is derived from Mycobacterium arginini. At physiological status, 70% of 
the enzyme activity of ADI is reserved with an optimal pH of approximately 6.0–7.5 at 
50 °C. However, in its native form it is strongly antigenic with a half-life of 
approximately 5 hours, which is clearly too short to be used in vivo (153). To help 
resolve these issues, ADI is conjugated with polyethylene glycol (PEG). The 
obtained ADI-PEG20 (Mw: 20,000Da) decreases antigenicity as well as dramatically 
increasing serum half life to 7 days, allowing weekly administration that reduces 











Arginase is a manganese-containing enzyme that degrades arginine into ornithine 
and urea. Currently, two different subtypes of human arginases (arginase I and 
arginase II) have been identified, and they share 60% similarity in their amino acid 
sequence. Arginase I, which is mainly detected in the liver, has received more 
attention. Unlike ADI, human arginase I has no antigenicity. However, its optimal pH 
is 9.6, meaning it is less effective in human plasma. Compared with ADI, a large 
amount of arginase I is required to achieve arginine depletion (155). Therefore, 
recombinant human arginase I is also conjugated with PEG (Mw: 5,000Da) to 
formulate rhArg-PEG.  This has an improved half-life time, increased from a few 
minutes to 3 days, and an improved Km value of arginine (Km is the concentration of 
substrate required to produce 50% of the maximal speed of activity of the enzyme), 
decreased from 6.0 to 2.9 mM, which makes rhArg-PEG usable in clinical application 
(156). However, animal toxicity testing indicates that citrulline supplementation is 
required since the ornithine produced by arginase cannot be recycled readily to 
citrulline (157). 
 
ADI-PEG20 has been used more extensively in the pre-clinical and clinical setting 
and is therefore discussed in more detail below.  
 




It is now well established that targeting extracellular arginine for degradation in the 
absence of ASS1 leads to cell death in arginine auxotrophs in vitro (112). More 
recent studies evaluating the efficacy of bioengineered arginine catabolising 
enzymes have confirmed that arginine depletion is also effective in various ASS1 –
deficient xenograft models. Thus, in mice bearing subcutaneous malignant 
melanoma (MM) and hepatocellular carcinoma (HCC) xenograft tumours, ADI-
PEG20 significantly suppressed tumour growth and extended animal survival time 
(123). The anti-tumour activity of ADI-PEG20 has also been validated in pancreatic 
cancer, prostate cancer, small cell lung cancer, lymphoma, head and neck cancer, 
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mesothelioma, bladder cancer, glioblastoma and breast cancer (127, 128, 131, 139, 
142, 146, 150). 
 
Whilst amino acid deprivation is known to induce nutritional starvation, the inhibitory 
effects of arginine depletors on tumour growth are not fully understood and remain 
an area of active investigation. ADI-PEG20 has been shown to down-regulate 
mammalian target of rapamycin (mTOR) and modulate phosphoinositide 3-kinase 
(PI3K) via suppression of phosphatase and tensin homolog (PTEN) in ASS1-
negative tumour cells (104). In fact, arginine is one of two key amino acid regulators 
of mTOR—the other being leucine—and this could explain, in part, the ability of 
arginine depletors to critically impair protein synthesis (158). In addition to 
modulating tumour biomass via suppression of nucleotide and protein synthesis, 
arginine depletion also affects tumour cell motility via a NO and focal adhesion 
kinase (FAK)-dependent pathway; importantly, FAK activation has been linked to 
deprivation of several other amino acids including glutamine and tyrosine (159, 160). 
Interestingly, ADI was also identified in an anti-angiogenic screen and an anti-
vascular effect has been confirmed both in HUVEC cells in vitro and in a xenograft 
melanoma study using fluorescence molecular tomography. Furthermore, ADI was 
anti- angiogenic and potentiated the effect of radiation in a neuroblastoma mouse 
model (161-163). 
 
Having established an anti-tumour effect using ADI-PEG20 alone, investigators are 
increasingly evaluating the therapeutic efficacy of ADI-PEG20 in combination with 
other anti-tumour modalities. To date several preclinical combinatorial studies have 
shown additive and/or synergistic effects of arginine depletion with taxanes, 5-
fluorouracil, pemetrexed, cytarabine, PI3K inhibitors, and modulators of autophagy 
using chloroquine and TRAIL (127, 133, 164, 165). For example, the combination of 
docetaxel and ADI-PEG20 exhibited synergistic effects in prostate cancer cells 
(127). ADI-PEG20 was also shown to potentiate the activity of pemetrexed in bladder 
cancer and mesothelioma (133), and more recently, Qui and colleagues (142) 
demonstrated a synergistic interaction between ADI-PEG20 and doxorubicin in 
breast cancer. Other interactions under investigation include the potentiation 
observed between arginine deprivation and radiotherapy in 3D spheroid models of 




These results suggest that using ADI-PEG20 as part of a rational treatment 
combination may improve outcome in the clinical setting. 
 
 
1.3.5 Arginine deprivation: clinical data 
 
 
The initial phase I/II studies of ADI-PEG20 were performed in patients with HCC and 
melanoma, tumours with a high frequency of ASS1 loss (see Table 1.3). 
Encouraging response rates of between 25-47% were observed in these small 
studies, with good safety and tolerability (167, 168). The common adverse reactions 
have been self-limiting grade 1-2 injection site reactions. Diffuse skin rashes and 
arthralgia have also been recorded, although less frequently, and neutropenia, 
anaphylactoid reactions and serum sickness are rare (104).  Following on from these 
studies, the latest ADI-PEG20 clinical trials in HCC and metastatic melanoma have 
recorded stable disease as the best response. Yang et al (169) performed a 
randomized phase II study of two different doses of ADI-PEG20 (320 IU/m2 vs. 160 
IU/m2) in HCC showing that disease control rates were similar in both groups. A 
trend towards better survival was observed in patients with >4 weeks (10.0 months) 
compared with <4 weeks (5.8 months) of arginine deprivation. A global phase III trial 
is now underway using the 160 IU/m2 dose (ClinicalTrials.gov Identifier: NCT01 
287585) to confirm the therapeutic efficacy of ADI-PEG20 in HCC. Results are 
expected in 2016. 
 
The role of ASS1 as a predictor of response to ADI-PEG20 has been explored only 
recently in clinical trials. The first prospective multi-centre randomised study of ADI-
PEG20 in patients pre-selected for ASS1 deficiency in cancer has recently been 
conducted in mesothelioma (the Arginine Deiminase And Mesothelioma or ADAM 
Phase II study). ADAM met its primary endpoint of an improvement in the 
progression-free survival in the best supportive care (BSC) plus ADI-PEG20 group 
compared to the BSC alone group of almost 6 weeks (p=0.02) (143). In addition, 
46% of patients achieved partial metabolic response by PET-CT, with stable disease 
as the best radiographic response (170). The data support differential methylation as 
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the basis for the loss of ASS1 observed in mesothelioma, consistent with earlier cell 
line studies.  
 
Following on from the ADAM trial, a phase I study evaluating ADI-PEG20 in 
combination with pemetrexed and cisplatin is currently recruiting patients with 
mesothelioma and other ASS1-deficient tumours (NCT0209690). In addition, several 
other ongoing clinical trials using ADI-PEG20 in combination are recruiting patients 
with advanced non-Hodgkin’s lymphoma (NCT01910025), acute myeloid leukemia 
(NCT01910012), prostate cancer (NCT01497925), HER2 negative metastatic breast 





Therefore, in summary, early signs suggest that arginine deprivation as a therapeutic 
strategy has the potential to make an impact across a broad range of human 
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PFS 3.3 vs 1.9 months 
[p=0.02] favoring ADI-
PEG20+BSC;  
ASS1 methylation status  
correlated with IHC 
[p=0.025]  





Table 1.3: Completed clinical studies of single agent ADI-PEG20 in advance cancer. Adapted 
from Phillips et al (104). 
‡ from diagnosis; PMR=partial metabolic response; MOA=mechanism of action;  







1.3.6 Resistance to arginine depletion 
 
 
However, despite promising results observed in both pre-clinical and clinical studies 
as a targeted therapy for arginine auxotrophic tumours, drug resistance remains a 
significant challenge for effective use of arginine depletors. The underlying 
mechanisms of resistance to arginine deprivation are being explored, and several 
have recently been identified. These mechanisms are discussed below and are also 
summarised in Figure 1.3.   
 
1.3.6.1 Re-expression of ASS1 
 
 
Re-expression of ASS1 results in the re-cycling of citrulline back to arginine. This 
has been described by Manca and colleagues (173) who found that thirty-three 
percent of initial ASS1-deficient malignant melanoma tumours became ASS1-
positive after ADI-PEG20 treatment, and therefore resistant to ADI-PEG20. ADI-
PEG20 was reported to activate the Ras/PI3K/ERK signaling pathway in melanoma 
cells and increase the stability of the transcription factor c-Myc, which subsequently 






Autophagy (‘self-eating’), leading to the provision of a temporary but finite supply of 
arginine via the breakdown of intracellular organelles (174), is also triggered by 
arginine deprivation, circumventing the depletion of arginine in several malignancies, 




1.3.6.3 Drug-neutralising antibodies 
 
ADI derived from mycobacterium arginini is still immunogenic in humans even after 
pegylation. As a result, anti-ADI antibodies have been detected in patients enrolled 
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in clinical trials. For example, in a phase II clinical trial for the treatment of HCC 
patients, anti-ADI antibodies were detected after the administration of ADI-PEG20 
and reached a plateau at day 50, which was accompanied by an arginine level that 
rebounded to baseline value (171). Although further investigations are needed to 
clarify the correlation between the onset/progression of the antibody and the 
therapeutic efficacy of ADI-PEG20, anti-ADI antibodies may contribute to the 
resistance to arginine deprivation. 
 
1.3.6.4. A role for the tumour microenvironment? 
 
 
Finally, the direct supply of arginine or its precursors by host cells within the tumour 
microenvironment (TME) may also be a resistance mechanism, as shown for other 
metabolites. For example, in acute lymphoblastic leukaemia (ALL), mesenchymal-
derived stromal cells were reported to provide asparagine for asparaginase-resistant 
ALL cells (179, 180). Thus, the basis for the current work is that the tumour 












Figure 1.3. Arginine deprivation: mechanisms of action and proposed resistance mechanisms. 
Recognised mechanisms mediating the anti-tumour activity of arginine deprivation include induction of 
cell cycle arrest, apoptosis and inhibition of angiogenesis. On the other hand, ASS1 re-expression, 
enhanced glycolysis and autophagy have been reported to be associated with resistance to arginine 
deprivation. Additionally, cells within the TME may act as ‘feeder cells’ providing MPM cells with 












Tumours evolve in a complex, dynamic, and functionally multifaceted 
microenvironment that includes the cancer cells, stromal tissue (fibroblasts, 
neuroendocrine cells, adipose cells, immune and inflammatory cells, and the 
blood and lymphatic vascular network) as well as the surrounding extracellular 
matrix (181, 182). Physiologically, the stroma is an essential compartment in 
maintaining homeostasis of normal tissue, and in healthy individuals it acts 
physical barrier against tumour development; however, malignant cells 
provoke various changes within this environment to convert it into a 
pathological entity.  Under such conditions, the stromal cells co-evolve with 
the cancer cells by being repeatedly re-educated or modified by the latter to 
produce a wide variety of cytokines, chemokines, growth factors, and 
proteinases, all of which can significantly promote cancer progression, 
invasion, metastasis and drug resistance (183, 184). Indeed, this 
‘transformed’ tumour-promoting stroma, or tumour microenvironment (TME), 
is characterised by a remodeled matrix, reprogrammed metabolism, activated 
transcription, and altered synthesis of repair-associated proteins (185-187).  
 
The concept of the tumour microenvironment was first suggested in the 
1880’s with Paget’s assertion that the microenvironment plays a critical role in 
regulating the growth of metastases - his ‘seed and soil’ theory (188): it is now 
recognised as an integral part of tumour physiology, structure and function. 
Indeed, there has been much interest in recent years on developing drugs 
that target the TME, as, unlike cancer cells, stromal populations within the 
TME are genetically stable, and thus represent an attractive therapeutic target 







1.4.1 Cells of the tumour stroma 
 
 
The most widely studied stromal cells in solid tumours, including MPM, are 
cancer-associated fibroblasts (CAF), tumour endothelial cells (TEC) and 
tumour-infiltrating immune cells (T lymphocytes and tumour–associated 
macrophages (TAM)). These cell-types will therefore be reviewed below, with 
a more detailed discussion on macrophages, which are abundant in MPM and 






In normal tissue, fibroblasts are the predominant mesenchyme-derived cell 
type in the connective tissue stroma and are the primary producers of the 
extracellular matrix (ECM). Fibroblasts are responsible for the deposition of 
the fibrillar ECM—type I, type III, and type V collagen and fibronectin—and 
contribute to the formation of the basement membrane by secreting type IV 
collagen and laminin. Connective tissue and the ECM are continually 
remodeled through a dynamic process of ECM protein production and 
degradation by fibroblast-derived matrix metalloproteinases (MMPs). This 
turnover is, however, well regulated and controlled (189). 
 
In cancer, fibroblasts are a major cellular component of the tumour 
microenvironment. Indeed, in some cancer types, fibroblasts comprise a 
larger proportion of cells within the tumour than the cancer cells themselves. 
Fibroblasts within tumours have an ‘activated’ phenotype, and therefore 
resemble fibroblasts in wound healing. They have been shown to assist in 
proliferation and progression of cancer through the secretion of growth 
factors, pro-inflammatory and pro-angiogenic cytokines, and extracellular 
matrix proteins, thereby permitting invasion and spread of cancer cells (190, 
191). Moreover, it has recently been shown that certain secreted factors (the 
nutrients lactate, ketone bodies and glutamine) sustain the survival of hypoxic 
cancer cells and the growth of normoxic cancer cells by serving as a source of 
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energy and/or as intermediates to biosynthesis (192). This is discussed in 
more detail in Chapter 4. 
 
Importantly, these cancer-associated fibroblasts (CAFs) are functionally and 
phenotypically distinct from normal fibroblasts. The difference between CAFs 
and physiologically activated fibroblasts is that CAFs are permanently 
activated, neither returning to a normal phenotype nor undergoing apoptosis 
and elimination (193). CAFs are recognised within tumor stroma by their 
spindyloid appearance and the expression of alpha-smooth muscle actin (α-
SMA); characteristics shared by activated fibroblasts in wounds. 
 
As with other solid tumours, CAFs are a major component of the MPM tumour 
microenvironment (194, 195). CAFs regulate tumour behavior through several 
mediators. For example, it was recently demonstrated using an in vitro co-
culture model that MPM cell lines produced fibroblast-growth factor 2 (FGF-2) 
and platelet-derived growth factor-AA (PDGF-AA), and that these growth 
factors stimulated CAFs to produce hepatocyte growth factor (HGF), thus 
promoting tumour progression through a malignant cytokine network. 
Furthermore, the significant infiltration of CAFs and the simultaneous 
expression of these three cytokines were also detected in 51 clinical 
specimens obtained from patients with MPM (196). This highlights the 
importance of stromal fibroblasts in MPM tumour progression and suggests 
that these three cytokines may be potential therapeutic targets in MPM 
treatment.  
 
1.4.1.2 Endothelial Cells 
 
 
Endothelial cells (ECs) remain quiescent for years, but when tissues are 
deprived of oxygen or nutrients, they sprout to vascularise these tissues 
(angiogenesis) (197). Tumours require the formation of a complex vascular 
network to meet their metabolic and nutritional needs for growth, and the 
vessel formation generated by angiogenesis addresses these needs. VEGF is 
the principal factor involved in the formation of tumour vessels. It is secreted 
68 
 
directly by the tumour cells, and by fibroblasts and inflammatory cells in the 
stroma. VEGF is important for the activation of the ‘‘angiogenic switch’’ (98), 
which causes the usually quiescent vasculature to sprout new vessels and, in 
turn, aid tumour growth and proliferation (189). However, tumour vessels 
formed as a result of VEGF are abnormal; they are inconsistently distributed 
and irregularly shaped, incorrectly branched and tortuous, often ending 
blindly. They do not have the classic hierachical arrangement of arterioles, 
venules, and capillaries and often form arterio-venous shunts. They are also 
fenestrated and leaky, leading to high interstitial pressures, further 
exacerbating tissue hypoxia and stimulating additional VEGF production 
(198). 
 
In vitro studies have shown that mesothelioma cell lines produce varying 
quantities of VEGF. In the MPM cells that produce large quantities, the 
interaction with endothelial cells seems to be particularly important. VEGF 
produced by MPM cells activates endothelial cells and induces angiogenesis, 
promoting tumour progression (199). In addition, by activating endothelial 
cells, VEGF induces hypervascular permeability to produce pleural effusion 
(200). Therapy targeting VEGF/endothelial cells may therefore be effective for 
MPM cells that produce large quantities of VEGF. 
 
1.4.1.3  T lymphocytes 
 
 
Infiltrating innate and adaptive immune cells comprise a large component of 
the TME. Key adaptive immune cells are the T lymphocytes. Many different T 
cell populations infiltrate the tumour; among these are the memory CD8+ T 
cells, which are capable of killing tumour cells and are generally associated 
with good prognosis (201). Indeed, a study to determine the impact of tumour 
infiltrating T lymphocytes on survival in MPM patients treated with induction 
chemotherapy followed by EPP found that patients with high levels of CD8+ 
tumour-infiltrating T lymphocytes demonstrated better survival than those with 
low levels (3-year survival: 83% versus 28%; p =0.06). Moreover, high levels 
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of CD8+ tumour-infiltrating lymphocytes were associated with a lower 
incidence of mediastinal node disease (p =0.004) and longer progression-free 
survival (p = 0.05) (202).  
These CD8+ T cells are supported by CD4+ T Helper 1 cells, which are which 
are characterised by production of the cytokines interleukin-2 (IL-2) and 
interferon gamma (IFN-γ); high numbers of these in the TME are also 
associated with good prognosis. Conversely, other CD4+ T cell populations, 
such as the T Helper 2 cells, are thought to promote tumour growth. These 
tumour-promoting CD4+ T cells are commonly described as the 
immunosuppressive T regulatory (Tregs) cells (203). They exert an immune 
suppressive function through the production of IL-10,TGFβ and cell-mediated 
contact through CTLA-4, inhibiting recognition and clearance of tumour cells 
by the immune system (204). High numbers of Tregs in the TME correlate 
with worse prognosis in many types of cancer (205), including in MPM, where 
patients with high levels of CD4+ tumour-infiltrating lymphocytes were found 






Below is a detailed review of macrophage biology and the role these cells play 
in tumour development and therapeutic resistance. This is followed by a 











Figure 1.4. Reciprocal interactions of tumour cells and stromal cells in the tumour 
microenvironment. Tumour-associated macrophages (TAM), carcinoma- associated 
fibroblasts (CAF), endothelial cells (EC) and the extracellular matrix (ECM). These 
interactions are mediated by direct cell-to- cell contact and/or the release of cytokines, 
chemokines, growth factors, matrix metalloproteases (MMPs), and ECM proteins. Eventually 
this results in tumour cell proliferation, epithelial-mesenchymal transition (EMT), migration, 
invasion and the formation of metastases. For reasons of clarity, other stromal cell 
populations, e.g. lymphocytes and known interactions among different stroma cell populations 









1.5 Macrophage Biology 
 
 
1.5.1 Macrophage development 
 
 
Macrophages are a heterogeneous population of terminally differentiated, 
tissue-resident, innate myeloid cells. They exist in almost all tissues and play 
important roles in development and the maintenance of tissue homeostasis 
(206). Under non-pathological conditions, most resident macrophage 
populations derive from embryonic (yolk sac) progenitors and are maintained 
through local proliferation (207). Exceptions to this include intestinal, dermal 
and alveolar macrophages (208, 209). These macrophages differentiate from 
peripheral blood monocytes, which develop from common myeloid progenitor 
cells. These cells are identified as granulocyte/ macrophage colony-forming 
units (GM-CFUs) in the bone marrow. In response to a macrophage colony-
forming factor, GM-CFUs sequentially give rise to macrophage colony-forming 
units (M-CFUs), monoblasts, and pro-monocytes. Subsequently, they move 
into the peripheral blood and differentiate into monocytes. Finally, the 
monocytes migrate into different tissues and replenish the populations of 
these tissue-specific macrophages (210, 211). Under pathological conditions 
there is evidence of both local proliferation and recruitment, depending on the 
tissue location and inflammatory insult (212).  
 
1.5.2 Macrophage activation and phenotypic diversity 
 
 
Macrophages display huge variation in phenotype, with specialised 
populations seen in different tissues. Well-described specialised resident 
tissue macrophages with distinct phenotypes include kuppfer cells (liver), 
osteoclasts (bone), microglia (brain), histiocytes (connective tissue) and 
alveolar macrophages (lung) (211). The phenotypic diversity in macrophages 
is influenced by activation signals from the surrounding microenvironment and 
can be strongly regulated by the products of T- lymphocytes, natural killer 
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(NK) cells and tumour cells, in particular interferon- gamma (IFN-γ) and a 
cytokine network involving IL-4, IL-10, IL-12, and IL-13, as well as tissue 
oxygen tension and pH (213). Macrophage activation states have been 
separated into two phenotypes, M1 or M2, which parallel the Th1/Th2 
paradigm, and in vitro data has established that peripheral blood monocyte- 
derived macrophages can be polarized into M1 or M2 phenotypes (see Figure 
1.5). This has also been validated in vivo for M1 macrophages, which are 
activated by IFN-γ or by bacterial cell wall-derived LPS, and predominate 
during acute inflammatory responses (214). M1, or ‘classically activated’ 
macrophages produce large quantities of pro-inflammatory cytokines (e.g. IL-
1β, IL-12, and TNF-α), present antigens via increased expression of MHC 
class II molecules, and are implicated in the killing of pathogens and tumour 
cells (215, 216). In contrast, M2, or ‘alternatively activated’, macrophages 
(217) are characterised by increased production of IL-10, amplification of 
metabolic pathways that can suppress adaptive immune responses, and up-
regulation of cell-surface scavenger receptors, such as mannose receptor 
(MRC1/CD206) and hemoglobin/aptoglobin scavenger receptor (CD163). As 
such, M2 macrophage activation moderates the inflammatory response and 
promotes tissue re-modeling/repair (including angiogenesis) (218, 219). 
Stimulation with IL-4, IL-13, TGFβ, IL-10, immune-complexes, glucocorticoid 
hormones, and agonists of certain TLRs or the IL-1R, drives macrophages 






















Figure 1.5. The differentiation pathways of ‘classically’-activated M1 macrophages and 




However, whilst the M1-M2 classification system is useful when attempting to 
understand macrophage plasticity, it oversimplifies the diversity of 
macrophage phenotypes.  Indeed, macrophage phenotype does not appear to 
be stereotyped or twofold in response to different stimuli, as may be assumed 
if incorrectly interpreting the M1-M2 model. Instead, macrophages often 
express a mixed M1/M2 phenotype; thus “M1” and “M2” polarisation should 
be considered as extreme ends of a continuum of activation states, with the 
position on this spectrum depending on the exact composition of the 
activating signals present in a given microenvironment (214, 221, 222). 
Furthermore, macrophages can also shift from one activation state to another, 
reflecting their dynamic interaction with the surrounding environment (223). 
The M1-M2 model remains, nonetheless, a useful tool for descriptive 




1.5.3 The arginine metabolome and macrophages 
 
Importantly, each pathway of macrophage activation employs arginine as a 
key substrate. Indeed, arginine can be utilised by macrophages in a variety of 
metabolic pathways, with the differential catabolism via the inducible form of 
nitric oxide synthase (iNOS) and arginase being the best characterised to 
date. Th1-type cytokines transcriptionally up-regulate iNOS (M1 
macrophages), and Th2-type cytokines activate arginase expression (M2 
macrophages) (224, 225). Arginine utilisation can therefore directly affect the 
role of macrophages and the type of host immune response within the tumour 






Figure 1.6. Schematic representation of TAM 1 and TAM 2 metabolic pathways. The 
activities of the enzymes in both ‘classically’ activated (M1), and ‘alternatively’ activated (M2) 
macrophages in the TME are illustrated. Solid arrows indicate the main enzymatic activity, 
whereas dashed arrows indicate alternative metabolic activity. In particular, when arginine 
concentrations are low (common within the TME), iNOS activity changes from the prevalent 
production of NO to the generation of superoxide and highly reactive nitrogen species (RNS). 
The T helper 1 cytokines (IFN γ) and T helper 2 cytokines (IL4, IL13) are the main inducers of 
iNOS and Arginase, respectively. Pro-inflammatory signals (such as IL1 and TNF α) and anti-
inflammatory signals (IL10) can contribute to regulate the final balance between iNOS and 
arginase activity. Moreover, arginase and iNOS directly activate several biochemical circuits 
that negatively regulate each other.  The depletion of L-arginine by overexpression of 
arginase reduces the activity of iNOS in the production of NO. Polyamines can also inhibit 
production of NO. Conversely, NOHA can inhibit arginase.  
NOHA, N hydroxy L-arginine; OAT, ornithine aminotransferase; ODC, ornithine 
decarboxylase; RNS, reactive nitrogen species; ROS, reactive oxygen species; ASS1 








As detailed in the section above, a wide variety of signals can profoundly 
affect the function of macrophages. This section will focus on the role of 
macrophages in the tumour microenvironment.  
 
1.5.4.1 Tumour-associated macrophages (TAM) 
 
 
1.5.4.1.1 TAM origin and recruitment 
 
 
Macrophages are a major component of the infiltrate of most tumours, where 
they are commonly termed tumour-associated macrophages (TAM). They 
represent a mature population of terminally differentiated myeloid lineage 
cells, derived from both local proliferation and bone marrow (BM) monocytes 
(212). Production of certain chemoattractants by tumour cells and stromal 
cells is essential to recruit and sustain large numbers of TAM. For instance, 
the C-C chemokine ligand 2 (CCL2) and colony-stimulating factor-1 (CSF-1) 
play a critical role in recruiting macrophages to neoplastic tissue. Indeed, 
CSF-1 was shown to selectively promote metastatic potential in mice with 
mammary tumours by regulating the infiltration and function of TAM. Here, it 
was reported that CSF-1 receptor expression was restricted to TAM at the 
tumour site (227). Similarly, it was reported that the recruitment of 
inflammatory monocytes, which express CCR2 (the receptor for chemokine 
CCL2), as well as the subsequent recruitment of metastasis-associated 
macrophages and their interaction with metastasising tumour cells, is 
dependent on CCL2. Inhibition of CCL2-CCR2 signalling blocks the 
recruitment of inflammatory monocytes, inhibits metastasis in vivo and 
prolongs the survival of mice bearing mammary tumours (228). Furthermore, 
in prostate cancer, CCL2 overexpression increased the growth of transplanted 
xenografts and increased macrophage accumulation in vivo (229). Other 
chemokines, including CCL3, CCL4, CCL5, CCL7, CCL8, CXCL8 and 
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CXCL12, and cytokines, including VEGF, platelet-derived growth factor 
(PDGF), and IL-10, are also reported to promote macrophage recruitment into 
tumours (230-233). 
 
Over a decade ago, it was proposed that TAM are primarily polarized in the 
tumour microenvironment toward an M2-like phenotype and that this underlies 
their ability to aid tumour growth (215). This is also supported by clinical 
studies showing the predictive value of M2-macrophage associated markers, 
like CD163 (234). However, it is becoming increasingly evident that distinct 
macrophage subpopulations with variable phenotypes coexist in tumours and 
that their relative abundance changes with the tumour type (235, 236). To 
illustrate this, recent work has identified varying proportions of M1 (arginase 
low and iNOS high) and M2 (arginase high and iNOS low) TAM depending 
upon the type of chemically or genetically induced epithelial tumour murine 
model. For example, macrophages exhibited arginase (high), iNOS (low) 
polarisation in early stage chemically induced lung tumours, whereas a mixed 
population of M1 and M2 TAM was observed with late stage lung 
adenocarcinomas (237). Moreover, lung tumour regression secondary to the 
inactivation of the Kras or FGF10-driven transgene was associated with a 
switch from an arginase (high) iNOS (low) TAM polarisation to an arginase 
(low) iNOS (low) pulmonary macrophage phenotype (no polarisation). In 
contrast, studies of TAM associated with different stages of melanoma 
progression, revealed dominant iNOS expression in in situ and thin 
melanomas which declined with the development of thicker melanomas (238). 




1.5.4.1.2 Role of TAM in tumour progression 
 
 
For many solid tumour types, high numbers of cells expressing macrophage-
associated markers have generally been found to be correlated with poor 
clinical outcome (212, 239). There are exceptions; for example, it has been 
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reported that macrophages in colorectal cancer play an anti-tumour role, 
which leads to a good prognosis (240, 241). Indeed, TAM do express a series 
of pro-inflammatory cytokines such as IFN-γ, IL-1, and IL-6, which can 
activate type-1 T-cells associated with anti-tumour immune responses (240). 
As illustrated in Figure 1.6, M1-skewed TAM also generate nitric oxide (NO) 
and its derivative reactive nitrogen species (RNS) via iNOS, which at high 
levels can initiate tumour cell apoptosis and destroy emerging transformed 
cells (242, 243).  
 
In addition, conflicting data exist for stomach, prostate and bone cancers, 
where both positive and negative outcome associations have been reported 
(239, 244). This may be related to the type/stage of cancer evaluated (e.g. 
Ewing sarcoma versus osteosarcoma), or to the type of analysis performed 
(e.g. quantification of stromal versus intra-tumoural macrophages). The use of 
different macrophage markers may also result in some discrepancy; for 
example CD68 represents a reasonably specific marker in murine 
macrophages and, in combination with F4/80, identifies the majority of TAM 
(212). However, in humans, CD68 expression is more widespread (245) and 
is therefore less useful for association studies, although it is commonly used.  
 
In many other tumours, including breast, pancreas, ovarian, lung carcinoma, 
cutaneous melanoma, and, importantly, mesothelioma, TAM are considered 
to be pro-tumourigenic (220, 239, 246-249). Added to this, epidemiological 
studies have suggested that a macrophage-rich microenvironment will 
promote an aggressive tumour with a high metastatic potential (250). The next 
section will therefore focus on the pro-tumoural properties of TAM. 
 
 
1.5.4.1.3 Pro-tumoural mechanisms of TAM 
 
 
The functional mechanisms underlying the tumour-promoting activities of TAM 






It is well established that the growth and spread of malignant tumours requires 
angiogenesis, and the majority of cancers and cancer models show increased 
tissue vascular density during transformation to the malignant state. Various 
cell types contribute to this “angiogenic switch” (121) of which macrophages 
are a major component (122). It appears that hypoxia plays a role in directing 
macrophages towards a pro-angiogenic phenotype, and so promoting tumour 
progression. Indeed, functional studies in mouse models of cancer provide 
evidence for a link between macrophages and the angiogenic switch. For 
instance, macrophage depletion is observed in CSF-1 constitutive genetic 
knockout mice, in which the Polyoma Middle T oncoprotein (PyMT) induced 
mammary tumours show a greatly attenuated angiogenic switch (251). 
Furthermore, there is evidence from this murine model of breast cancer that 
VEGF production by TAM is key to the angiogenic switch. Using transgenic 
VEGF-A op/op PyMT mice, VEGF over-expression at a benign stage in such 
macrophage-depleted mice produces increased angiogenesis and 
accelerates the transition to outright malignancy (252). Characterisation of 
angiogenic TAM show that they express TIE2. Genetic ablation of this 
population inhibits angiogenesis in a variety of models, including glioblastoma 
and the PyMT model (253). Interestingly, CSF-1 upregulates TIE2 on TAM 
(254), indicating a link between CSF-1, TIE2+ macrophages and the induction 
of the angiogenic switch. There are now numerous additional reports of TAM 
affecting angiogenesis in a wide range of models, primarily xenograft models, 
highlighting this key protumoural role (255). 
 
 




Tumour cell migration, particularly in epithelial tumours, relies on proteolytic 
destruction of the surrounding ECM to facilitate the escape of tumour cells 
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from the confines of the basement membrane. Common to all spreading 
tumours is the need for subsequent proteolysis of surrounding dense tissue 
stroma. Macrophages are potent producers of many proteases, including 
cathepsins, MMPs, and serine proteases (256). Increased production of 
MMPs is a feature of the M2 macrophage phenotype and is typical of TAM 
(257). Cathespin proteases remodel the ECM and release sequestered 
growth factors. Macrophage-specific depletion of cathepsins or urokinase 
plasminogen activator, results in reduced tumour cell invasion and inhibition of 
metastasis in mouse mammary tumour models (258, 259). Macrophages also 
produce other molecules that advance tumour cell invasion, including 
Osteonectin (known as SPARC) (260), which increases tumour cell-ECM 
interaction and thus migration, and TGFβ, that promotes EMT of the invading 






Macrophages are central to many immune responses and under certain 
conditions, in particular during bacterial infection, they act as potent antigen 
presenting cells. However, within the tumour microenvironment, it appears 
that TAM assume an immune-regulatory role, suppressing anti-tumour 
immune responses. TAM can inhibit cytotoxic T-cell responses through 
several mechanisms. For example, they produce IL-10, which is commonly 
regarded as an anti-inflammatory, immunosuppressive cytokine that aids 
tumour escape from immune surveillance. TAM-derived IL-10 stimulates 
expression of the co-stimulatory molecule B7-H3 on tumour cells, and induces 
monocytes to express the co-stimulatory molecule PDL-1, both of which have 
been shown to suppress cytotoxic T-cell responses (262, 263). Furthermore, it 
was recently shown by Noman et al (264) that TAM in hypoxic tumour regions 
also up-regulate the expression of PDL-1 as a consequence of hypoxia 
inducible factor 1-α (HIF1α) signaling. This has also been demonstrated in 
HCC (262). Notably, the response rates in the PD-1/PD-L1 trials have been 
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shown to relate, at least partially, to PD-L1 expression in the stroma (265, 
266), supporting a role for macrophages in blocking anti-tumour T cell 
responses.  However, it is difficult to determine the exact impact of TAM PD-1 
ligand expression on effector cell inhibition in vivo, since several cells within 
the TME express PD-L1.  
 
In another study, a recruited macrophage population into mammary tumour 
xenografts suppressed immune responses through synthesis of 
prostaglandin-E2 and TGFβ (267). A similar response was also seen when 
macrophages were co-cultivated with mesothelioma cells: here, macrophages 
released a significant amount of prostaglandin-E2, stimulating the 
development of regulatory T cells, thereby promoting an immunosuppressive 
TME (268). 
 
Several studies have found that chemokines secreted by macrophages also 
play an important role in immunosuppression. In human ovarian cancers, TAM 
produce CCL22, a chemokine that regulates the influx of regulatory T-cells 
(Tregs) that suppress cytotoxic T-cell responses. The abundance of these 
Tregs in ovarian cancer predicts poor survival (269). More recently, it was 
shown that in colorectal cancer CCL20 secreted by TAM also recruits Tregs 
(270).  
  
In addition, TAM have been shown to secrete arginase into the 
microenvironment in different mouse cancer models (271), and the 
subsequent depletion of arginine in the TME can suppress T cell activity. 
Indeed, arginine is required for effective T cell function, and its depletion has 
been shown to inhibit the re-expression of the CD3ξ chain after internalization 
caused by antigen stimulation and T cell receptor (TCR) signaling, resulting in 
CD8+ T cell unresponsiveness (272, 273). However, it is interesting to note 
that inhibition of arginase activity does not blunt in vitro suppressive functions 
of TAM (235).   
 
The effect of TAM-derived arginase on reducing arginine within the TME also 
raises the question; can this method of arginine depletion cause cell death in 
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arginine auxotrophic tumour cells? This was recently evaluated in ASS1 
negative melanoma (274), and results revealed that arginase depletion of 
arginine by TAM did result in the direct inhibition of B16-F1 melanoma cell 
proliferation in vitro. However, importantly, it was also noted that the ratio of 
macrophages (effector, E) to tumour (T) cells impacted tumour survival: low 
E:T ratios (<4:1) increased tumour growth, whereas only much higher E:T 
ratios (>10:1) elicited anti-tumour immunity. It was suggested that above a 
certain E:T ratio, macrophages release enough arginase to deplete arginine 
adequately from the TME to inhibit growth in arginine auxotrophic melanoma 
cells. However, at lower E:T ratios, more representative of the TME, the 
arginine depletion would be insufficient to have a negative effect on tumour 
growth, and instead the tumour promoting properties of TAM remain 
dominant.  
 
Lastly, a subpopulation of macrophages found within hypoxic regions of 
tumours express low levels of major histocompatibility complex (MHC) II. The 
decrease in MHC II expression in this population supports an 
immunosuppressive phenotype (275). 
 
1.5.4.1.3.4 Tumour cell proliferation 
 
 
TAMs secrete an array of cytokines, chemokines and growth factors that can 
stimulate the differentiation and proliferation of other cells. Indeed, 
macrophage-elicited PDGF and TGFβ are known to stimulate the 
differentiation of fibroblasts and myofibroblasts. It seems plausible then, as 
postulated by Mantovani (276), that these and other growth factors might also 
promote the differentiation and proliferation of malignant cells. Furthermore, 
arginase generates urea and ornithine, the latter a precursor for various 
polyamines produced via ornithine decarboxylase (ODC), and proline via 
ornithine aminotransferase, thereby playing an important role in tumour cell 
proliferation and collagen production, respectively (112). Indeed, it has been 
demonstrated that TAM infiltration is positively correlated with the proliferation 
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of tumour cells in several tumours, such as breast cancer, endometrial 




































































Figure 1.7. The various pro-tumoural effector functions of TAM. Abbreviations: FGF, 
fibroblast growth factor; IL, interleukin; MMP, matrix metalloproteinase; NO, nitric oxide; PG, 
prostaglandin; TAM, tumour-associated macrophage; TNF, tumor necrosis factor; 
TGF, transforming growth factor; VEGF, vascular endothelial growth factor. Adapted from 








TAMs are not a single uniform population; thus, their phenotype and role are 
not entirely consistent amongst cancers. Indeed, multiple specialised 
macrophage subpopulations within each tumour appear to have very different 
roles in supporting tumour progression. Therefore, detailed study of the 
specific features of TAM in individual tumour types is required in order to gain 
a better understanding of the role these phenotypically diverse cells play in 














1.5.5 TAM and mesothelioma 
 
 
Inflammation is an early and consistent feature of mesothelioma and 
macrophages are key regulators of the link between inflammation and cancer. 
Macrophages are involved in mesothelioma development from the initial 
introduction of asbestos fibres into the lung, when they are recruited and 
activated both by mesothelium-derived inflammatory factors and by the 
engulfment which they themselves undergo in an attempt to clear away the 
fibres. These events trigger a long-lasting inflammation, directly influencing 
mesothelioma tumourigenesis (279). 
 
 As with many other epithelial tumours, macrophages infiltrating the 
established mesothelioma tumour mass constitute the majority of infiltrating 
leukocytes, accounting for up to 30% of the solid mass (248). Indeed, 
Hegmans et al identified macrophages as the most representative immune 
cell type in human MPM biopsies (280), and Burt et al retrospectively 
reviewed 667 cases of MPM patients who underwent cytoreduction between 
1989 and 2009, reporting that all the biopsies showed high levels of TAM 
infiltration, mainly characterised by the immunosuppressive phenotype 
expressing high levels of CD163, CD206 and IL-4 receptor α (248) . Similar 
findings were observed by Bielefeldt-Ohmann and colleagues (281), who 
demonstrated that TAM infiltrating mesothelioma in an orthotopic murine 
model exhibited low or absent expression of class-II MHC and integrins, 
indicating their polarisation towards an altered, immunosuppressive (M2) 
phenotype. Furthermore, it was recently demonstrated that C57 Black 6 
(C57/B6) mice transplanted with malignant mesothelioma cells also had 
macrophages with an immunosuppressive phenotype that expressed arginase 
and F4/80, both in solid tumours and spheroids (282).  
 
Notably, as for other solid tumours, high TAM counts are inversely correlated 
with the survival of patients with mesothelioma. The prognostic significance of 
both circulating blood monocytes and TAM was evaluated and it was found 
that higher numbers of circulating blood monocytes are associated with poor 
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survival in patients with both epithelial and non-epithelial mesothelioma and 
that a high TAM count was negatively correlated with the survival of patients 
with non-epithelioid mesothelioma, independent of tumour stage (248). A 
more recent study found that the macrophage CD163/CD68 ratio 
(representative of M2 phenotype) negatively correlated with overall survival in 
epithelioid mesothelioma (283). 
  
The immunosuppressive nature of TAM in mesothelioma has been widely 
reported (280) (284). In addition, other pro-tumoural functions of TAM, 
including promotion of mesothelioma growth, invasion and metastasis, have 
also been described. For example, when investigating the effects of 
macrophage depletion on tumour progression, Veltman et al. reported that 
tumour weights in mice injected with lethal doses of AC29 tumour cells (a 
murine malignant mesothelioma cell line) were drastically decreased following 
macrophage depletion with liposomal clodronate (285).  Miselis et al also 
demonstrated that macrophage depletion with liposomal clodronate 
significantly reduced the number of tumours, the area of tumour burden and 
the percentage of liver and lung metastasis in an orthotopic, 
immunocompetent murine model of diffuse peritoneal mesothelioma (282).  
 
These studies identify TAM as abundant and important host-derived cells that 
contribute to development, growth, invasion and metastasis in mesothelioma. 
 
1.5.5.1 Myeloid-derived suppressor cells 
 
In addition to TAM, it is also important to mention a group of cells collectively 
called myeloid-derived suppressor cells (MDSC). These cells have been 
found to accumulate in some solid tumours, including MPM, during tumour 
progression and are recognised as being immunosuppressive. In mice, MDSC 
are defined as being CD11b+ and Gr1+, therefore incorporating a mixed 
population of both monocytic and granulocytic cells (286). The majority of 
these cells are granulocytic and will not be discussed here. The smaller group 
are Ly6C+ Ly6G –, and are monocytic in origin, therefore termed monocytic 
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MDSC (M-MDSC). These immunosuppressive cells display low expression of 
MHC class II and are also co-stimulatory molecule low or negative, indicating 
that they do not directly induce anti-T cell activity. Instead, they highly express 
TGF-β and arginase, promoting nonspecific immune suppression. In an 
orthotopic murine model of mesothelioma, it was found that MDSCs arise late 
in tumour development and their appearance is preceded by the accumulation 
of TAM and T cells. Furthermore, the expansion of the MDSC population was 
described as being concurrent with that of the tumour burden, leading to the 
hypothesis that MDSCs are required for tumour progression and outgrowth in 
MPM (287). It is currently unclear whether these cells accumulate in 
excessive numbers in tumours as a transient to mature macrophages (or 
TAM), or whether M-MDSC represent a monocyte-derived terminal sub-type. 
Regardless, these are important myeloid-derived cells that influence the 
immune response within the TME (286, 288). 
 
 




Despite increasing recognition of the involvement of macrophages in cancer 
invasion and progression, their role in mediating drug resistance has received 
comparatively little attention amongst researchers until recently. Earlier 
studies had suggested that the sensitivity of myelomas to melphalan and 
mitoxantrone may be influenced by macrophages (289, 290). More recently, a 
number of independent studies have revealed that macrophages can mediate 
chemotherapy resistance by modulating cellular immunity, providing survival 
factors, and/or activating anti-apoptotic pathways in tumour cells. For 
example, it was demonstrated that the response of mammary tumour-bearing 
mice to paclitaxel could be regulated by macrophages in CD8+ T-cell 
dependent mechanisms: here, the inhibition of TAM recruitment improved 
chemosensitivity, reduced tumour progression and reduced metastasis, 
associated with an increased survival of CD8+ T-cells (291). Furthermore, 
Shree et al. showed that cathepsin-expressing macrophages protect breast 
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cancer cells from cell death induced by the following chemotherapeutic drugs: 
taxol, etoposide and doxorubicin. They reported that the combination of anti-
cathepsin with taxol treatment enhanced the anti-tumour efficacy, the late-
stage survival and decreased metastatic burden compared to taxol alone in a 
breast cancer mouse model (292).  
 
In addition, in pancreatic adenocarcinoma (PDA), macrophages were found to 
induce chemoresistance by reducing gemcitabine-induced apoptosis, via up-
regulation of tumoural cytidine deaminase, the enzyme that metabolises 
gemcitabine (293).  
 
It has also recently been reported that macrophage-derived TNF-α provides 
resistance to mitogen activated protein kinase (MAPK) pathway inhibitors in 
melanoma through NF-κβ- dependent expression of microphthalmia 
transcription factor (294).  Inhibiting TNF-α signaling with IκB kinase inhibitors 
profoundly enhanced the efficacy of MAPK pathway suppression by targeting 
not only the melanoma cells but also the microenvironment. Another study 
reported that macrophages play a critical role in melanoma resistance to 
BRAF inhibitors, via the production of VEGF, which reactivates the MAPK 
pathway and stimulates cell growth (295).  
 
On the other hand, there is also evidence that activation or re-activation of 
immune responses is a key component of the anti-neoplastic efficacy of drugs 
such as Doxorubicin (233). Specifically, in a model of breast cancer, 
Doxorubicin reduced the levels of MDSCs, improving the efficacy of adoptive 
transfer of T cells (296). Macrophages can also contribute in other ways to the 
modulation of tumour response to chemotherapy. For example, the antitumor 
activity of docetaxel involves the depletion of immunosuppressive (M2-like) 
TAM and the concomitant activation or expansion of antitumoral (M1-like) 
monocytes/MDSC in 4T1-Neu mammary tumour implants. Indeed, in vitro 
T cell assays showed that the docetaxel-treated M1-like monocytes/MDSC 




Therefore, it is clear that different mechanisms regulate TAM functions during 
chemotherapy and other forms of therapy, and this can either enhance or 
antagonize the activity of the anticancer drug, depending on the type of 
treatment and the tumour model (298). As TAM have been shown to nurture 
mesothelioma cells and promote tumour progression, could they also be 






















Tumour-associated macrophages are an integral part of the interaction 
between cancer cells and their microenvironment.  
 
My thesis is driven by the hypothesis that macrophages maintain the right 
metabolic environment in MPM to support tumour growth. Under conditions of 
arginine deprivation, this results in the provision of arginine (or its precursors) 
to the arginine auxotrophic tumour cells, thereby mediating resistance to ADI-






































The aims of this thesis were to determine whether macrophages are critical 
modulators of the response of ASS1 negative MPM cells to the arginine-
depleting agent ADI-PEG20, to establish how macrophages mediate tumoural 
resistance to ADI-PEG20 and, finally, to develop strategies to overcome 
macrophage-mediated MPM resistance to arginine depletion.  
 
 
The specific aims of each chapter are detailed below. 
 
 
Aims of Chapter 3: 
 
 To validate the ADI-PEG20-induced pro-inflammatory gene expression 
signature identified in ASS1 negative mesothelioma cells 
 To determine how ADI-PEG20 provokes a pro-inflammatory cytokine 
response in ASS1 negative mesothelioma cells 
 To assess whether the in vitro pro-inflammatory cytokine response is 
relevant in vivo. 
 
Aims of Chapter 4: 
 
 To investigate whether macrophages are able to modulate the 
therapeutic response of ASS1 negative mesothelioma cells to ADI-
PEG20 
 To identify mechanisms behind the macrophage-mediated resistance  
 
 
Aims of Chapter 5: 
 
 To evaluate whether targeting macrophages in combination with ADI-
PEG20 potentiates the cytotoxic effect of ADI-PEG20 in vivo. 
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Chapter 2. Materials and Methods  
 
2.1 Cell Culture 
 
 
The tumour cell lines MSTO, H226 and H28 were obtained from American 
Type Culture Collection (ATCC; Manassas, USA), 2591 was obtained from 
Professor Pasi Janne (Harvard, USA), and Ju77 was obtained from Professor 
Ken O’Byrne (Dublin, Ireland). All cell lines were Short Tandem Repeat (STR) 
profiled to ensure quality and integrity. Buffy cones of lymphocyte-rich 
peripheral blood from healthy volunteers were obtained from the National 
Blood Service (Tooting, London). All cells were cultured at 37° in a humidified 
atmosphere of 5% CO2. 
 
2.1.1 Tumour cell lines (MSTO, Ju77, 2591, H28 and H226) 
 
 
All tumour cell lines were maintained in endotoxin free-RPMI 1640 media 
supplemented with 10% heat-inactivated fetal bovine serum (FBS; Gibco® 
Life Technologies) in T175 flasks (Corning). Cells were split 1:6 when 
confluency of 80%-90% was reached. The cells were washed with phosphate 
buffered saline (PBS) and then incubated for up to five minutes at 37°C with 
5mls of 1x trypsin-EDTA (Gibco®, Life Technologies). Once the majority of 
cells had detached from the flask the trypsin-EDTA was quenched by the 
addition of an equal volume of RPMI. Cells were collected and then pelleted 
by centrifugation for 5 min at 1500 rpm. Cells were then re-suspended in 
RPMI and seeded at a density of ~1.5x106 cells per T175 flask. Similar 
passage numbers were used for all experiments. Cell lines were tested 




2.1.2 Human monocyte-derived macrophages 
 
2.1.2.1 Generation of macrophages from human peripheral blood mononuclear 
cells (PBMC) 
 
2.1.2.1.1 Purification of leukocytes 
 
Two ‘Buffy cones’ of lymphocyte-rich peripheral blood from healthy human 
donors were purchased from the National Blood Service and stored at 4ºC to 
maintain cell viability. Cones were always used within 24 hours of delivery. In 
a large 175cm3 flask the combined 100ml volume of the two ‘buffy cones’ was 
added to 180mls of sterile PBS and mixed. 15mls of Ficoll-PaqueTMPLUS (a 
density gradient media used for the separation of PBMCs; GE Healthcare) 
was added to each of eight 50ml capacity polypropylene centrifuge tubes 
(Corning). 35ml volumes of ‘buffy cone’ mixture were carefully layered onto 
the Ficoll-PaqueTMPLUS at an oblique angle, using a pipette controller set to 
gravity powered expulsion only. The full tubes were then spun at 1200rcf for 
60 minutes at 4ºC, set to decelerate slowly without a break. 
 
Spun tubes were handled extremely carefully to avoid agitation and mixing of 
the separated layers. The lymphocyte–rich white layer was then aspirated 
from the middle, between the plasma above and the red cell-rich layer 
beneath, and mixed with sterile PBS in each of eight 50ml centrifuge tubes 
(see Figure 2.1). The tubes were spun at 1400rpm for 10 minutes and the 
supernatant aspirated and discarded. The pellet from each tube was re-
suspended in Pharma LyseTM (BD Biosciences) red cell lysis buffer and left for 
5 minutes at room temperature, then spun at 1400rpm for 5 minutes. The 
























Figure 2.1. Diagram demonstrating the different layers following Ficoll separation. The 
lymphocyte-rich layer is shown in white. 
Blood 
Ficoll 





Layers before Ficoll Spin Layers after Ficoll Spin 
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2.1.2.1.2 Magnetic bead and column positive selection of CD14+monocytes 
 
MACS buffer was made up as follows: 
 
500mls PBS (without calcium and magnesium) 
2.5g  Bovine Serum Albumin 
2ml  500mM EDTA 
 
This was mixed until fully dissolved, before sterile filtration.  
The pellets were re-suspended and pooled in 50mls MACS buffer and a 550µl 
aliquot sampled to calculate cell number and viability by trypan blue exclusion 
assay using a Beckman Coulter Vi-CELL™ XR viability analyser. The 
remaining cells in MACS buffer were spun at 1400rpm for 5 minutes and re-
suspended in MACS buffer at 1.25x108cells/ml.  
 
Human anti-CD14 MicroBeads (Miltenyi Biotec) were mixed with cells at a 
dose of 1ml per 5x108 cells and placed at 4ºC to stain for 15 minutes.  
This mixture was then made up to a total volume of 50mls with MACS buffer 
and spun at 1400rpm for 5 minutes, before re-suspending in 8mls of MACS 
buffer. 
 
2 LS+ columns (Miltenyi Biotec) were placed into appropriate holders on a 
MidiMACS magnet and primed with 4mls each of MACS buffer. 4mls of CD14-
labelled cell suspension was then passed through each column. 3 washes of 
4mls each of MACS buffer were run through each column and the run-through 
was discarded. Each column was then individually removed from the magnet 
and vigorously flushed with 5mls MACS buffer, forcing through with a column 
plunger. This flush was collected, made up to 50mls with DMEM, and spun at 
1400rpm for 5 minutes. The pellet was re-suspended in DMEM with 5% 
Human AB serum (Sigma-Aldrich) for differentiation into mature 
macrophages, and placed into 150mm x 25mm sterile cell culture dishes 
(Corning). A sample of cells was taken prior to transferring to the culture 
dishes for FACS analysis to assess the purity of CD14+ve cells (detailed in 
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section 2.9.2): >97% of cells were consistently CD14+ve by FACS analysis 
(see Figure 2.2).  The culture dishes were incubated at 37ºc in 5% CO2 for 8 
days to allow differentiation. 
 
After 8 days the differentiated macrophages were washed with warm PBS and 
gently detached using cold PBS and a cell scraper. The cell suspension was 
poured into a sterile flask and viable cells were counted from a 550µl aliquot 
using the Beckman Coulter Vi-CELL™ XR cell viability analyser. Mature 
macrophages were then ready for immediate use in co-culture experiments 
































Figure 2.2. Flow cytometry analysis assessing the % of CD14 positive cells following 
MACS selection. Cells were prepared for flow cytometry as described in section 2.9.2. The 
raw data presented here is a representative example of cell purity obtained following 




2.1.2.2 Matured macrophages 
 
Matured macrophages were maintained in endotoxin free-RPMI 1640 media 
supplemented with 10% heat-inactivated FBS, as for the tumour cell lines. 
Macrophages were used immediately in experiments once matured. They 
were not split as they were fully differentiated at the time of use.  
 
2.1.3 Freezing and thawing cells 
 
 
The following procedure was used to cryogenically store all tumour cell types 
used. Monocytes/macrophages were always used in experiments immediately 
after maturation and were therefore not cryogenically stored.  
 
Live cell pellets were re-suspended in 45% RPMI, 45% FBS and 10% 
dimethyl sulphoxide (DMSO). The cell suspension was aliquoted into 
cryovials, which were insulated in polystyrene containers and placed at -80°C 
for 48 h before being transferred into liquid nitrogen for long term storage. 
 
Frozen cells were recovered by placing a frozen cryovial immediately into a 
37°C water bath until thawed. The thawed cell suspension was added to 
10mls of pre- warmed RPMI and then spun at 1200rpm for five minutes. The 
supernatant was removed and the cell pellet was re-suspended in RPMI and 
placed into a T175 flask. 
 
2.2 Transfection techniques 
 
2.2.1 ASS1 overexpression 
 
Human ASS1 cDNA was cloned into pIREShyg3 (Clontech Laboratories, UK) 
to produce ASS1 pIREShyg3. Ju77 cells were transfected with empty vector 
or ASS1 pIREShyg3 using Effectene (Qiagen) according to the 
manufacturer’s instructions. Stable, pooled populations of transfectants were 
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obtained following selection with hygromycin (200µl/ml) for three to four 
weeks. Ju77 ASS1 overexpression was performed by Dr Barbara Delage.  
 
2.2.2 ASL/XBP1 SiRNA transfection 
 
SiRNA ASL (SMARTpool, Dharmacon) 20µM stock; SiRNA XBP1 
SMARTpool, Dharmacon) 20µM stock; SiControl (Dharmacon) 100µM stock.  
 
To establish ASL/XBP1 knockdown in the tumour cells, 2x104 tumour cells 
were seeded in each well of a 6 well plate. After 24 hours (at approximately 
30% confluent), either the SiRNA or SiControl was added at a concentration 
of 50nM to 1.5ml Eppendorfs containing 200µl of serum free RPMI media 
(one Eppendorf per well). 10µl of INTERFERin™ (Peqlab, Fareham, UK) was 
then added to each of the Eppendorfs and these were vortexed for 10 
seconds. The Eppendorfs were then incubated at room temperature for 10 
minutes. At the same time, media was removed from the cells and discarded. 
2mls of RPMI 10% FBS was then added to each well followed by the addition 
of the 200µl of either SiRNA or SiControl into the appropriate wells and gently 
mixed. After 8 hours, the media was replaced with 2mls RPMI 10% FBS. 
Plates were incubated at 37ºc for either 24 hours (XBP1), or 48hrs and 96hrs 
(ASL). RNA was then extracted as described in section 2.5 to confirm 
knockdown.  
 




ADI-PEG20 (Polaris Pharmaceuticals) is arginine deiminase (ADI), a 
mycoplasma – derived enzyme, formulated with polyethylene glycol (PEG) of 
20,000 dalton molecular weight to increase the circulating half life and 
decrease antigenicity of ADI, that catabolises circulating arginine to yield 
citrulline and ammonia. This was used at a dose of 750ng/ml in all in vitro 
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experiments and at a dose of 5IU for all in vivo experiments unless otherwise 
specified.  
 
2.3.2 Liposomal Clodronate and Liposomal PBS 
 
Liposome preparations were obtained from Dr Nico van Rooijen, Department 
of Molecular Cell Biology, Vrije Universiteit, Amsterdam. Liposomes contained 
either clodronate at 7 mg/ml, or simply PBS as a vehicle control, which were 
manufactured by Dr van Rooijen as previously described (299). Animals were 
injected into the peritoneum with 200µl of Liposomal Clodronate 





Tunicamycin (Sigma-Aldrich) was used to induce endoplasmic reticulum 




SB 225002 (Cayman Chemical) is a selective non-peptide inhibitor of CXCR2. 
This was dissolved in 100% ethanol to give a soluble concentration of 
10mg/ml. The stock solution was then further diluted to give the desired 
concentration using sterile PBS to ensure any residual amount of ethanol was 
insignificant for use in experiments. Concentration used for in vitro 
experiments: 750nM. Concentration used for in vivo experiment: 1mg/kg 
SB225002 made up to 100µl in sterile PBS. 
 
2.3.5 Recombinant human cytokines 
 
Recombinant human IL-8, CXCL2, CXCL3, IL-1 alpha and VEGFA were 
purchased from R&D Systems. These were used in in vitro assays at optimal 
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concentrations of: 100ng/ml for IL-8, 1ng/ml for IL-1α, and 10ng/ml of CXCL2, 
CXCL3 and VEGFA. 
 
2.3.6  Argininosuccinic Acid (ASA) 
 
Argininosuccinic acid disodium salt hydrate was purchased from Sigma-
Aldrich (UK). This was dissolved in distilled water to give a stock 
concentration of 50mg/ml (MW 334.24g/mol). This was used at concentrations 
of 0.25mmol/l - 2mmol/l.  
 
 




Cells were seeded at 2.5 x 103 cells per well on 96 well plates and cultured in 
100µl RPMI 10% FBS for 24 hrs. The following day the media was changed 
and 100µl of ADI-PEG20 was added to achieve a final concentration range of 
between 0 and 20,000ng/ml. Cell viability was determined after 6 days, using 
the Cell Proliferation assay kit (Promega) that contains the tetrazolium salt 3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium known as MTS, used in conjunction with the electron coupling 
reagent phenazine methosulfate (PMS). Mitochondrial enzymatic activity in 
viable cells reduces MTS to the water-soluble product formazan, and this 
reduction is facilitated by PMS. The number of living cells is directly 
proportional to the concentration of formazan in the sample, determined by 
the absorbance at 490nm. After 6 days media was removed and replaced with 
20µl of MTS/PMS in a 20:1 ratio added to a final volume of 100µl RPMI per 
well. Plates were incubated for up to 4 hours and following this the plate was 
read at 490nm using an OpsysMR plate reader (DynexTechnologies Inc, 
Chantilly, US).  Cell survival was normalised for background absorbance and 







2.4.2 Liposomal Clodronate (CLIP) 
 
 
Cells were seeded at 2.5 x 103 cells per well on 96 well plates and cultured in 
100µl RPMI 10% FBS for 24 hrs. The following day the media was changed 
and 125µl CLIP was added to achieve a final range of between 0 and 125µl. 
Cell viability was determined after 6 days, as described above.  
 
2.4.3 ADI-PEG20 plus argininosuccinic acid (ASA) 
 
 
Cells were seeded at 2.5 x 103 cells per well on 96 well plates and cultured in 
100µl RPMI 10% FBS for 24 hrs. The following day the media was changed 
and ADI-PEG20 was added at a concentration of 750ng/ml, plus ASA at 
concentrations of 0.25mmol/l, 0.5mmol/l, 1mmol/l and 2mmol/l, in 100µl RPMI 
10% FBS. Cell viability was determined after 4 days as described above. 
 
 
2.5 Real-time PCR analysis 
 
2.5.1 RNA extraction 
 
Cells were washed 3 times in PBS and 350µl Buffer RLT lysis buffer (Qiagen) 
was added to each well to disrupt the cells. RNA was then extracted 
according to tailored protocols from the RNeasy Mini Handbook (Qiagen).  
 
Each of the 350µl cell lysate samples was transferred into a QIAshredder spin 
column placed in a 2 ml collection tube and spun for 2 minutes at full speed in 
an Eppendorf Microcentrifuge. The supernatant was transferred to a fresh 2ml 
collection tube. 350µl of 70% Ethanol was added and thoroughly mixed by 
pipetting. 700µl of each sample was transferred to an RNeasy spin column 
placed in a 2 ml collection tube and spun for 15 seconds at 10,000G. The flow 
through was discarded. On-column DNase digestion was then performed. 
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350µl of Buffer RW1 was added to each sample and spun for 15 seconds at 
10,000G. The flow through was discarded and 80µl of DNase solution in 
Buffer RDD was added directly to the RNeasy spin column and left at room 
temperature for 15 minutes. 350µl of Buffer RW1 was then added to the 
RNeasy spin column and spun for 15 seconds at 10000G, with the flow 
through being discarded. 500µl Buffer RPE was added to the RNeasy spin 
column and spun for 15 seconds at 10,000G, and the flow through discarded. 
This step was repeated but spinning for 2 minutes to dry the RNeasy spin 
column membrane, and the flow trough discarded. The RNeasy spin column 
was placed in a new 2ml collection tube and spun for a further 1minute at full 
speed without the addition of buffers to ensure there was no ethanol carry 
over. The column was then carefully removed and placed in a fresh collection 
tube. Between 15µl and 30µl (depending on the expected yield of RNA) of 
RNase-free water was added directly to the column and spun for 1 minute at 
10,000G to elute the RNA. The flow through was collected in a labelled 1.5ml 
collection tube and stored at -80°C until required. 
 
2.5.2 RNA analysis 
 
Purity and quantity was analysed using the ND1000 Spectophotometer, 
reading absorbance at 260/280nm (NanoDrop, Wilmington, US). All samples 
were expected to exhibit a 260/280 ratio of approximately 2, indicating that the 
RNA was pure and free of contaminants.  
  
2.5.3 Reverse transcription of RNA to yield cDNA 
 
Complimentary DNA (cDNA) synthesis was carried out using the Applied 
Biosystems High Capacity cDNA Reverse Transcription (RT) Kit on a thermal 
cycler as per the manufacturer’s instructions.  
 






Per 20µl reaction: 
2µl 10x RT Buffer 
2µl 10x Random Primers 
1µl MultiScribe™ Reverse Transcriptase (50Units/µl) 
0.8µl 25x dNTP mix (100mM) 
4.2µl Nuclease-free water 
 
This was mixed gently and added to 10µl of RNA sample.  
Each sample was briefly centrifuged to eliminate air bubbles before being 
before being placed in the thermal cycler. The reaction conditions in the 
thermal cycle were as follows: 25°C for 10 minutes, 37°C for 120 minutes, 
85°C for 5 minutes. Samples were then cooled to 4°C.    
Each 20µl tumour cell cDNA sample was then diluted with distilled water to 
give a final concentration of 20ng/µl cDNA. Each 20µl macrophage cDNA 
sample was diluted to give a final concentration of 5ng/µl (due to less RNA 
being yielded). Samples were stored at -20ºC until required.  
 
2.5.4 Quantitative RT-PCR (qRT-PCR) 
 
Analyses were performed using the ABI Prism 7500 Sequence Detection 
system Instrument and software (PE Applied Biosystems). qRT-PCR was 
performed using sample cDNA (FAM), an internal control 18sRNA (VIC) and 
specific TaqMan® probes.  
 
qRT-PCR was carried out using the TaqMan® Universal PCR Master Mix (PE 
Applied Biosystems) in a 96 well plate. Each well contained the following 
reagents to make up a total volume of 25µl: 
 
12.5µl TaqMan® Universal PCR Master Mix 
8µl DEPC H20  
2µl Sample cDNA 
1.25µl Probe/primer set for gene of interest 
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1.25µl Probe/primer set for 18sRNA 
 
 
The cycling program consisted of 10min at 95°C followed by 40 cycles of 
95°C for 15 sec and 1 min at 60°C.  
All samples were tested in duplicate.  
Target mRNA was normalised (∆CT) to 18sRNA by subtracting the cycle 
threshold (CT) of the 18sRNA sample from the cycle threshold (CT) of each 
sample.  
 
The expression level of each target gene in the treatment group samples was 
determined relative to the initial experimental controls: 
 
∆∆CT = ∆CT treatment - ∆CT control group 
This was expressed as a fold change in gene expression using the formula: 
 
Fold change = 2-∆∆CT 
 
 
2.6 Western Blot 
 
2.6.1 Protein Extraction 
 
For extraction, NP40 lysis buffer (50mM Tris-HCL pH 8, 150mM NaCl, 1% 
NP40) was used with a proteinase inhibitor added at a concentration of 1 in 
50 and a phosphatase inhibitor added at a concentration of 1 in 20 (Roche 
Diagnostics, UK).  
 
To remove any traces of medium, cells were washed twice with cold PBS. 
The plates were then placed on ice, to prevent evaporation and reduce 
protein degradation, and protein was extracted by adding 50µl NP40 lysis 
buffer directly into wells (6-well plates). Cells were harvested using a cell 
scraper (BD Falcon, UK) and collected in a 1.5 ml Eppendorf tube. Samples 
were vortexed and incubated on ice for 15 minutes before centrifugation at 
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14000G for 10 minutes at 4ºC to pellet the cell debris. The supernatant 
containing the protein was removed and stored at -80°C until required for 
immunoblotting.  
 
2.6.2 Protein concentration assay 
 
For protein quantification a working reagent was prepared by combining 1 part 
Bio-Rad with 4 parts water. Protein standards were produced by performing 
serial dilutions of the provided albumin (BSA) stock (2µg/µl; Sigma-Aldrich) in 
ddH20 to give standards at the following concentrations: 0.1, 0.25, 0.5, 0.8, 1, 
1.4µg/µl protein. The standards could be kept at 4°C for two to three weeks, 
or at -20°C for long-term storage. Protein samples were diluted 1 in 10 and 
10µl of diluted protein or standard (in triplicate) was plated in a 96 well plate 
with 200µl of working reagent and incubated at room temperature for 30 
minutes. Samples were then read using a plate reader at 595nm.  
 
2.6.3 Western Blotting 
 
The range of protein concentrations amongst all the samples from the same 
experiment as determined by the plate reader was examined and then the 
same amount of protein for each sample (10-30µg) was made up to the same 
total volume with distilled water. The protein samples were then mixed with 
Sample Buffer (62.5mm tris-HCl, 2% SDS, 25% glycerol, 0.01% bromophenol 
blue, 1mM DTT) at a ratio of 1 in 4 (sample buffer to protein sample). Prior to 
loading, the protein samples were denatured by heating at 95ºC for 10 
minutes. Samples were then spun down and allowed to cool. For each gel, 
10µl of Color Pre-stained Protein Standard, Broad Range (11-245 kDa) (NEB) 
was also mixed with sample loading buffer at the same ratio as the samples 
and made up to the same total volume as the samples using distilled water.  
 
Protein was separated in pre-cast 4-12% Bis-Tris NuPAGE gels (Invitrogen, 
UK) using 1 x MOPS buffer (50mM MOPS, 50mM Tris Base, 0.1% SDS, 1mM 
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EDTA). The gel was run at 150V for 45 minutes-1 hour, until the bromophenol 
blue marker ran off the bottom of the gel.  
Next, proteins on the gel were transferred onto a nitrocellulose membrane at 
20 V for 45 min using a semi-dry transfer apparatus (Bio-Rad) and transfer 
buffer. Prior to transfer the membrane was activated by being soaked in 
methanol for 1 minute, washed in distilled water, then equilibrated in transfer 
buffer (9.6mM glycine, 1.2mM Tris base, 10% methanol in distilled water). All 
Extra ThickBlot Paper (Bio-Rad) used for the transfer was previously soaked 
in transfer buffer and the negative electrode of the transfer apparatus was wet 
with transfer buffer. 
 
 
Following transfer, the membrane was blocked in blocking solution (5% (w/v)) 
milk powder in PBS) for 1 hour at room temperature.  The membrane was 
then incubated in primary antibody diluted in blocking buffer (normally 5% milk 
powder unless the manufacturer’s instructions specified blocking in 5% BSA, 
1x TBS, 0.1% Tween® 20 as for phosphorylated NFкB) overnight at 4ºC on a 
roller mixer. The primary antibodies used and the dilutions at which they were 
used are listed in Table 2.1. The membrane was then washed 3 times for 10 
minutes in wash buffer (PBS/Tween® 20 0.05%) and incubated with the 
appropriate horse-radish peroxidase (HRP) conjugated secondary antibody 
diluted 1/1000 in blocking solution and incubated for 1 hour at room 
temperature on a roller mixer.  The secondary antibodies used are listed in 
Table 2.2. The membrane was washed a further 3 times for 10 minutes in 
wash buffer before incubation in Amersham ECL (GE Healthcare, UK). For 
ECL, Reagents 1 and 2 were mixed 1:1 and used to completely cover the 
membrane for 3 minutes incubation at room temperature. Excess ECL was 
removed from the membrane and the resulting chemiluminescence signal was 
detected with Amersham Hyperfilm™ ECL (GE Healthcare).   
Re-incubation with a β-actin antibody for 1 hour provided a loading control.  
 
After development, ECL was washed off with 3 x 10 minute washes at room 
temperature. The membrane was then incubated with Restore™ Western Blot 
Stripping Buffer (ThermoScientific) for 10 min at room temperature with 
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rocking. The stripping buffer was removed with 3 x 10 minute washes at room 
temperature. The membrane was then dried out, wrapped in clingfilm and 
stored at -20°C. 
 
 
Protein Raised in Made by Clone Dilution Reagent 
ASS1 Mouse BD 
Biosciences 
Monoclonal 1:200 ECL 
ASL Rabbit Sigma-Aldrich Polyclonal 1:200 ECL 
XBP1  Rabbit Santa Cruz Polyclonal 1:50 ECL 
β-actin Mouse Dako Monoclonal 1:10000 ECL 
NFкB Rabbit Cell Signalling Monoclonal 1:200 ECL 
 
 






Raised in Anti- Made by Dilution 
Rat Mouse Dako 1:1000 
Goat Rabbit Dako 1:1000 
 





2.7 Enzyme-linked immunosorbent assay (ELISA) 
 
2.7.1 Cell Supernatants 
 
Quantikine ELISA kits (R&D Systems) were used to measure levels of 
VEGFA, IL-8 and IL-1α in the supernatant. For the cell line MSTO, 
measurement of these cytokines was repeated using Meso Scale Discovery® 
(MSD) ELISA kits (see section 2.7.2 for further detail on MSD ELISAs) to 
confirm the high concentration of these cytokines present in MSTO cell 
supernatant.  Human GRO-beta and GRO-gamma ELISA Construction kits 
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(Antigenix America Inc.) were used to measure supernatant levels of CXCL2 
and CXCL3, respectively.  
 




2.7.1.1.1. Assay Principle 
 
This is a Sandwich immunoassay. The 96-well plate is pre-coated with 
capture antibody. Samples or standards are added and any analyte present is 
bound by immobilised antibody. Unbound materials are washed away. 
Secondary HRP-labeled (detection) antibody is added and binds to the 
captured analyte. Tetramethylbenzidine (TMB) substrate solution is added to 
the well and a blue colour develops in proportion to the amount of analyte 
present. Colour development is stopped and absorbance of the colour at 
450nm is then measured.  
 
2.7.1.1.2 Reagent preparation 
 
All reagents were brought to room temperature before use. 
The substrate solution was prepared by mixing Colour reagents A + B in equal 
volumes 15 minutes prior to use.  
 
Standards were reconstituted with the appropriate Diluent to create an 8-point 
standard curve, described in Table 2.3 below.  
 
 




VEGFA RD5K 2000 – 0 5 
IL-8 RD5P 2000 – 0 3.5 
IL-1α RD5-5 250 – 0 <1 
 
 







2.7.1.1.3 Assay procedure 
 
50µl of the appropriate assay Diluent was added to each well, followed by 
200µl of the standard or sample. The plate was sealed and incubated at room 
temperature for 2 hours. The plate was aspirated and thoroughly washed 
three times with PBS plus 0.05% Tween®20, and 200µl of conjugate was 
added to each well, the plate sealed and incubated for a further 2 hours. The 
plate was then aspirated and washed as before and 200µl of substrate 
solution was added to each well for 20 minutes, protected from the light. 50µl 
of stop solution was the added directly to each well of the plate and the plate 
was read within 30 minutes.   
 
2.7.1.2 Antigenix America (CXCL2 and CXCL3) 
 
2.7.1.2.1 Assay principle 
 
The assay principle is as described in 2.7.1.1.1 
 
2.7.1.2.2 Reagent preparation 
 
All reagents were brought to room temperature before use. 
The substrate solution was prepared by mixing Colour reagents A + B in equal 
volumes 15 minutes prior to use.  
Capture antibody was diluted to 1µg/ml in PBS 
Detection antibody was diluted to 0.25µg/ml in PBS 
 
Standards were reconstituted with 0.05% Tween®20, 0.1% BSA in PBS to 
create an 8-point standard curve, to give a concentration range of 625pg/ml-0. 
 
2.7.1.2.3 Assay procedure 
 
A portion of the capture antibody was diluted with PBS to a concentration of 
1µg/ml, and 100µl of this was added to each well of a 96 well plate. The plate 
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was sealed and left overnight at room temperature. The following day the 
wells were aspirated and plate washed 3 times with PBS plus 0.05% 
Tween®20. The plate was then blocked in 1% BSA for 1 hour followed by a 
washing step as previously described. 100µl standard or sample was added 
to each well in duplicate and the plate was sealed and incubated at room 
temperature for 2 hours. The plate was washed as previously described, 
followed by the addition of 100µl of 0.25µg/ml (Biotin tracer) detection 
antibody. The plate was sealed and incubated for 2 hours at room 
temperature. The plate was then washed as previously described. 100µl of 
Streptavidin-HRP conjugate (diluted 1:2000) was added to each well for 30 
minutes. The plate was washed as previously described and 100µl of 
substrate solution was added. After 20 minutes the stop solution was added 
(2N Sulfuric acid) and the plate was immediately read at 450nm. 
 
 
2.7.2 Human Plasma 
 
 
ELISA-based assays for analysis of cytokine concentrations in human plasma 
samples were purchased from Meso Scale Discovery® (MSD), (Maryland, 
USA). Sample cytokines (VEGFA, IL-1α and IL-8) were measured using a 
Custom V-PLEX Assay, specifically designed to analyse the cytokines of 
interest.  CXCL2 and CXCL3 concentrations were analysed using the ELISA 
construction Kits from Antigenix America (see section 2.7.1.2).  
 
2.7.2.1 MSD Assay principle 
 
 
The MSD plates are sandwich immunoassays. Each well of a 96-well plate 
contains independent and well-defined spots, each with a separate pre-coated 
specific capture antibody bound to a base-plate that can act as an electrode. 
The sample is added and binds to the capture antibody. A detection antibody 
is then added and will bind any sample antigen held by the capture antibody. 
The detection antibody is conjugated with electrochemiluminescent labels 
(MSD SULFO-TAG™). After incubation and washing steps, a read buffer is 
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added and the plate loaded to a MSD SECTOR™ Imager 6000 reader 
instrument. Here, a voltage is applied across the base plate electrode, 
causing any bound SULF-TAG molecules to emit light at an intensity 
proportional to the amount of bound sample. Multiple excitation cycles provide 
signal amplification, adding to the sensitivity of this technique. 
 
The Custom V-PLEX Assay I used contained the human pro-inflammatory 
panel 1 (for IL-8) and the human cytokine panel 1 (for VEGFA and IL-1α). 
There were individual spots in the wells of a 96 well plate, each coated with 
these cytokines.   
 
2.7.2.2 Reagent preparation 
 
 
All reagents were brought to room temperature except the Calibrator stock, 
which was thawed on ice. 
 
In order that an 8-point standard curve could be constructed, 4-fold serial 
dilutions of Calibrator were made from a first standard point solution prepared 
by combining 200µl of the human pro-inflammatory panel 1 V-PLEX calibrator 
blend with 200µl of the human cytokine panel 1 V-PLEX calibrator blend, 
brought to a final volume of 800µl with diluent 43. The final standard was 
Diluent 43 alone. This gave a range for the standard curves for each cytokine 
(detailed in table 2.4).   
 





Table 2.4. Standard curve range for each cytokine. 
 
 
60µl of each Detection antibody was added to Diluent 3 to make up a final 




Equal volumes of 4X Read Buffer and deionized water were mixed to give a 
2x working solution. 
2.7.2.3 Assay protocol. 
 
 
25µl of Diluent 2 was dispensed to each well of the pre-coated plate. 
25µl of sample plasma or Calibrator standard was then dispensed to 
individual wells in duplicate (resulting in a 2-fold dilution of sample plasma). 
The plate was sealed and agitated at 700rpm at room temperature for 2 
hours. The plate was washed 3 times with PBS plus 0.05% Tween®20. 25µl 
of 1X Detection Antibody Solution was dispensed to each well, and the plate 
sealed and agitated as before at room temperature for 2 hours. 
The plate was washed 3 times as before. 150µl of 2X Read Buffer was then 
dispensed using careful reverse pipetting into each well of the plate. This was 
to ensure no fluid bubbles were formed that might interfere with the 
subsequent plate reading process. 
The plate was read using MSD SECTOR ™ Imager 6000. This imager uses a 
charge-coupled device (CCD) camera. This digital imaging technology allows 
high quality images to be constructed from emitted light by converting 







Paraffin sections were dewaxed in xylene and immersed in 100% ethanol for 
5 minutes. Following this, endogenous peroxidase was blocked using 100% 
methanol and 3% hydrogen peroxide for 10 minutes, followed by rehydration 
of sections in graded alcohols. Antigens were retrieved by microwaving in pre-
heated 0.1M citrate (pH 6) buffer for 10 minutes (buffer:  2.94g Tri-sodium 
Citrate in 1000ml distilled water; pH adjustment using Acetic acid). Sections 
were incubated in horse serum (1:75) for 15 minutes and then drained. The 
appropriate primary antibody was then applied for 1hour at optimal dilution. 
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The primary antibodies and the dilutions at which they were used are listed in 
Table 2.5. After 1 hour sections were washed in two changes of PBS (5 
minutes each). This was followed by incubation with biotinylated secondary 
(1:200) for 40 minutes, further washes in two changes of PBS (5 minutes 
each), and incubation with horseradish peroxidise-conjugated avidin (ABC 
Standard: Vector Laboratories). After two more washes in PBS (5 minutes 
each), formation was detected by the use of 3,3’diaminobenzidine (DAB) 
chromogen (DakoCytomation) for 2 minutes.  Sections were then 
counterstained in Mayer Haematoxylin for 2 minutes. Once the antibodies 
were optimised manually, the slides were stained using the Ventana Classic 




2.8.2.1 Cell staining 
 
Cells were plated on cover slides in 500µl RPMI 10% FBS in a 24 well plate 
and incubated overnight. After incubation, media was aspirated and cells were 
washed twice with cold PBS. Cells were fixed in 4% paraformaldehyde for 15 
minutes at room temperature, washed twice in PBS and permeabilised in 
0.5% Triton PBS for 10 minutes. Cells were then washed in PBS and blocked 
with 300µl of 10% goat serum for 45 minutes at room temperature. Blocking 
solution was removed and cells were incubated with primary antibody for 1 
hour at room temperature. Cells were washed 3 times with PBS and 
incubated for 1 hour with secondary antibody at room temperature in the dark. 
Wells were then washed 3 times with PBS in the dark, counter-stained with 
DAPI and mounted using Mowiol (5µl/slide) (Sigma-Aldrich). 
  
2.8.2.2 Tissue staining 
 
Paraffin sections were dewaxed in xylene, and immersed in 100% ethanol for 
5 minutes, followed by rehydration of sections in graded alcohols. Antigens 
were retrieved by microwaving for 10 minutes in Citra Solution (Vecton 
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Antigen Unmasking Solution 2.5mls in 250mls distilled water). Slides were 
then washed in PBS three times (5 minutes each) and cells were 
permeabilised with 0.1% Triton-X100 in PBS for 5 minutes at room 
temperature followed by washing with PBS. Using 50mM NH4Cl in PBS, cells 
were then quenched for 15 minutes at room temperature and washed in PBS. 
Sections were blocked using 20% goat serum and 2% BSA in PBS for 1 hour 
at room temperature and then drained. The primary antibody was then applied 
in block solution (5% goat serum, 2.5% BSA, 0.3% fish gelatine, glycine) for 
1hr in the dark at room temperature at optimal dilution and then washed 3 
times in PBS (5 minutes each). The primary antibodies used and the dilutions 
at which they were used are listed in Table 7. Following this, the secondary 
antibody was added in block solution and incubated in the dark at room 
temperature for 1 hour. The secondary antibodies used were anti-mouse 
AlexaFluor 488 and anti-rabbit AlexaFluor 568, 1:1000 (Invitrogen). Sections 
were washed twice in PBS (5 minutes each) and once in distilled water. They 
were then dehydrated in 100% isobutanol followed by xylene and mounted in 




Protein Raised in Made by Clone Dilution 
CD68 Mouse Dako Monoclonal 1:200 
F4/80 Rat Abcam Monoclonal 1:100 









2.8.2.3 Confocal Microscopy 
 




2.8.2.4 Ariol Imaging 
 
The ARIOL imaging system (Genetix, San Jose, CA) was used to quantify 
antibody staining of the tissue microarrays (TMAs) and murine tumours. The 
specimens were scanned at a low resolution (1.25×) and high resolution (20×) 
using the Olympus BX 61 microscope with an automated platform (Prior). The 
slides were loaded in the automated slide loader (Applied Imaging SL 50). 
The images with high resolution were used for training and quantification 
purposes. The system was trained to select the stained and unstained cells by 
the colour of staining and shape of nuclei, such that brown staining was 
considered positive and blue staining was considered negative. The number 
of cells stained was calculated and represented as percentage of total cells 
stained positively, using the following formula: 
Percentage area of total cells stained positively = colour 1 (brown)/ colour 2 
(blue) x 100. 
 This method has been previously validated (300).  
2.8.2.4.1 Tissue Microarrays (TMAs) 
 
Prior to randomisation, patients considered for the ADAM trial had their 
biopsies analysed by IHC for ASS1 status. The cut off for inclusion in the trial 
was >50% ASS1 negativity within an individual’s tumour biopsy (ASS1 ‘low’). 
TMAs of ASS1 ‘low’ and ‘high’ biopsies were then created for further analysis 
in our lab (by Ms Fiona Luong). Core biopsies from 108 patients were used to 
make the TMAs, with each individual having between 1 and 4 biopsy cores, 
creating a total of 5 TMAs. TMA maps were formulated in order to identify 
individual patients and their ASS1 status. Each TMA was then stained with 
the macrophage marker CD68. Prior to calculation of the percentage area of 
CD68 positive staining, all TMA cores were first reviewed manually and only 
included in the analysis if the core was intact with minimal fibrotic or acellular 
areas. This was to standardise tumour area and cellularity and enable valid 
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comparisons. The Ariol image analyser was then trained to select the stained 
and unstained cells as described above. 
 
2.9 Flow Cytometry 
 
2.9.1 FACS antibody staining of co-cultured tumour cells  
 
Tumour cells were harvested using 1% trypsin-EDTA, centrifuged at 1500rpm 
for 5 minutes, the supernatant aspirated from each sample and the cells re-
suspended in 1ml of PBS. The washed cells were then re-centrifuged, the 
supernatant discarded and the cells (<1x106) re-suspended in 100µl annexin 
binding buffer (Invitrogen, UK). 5µl of Alexa Fluor 488 Annexin V (FITC, 
Invitrogen, UK), 5µl of CD14 (APC, BD Pharmingen) and 5µl of CD11b (PE, 
BD Pharmingen) were added to each 100µl cell suspension and the samples 
were incubated at 4ºC for 30 minutes. After the incubation period, 400µl of 
annexin binding buffer was added to each sample, gently mixed and the 
samples were then kept on ice. Finally, DAPI (1:10,000; 1mg/ml stock) was 




2.9.2 FACS antibody staining of monocytes  
 
To check purity of monocytes following CD14-positive selection, a sample of 
cells were centrifuged at 1500rpm for 5 minutes, the supernatant aspirated 
and the cells re-suspended in 1ml PBS. The washed cells (< 1x106) were then 
re-centrifuged, the supernatant discarded and the cells re-suspended in 100µl 
PBS. 5µl of CD14 (APC) was added to each 100µl cell suspension and the 
samples were then incubated at 4ºc. After 30 minutes, the cells were washed 
with a further 2mls of PBS and re-centrifuged at 1500rpm for 5 minutes. The 
supernatant was discarded and the cells were re-suspended in 350µl PBS. 
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2.9.3 FACS antibody staining of macrophages 
 
Macrophages were harvested using cold PBS, centrifuged at 1500rpm for 5 
minutes, the supernatant aspirated from each sample and the cells re-
suspended in PBS. The washed cells (<1x106) were then re-centrifuged, the 
supernatant discarded and the cells re-suspended in 100µl PBS. 5µl of 
CD11b (APC; BD Pharmingen), 5µl CD80 (PE), 5µl of CD163 (PECy7), 5 µl of 
CD206 (FITC), and 5µl of HLA-DR (Alexa Fluor 700) (all Biolegend) were 
added to each 100µl cell suspension (with each fluorochrome having a control 
sample plus a no stain control for the purposes of compensation) and the 
samples were then incubated at 4ºC. After 30 minutes, the cells were washed 
with a further 2mls of PBS and re-centrifuged at 1500rpm for 5 minutes. The 
supernatant was discarded and the cells were re-suspended in 350µl PBS. 
Cells were then taken for analysis by flow cytometry. Immediately prior to 
analysis, DAPI was added to each sample. 
 
 
2.9.4 FACS antibody staining of co-cultured cells for live sorting  
 
Co-cultured tumour cells that were used for proteomics analysis went through 
live sorting to separate them from macrophages. Cells were harvested using 
cold PBS and centrifuged at 1500rpm for 5 minutes. The supernatant was 
aspirated and the cells re-suspended in 1ml PBS. The washed cells (< 1x106) 
were then re-centrifuged, the supernatant discarded and the cells re-
suspended in 100µl PBS. 5µl of CD14 (APC) and 5µl of CD11b (PE) were 
added to each 100µl cell suspension and the samples were then incubated at 
4ºC. After 30 minutes, the cells were washed with a further 2mls of PBS and 
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re-centrifuged at 1500rpm for 5 minutes. The supernatant was discarded and 
the cells were re-suspended in 350µl PBS. Immediately prior to sorting, DAPI 
was added to each sample. 
 
2.9.5 FACS analysis 
 
Samples were read using the BD LSR Fortessa™ Cell Analyser platform. 
Accurate analysis of fluorochrome detection was achieved with unstained and 
isotype controls, and compensation was performed with positively staining 
cellular samples.  
Data was analysed using FlowJo 7.6.5 version software 
 
 
2.10 Preparation of supernatant for Mass Spectrometry 
analysis 
 
Supernatant from tumour cells and macrophages in co-culture and cultured 
individually, together with control samples of dialysed FBS and complete 
RPMI (no FBS), were collected and centrifuged at 1500rpm for 5 minutes. 
100µl of supernatant from each sample was added to 300µl of cold methanol 
and immediately vortexed for 5 minutes then put on ice. After 30 minutes the 
samples were centrifuged at 10000rpm for 15 minutes at 4ºc and the 
supernatant was transferred in to another 1.5ml Eppendorf. The samples 
were then placed in a speed vac for 1 hour, collected and stored for analysis 





2.11 Preparation of cells for proteomics analysis 
 
Preparation of cell lysates was carried out by Dr Pedro-Maria Casado 
(observed by Melissa Phillips). Proteomics analysis was performed by Dr 
Pedro Cutillas. 
 
Proteins were lysed in Urea lysis buffer (8M urea and 20mM HEPES) for 15 
minutes on ice to ensure they were homogenised. Samples were then 
sonicated (3 pulses of 15 seconds) to ensure protein breakdown. Samples 
were centrifuged at 20000G for 10 minutes at 5°C to pellet cell debris and the 
supernatant was transferred to new 1.5ml tubes. Protein concentration was 
measured using a BCA protein assay kit. Each protein sample was added to 
buffer to give the same amount of protein across conditions (made up to 
200µl). Protein was then denatured by adding 10µl of Dithiothretiol (DTT) to 
each sample and incubating for 1 hour in the dark (with agitation). This was 
followed by the addition of 20µl of 415mM lodoacetamide (IAM) to each 
sample for alkylation of cysteines, again with incubation for 1 hour in the dark 
with agitation. Samples were then diluted with 20mM HEPES (1 in 4) to 
remove the urea. Protein digestion was achieved with the use of immobilised 
trypsin beads. Samples with trypsin beads added were incubated at 37°C for 
16 hours with shaking. After this incubation, the tryptic protein digests were 
de-salted (using trifluoroacetic acid (TFA) and acetonitrile (ACN)). Samples 




2.12 In vitro co-culture experiments 
 
2.12.1 Co-culture experiments to assess tumour viability 
 
1x 105 MSTO cells were seeded wells of three 6 well plates, in 2mls RPMI 
10% FBS for plate1, and in 1ml RPMI 10% FBS for plates 2 and 3. At the 
same time macrophages were plated in different conditions: alone in 2mls 
RPMI with 10% FBS (plate 4; control), in co-culture with the MSTO cells 
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without direct cell contact (plate 2), in co-culture with the MSTO cells in direct 
cell contact (plate 3). In the wells without direct cell contact, a 0.4µm pore 
transwell cell culture insert (BD Falcon) was placed in each well to allow free 
flow of media but no cell contact. 2x105 macrophages were then added on top 
of the insert in 1ml of RPMI 10% FBS for a ratio of 1:2 tumour cells to 
macrophages. In the wells with direct cell contact, 2x105 macrophages in 1ml 
RPMI with 10% FBS were added to the MSTO cells directly (therefore all 
wells had a total of 2mls RPMI media). After 24 hours (tumour cells approx. 
70% confluent) the media in each well was discarded and the cells were 
gently washed three times with PBS. Media was replaced with 2mls RPMI 
10% FBS, with ADI-PEG20 added at a concentration of 750ng/ml for the 
treatment wells. The plates were then incubated for 4 days. Following this, the 
cells were collected as described for FACS staining in section 2.9.1. The cell 
viability was then analysed by flow cytometry.  
 
 
2.12.2 Co-culture experiments for qRT-PCR and Western blot analysis 
 
Co-culture experiments were set up as described above but without a ‘direct 
cell contact’ condition. Thus, co-cultured tumour cells and macrophages were 
always separated by a 0.4µm transwell insert. For qRT-PCR and western blot 
analysis, cells were incubated for 48 hours +/- ADI-PEG20 750ng/ml. The 
media was then discarded and cells washed three times with PBS. Cells were 
lysed with Buffer RLT lysis buffer (for qRT-PCR) or NP40 (for western blot) 
(please refer to sections 2.5.1 and 2.6.1, respectively, for more detail) and 
stored at -80°C until required.  
 
2.12.3 Co-culture experiments for mass spectrometry 
 
Co-culture experiments were set up as described in section 2.12.1 but 10% 
dialysed FBS (Gibco®, Life Technologies) was used with the RPMI to ensure 
no false positives on mass spectrometry analysis. Supernatant from each 




2.12.4 Co-culture experiments for Proteomics 
 
1x106 MSTO cells were seeded on each of sixteen 10cm3 plates (Corning) in 
10mls RPMI 10% dialysed FBS for plates 1-8 and 5mls RPMI 10% dialysed 
FBS for plates 9-16. 2x106 macrophages were added to plates 9-16 in 5mls 
10% dialysed FBS. After 24 hours media was removed and cells were 
washed three times with PBS. Media was replaced to achieve the following 
six different conditions: 
  
1. MSTO cells alone in 10mls SILAC media (Thermo Scientific) with 
added arginine and lysine (Thermo Scientific) at concentrations 
representative of RPMI (0.2g/l arginine, 0.04g/l lysine), 10% dialysed 
FBS (two plates) 
2. Co-cultured tumour cells and macrophages in SILAC media with added 
arginine and lysine at concentrations representative of RPMI 10% 
dialysed FBS (two plates) 
3. MSTO cells alone in 10mls SILAC media (with added 13C arginine 
(Thermo Scientific) and lysine at concentrations representative of 
RPMI) 10% dialysed FBS plus ADI-PEG20 750ng/ml (three plates) 
4. Co-cultured tumour cells and macrophages in SILAC media (with 
added 13C arginine and lysine at concentrations representative of 
RPMI) 10% dialysed FBS plus ADI-PEG20 750ng/ml (three plates) 
5. MSTO cells alone in 10mls SILAC media (with added 13C arginine and 
lysine at concentrations representative of RPMI) 10% dialysed FBS 
(three plates) 
6. Co-cultured tumour cells and macrophages in SILAC media (with 13C 
arginine and lysine at concentrations representative of RPMI) 10% 
dialysed FBS (three plates).  
 
 
Cells were incubated for 48 hours. After 48 hours, media was removed and 
cells were gently washed three times with PBS. Cells were detached with cold 
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PBS and a gentle cell scraper. Cells were prepared for live flow cytometric 
sorting as detailed in section 2.9.4. Using his method, tumour cells were 
separated from the macrophages with 99% purity. Tumour cells were then 
washed with PBS and centrifuged at 1500rpm. The cell pellets were lysed in 
8M urea lysis buffer. They were stored at -80°C in preparation for proteomic 
analysis.  
 
2.13 Cytokine Stimulation of macrophages 
 
2.13.1 Determining the optimal concentration of individual cytokines 
 
2x105 macrophages were seeded into wells of eight 6 well plates, in 2mls 
RPMI 10% FBS. After 24 hours, media was removed and cells gently washed 
three times with PBS. Media was replaced with 2mls RPMI 10% FBS plus 
either IL-8 at 0ng/ml, 1ng/ml, 10ng/ml and 100ng/ml; IL1α at 0ng/ml, 0.1ng/ml, 
1ng/ml and 10ng/ml; CXCL2 at 0ng/ml, 1ng/ml, 10ng/ml and100ng/ml; CXCL3 
at 0ng/ml, 1ng/l, 10ng/ml and 100ng/ml, or VEGFA at 0ng/ml, 1ng/ml, 10ng/ml 
and100ng/ml, with a combination of all five as a final condition. Each condition 
was in duplicate. After 48 hours, media was removed and cells were washed 
three times in PBS. Cells were lysed in 350µl RLT lysis buffer and stored at -
80°C until required.  
 
2.13.2 Cytokine stimulation of macrophages 
 
Once the optimum concentration was identified by qRT-PCR analysis of 
macrophage ASS1 expression relative to no cytokine control, the experiment 
was repeated again using the identified optimum concentration in triplicate 
plus a no cytokine control for each cytokine. After 48 hours, the cells were 
washed three times with PBS and lysed with 350µl RLT lysis buffer. Cells 
were stored at -80°C until required.  
 
2.13.3 Cytokine stimulation of tumour cells 
 
This was performed as detailed in section 2.13.2 using 2x105 MSTO cells. 
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For each tumour cell line (2591, MSTO, Ju77 wild-type, Ju77 ASS1, H28, 
H226) 2x105 tumour cells were seeded in wells of four 6 well plates in 2mls 
RPMI 10% FBS. After 24 hours (approx. 70% confluent), media was removed 
and cells were washed three times with PBS. Media was replaced with 2mls 
RPMI +/- ADI-PEG20 750ng/ml.  At specific time points (0 hours, 8 hours, 24 
hours and 48 hours), media was collected into labelled 1.5ml collection tubes 
for later ELISA analysis, and cells were washed three times with PBS. Cells 
were lysed with 350µl Buffer RLT for later qRT-PCR analysis. Cells lysates 
and supernatant were stored at -80°C until required. 
 
2.14.2 Arginine-deficient media 
 
The tumour cells were seeded as detailed in section 2.14.1. After 24 hours, 
media was replaced with either 2mls RPMI 10% FBS or 2mls SILAC media 
(deficient in arginine; ThermoScientific) plus added citrulline (1mM 
concentration) and lysine 0.04g/l, 10% dialysed FBS. Cells and supernatant 
were collected as detailed in section 2.14.1 and stored at -80°C until required. 
 
 
2.15 Animal Studies 
 
2.15.1 Mouse xenograft model 
 
5 week old female CD-1 homozygous Nu/Nu mice were purchased from 
Charles River Laboratories for xenograft studies. All mice were housed with a 
maximum of 6 mice per cage in a temperature-controlled pathogen-free 
animal facility. Water and food were freely available. All experiments were 
commenced at age 6 weeks and were conducted under the scope of my 
personal licence, awarded after completion of accredited training, and under 
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the Project Licence of Professor Nicholas Lemoine, in accordance with the 
Home Office Animals (Scientific Procedures) Act in 1986. All animals weighed 
between 22-24lbs at the start of experiments and were weighed weekly. 




2.15.2 Mesotheliomal cell preparation and transplantation 
 
MSTO cells were cultured as previously described in section 2.1.1, in 175cm3 
flasks. Prior to use for animal experiments, cells were detached with 1x 
trypsin-EDTA, washed twice in PBS and re-suspended in filtered PBS at a 
concentration of 30x106 cells/ml. Subcutaneous xenografts were seeded into 
the right flank of each mouse with 100µl volume containing 3x106 MSTO cells. 
MSTO cells were seeded for each experiment by Dr Ming Yuan. Once the 





Intraperitoneal injections were administered into the mouse peritoneum using 
a 1ml capacity syringe and a 25-gauge needle (BD microlance). 
 
2.15.4 Treatment schedules 
 
2.15.4.1 ADI-PEG20 plus CLIP 
 
Mice were placed into 5 different groups with 12 mice per group. Groups were 
as follows: 
 
 PBS (100µl) 
 CLIP (200µl) 
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 PLIP (200µl) 
 ADI-PEG20 (100µl at a dose of 5IU/100µl) 
 ADI-PEG20+CLIP 
200µl of CLIP (or PLIP as vehicle control) was injected twice a week for the 
first 3 doses to initiate macrophage depletion (Friday, Monday, Wednesday), 
and then continued on a weekly basis (every Wednesday) for the duration of 
the experiment for maintenance.  
 
100µl of ADI PEG20 (or PBS as vehicle control) was injected on a weekly 
basis (every Thursday) after the first 3 doses of CLIP (or PLIP) had been 
administered.  
 
2.15.4.2 ADI-PEG20 plus SB225002 (Pilot) 
 
Mice were placed into 4 different groups with 5 mice per group.Groups were 
as follows: 
 
 PBS (100µl) 
 
 ADI-PEG20 (100µl at a dose of 5IU/100µl) 
 
 SB225002 (100µl at a dose of 1mg/kg) 
 
 ADI-PEG20 + SB225002 
 
SB225002 was given daily and ADI-PEG20 was given weekly (every 







2.15.5 Mesothelioma tumour progression assessment  
 
This was performed with the observer blinded to the therapy received by each 
group. Assessment of tumour volume initially involved measurement of the 
long axis and perpendicular axis of the tumours using 0-200mm electronic 
digital callipers with 0.01mm resolution. Tumour volumes were then calculated 
according to the following formula (301):  
 
Tumour Volume = 0.5 (length x width2) 
 
Tumours were measured twice weekly.  
 
2.15.6 Sacrifice and tumour removal 
 
Mice were sacrificed by cervical dislocation. Subcutaneous tumours were 
immediately removed and placed in appropriate storage depending on 
subsequent intended use. 
 
 
FFPE sections  10% Formalin 
RNA extraction 2ml micro-centrifuge tube on dry ice 
 
 
2.16 Statistical analysis 
 
All statistical analysis was undertaken in GraphPad Prism 5. 
Standard error of the mean (SEM) was used to determine the confidence 
limits for all experiments which had been performed in replicate. SEM is a 
method used to estimate the standard deviation (SD) of a sampling 
distribution.  
 
To determine whether the difference between two experimental conditions 
was significant, p values were calculated using a two-sided unpaired 
Student's t test. To determine the difference between three or more 
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experimental conditions, p values were calculated using a 1 way ANOVA with 
Newman-Keuls multiple comparison post test analysis. A p-value of <0.05 
was considered to be statistically significant. To determine the difference in 
plasma cytokine levels in one group of patients before and after the 
administration of ADI-PEG20, p values were calculated using a paired t test. A 
p-value of <0.05 was considered to be statistically significant. 
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Chapter 3. ADI-PEG20 induces pro-inflammatory 







Despite promising results observed in vitro and in vivo as a targeted therapy 
for arginine auxotrophic tumours, drug resistance remains a significant 
challenge for effective use of arginine depletors in the clinical setting. 
Understanding and identifying novel tumoural mechanisms involved in the 
efficacy and resistance of arginine depletors will be critical in exploiting 
arginine deprivation with rationally selected drugs for cancer therapy. 
Ultimately, identifying tumoural resistance mechanisms may improve the 
treatment efficacy of many different ASS1 deficient cancers.  
 
Therefore, to investigate mechanisms of tumoural resistance to ADI-PEG20, 
the gene expression profile of three ASS1 negative mesothelioma cell lines 
(plus one bladder cell line) was analysed using the Affymetrix Human 
Genome U133 plus 2.0 microarray platform, in order to gain a better 
understanding of the response of these cells to ADI-PEG20 treatment. The 
Affymetrix data, generated by our laboratory, was analysed by the 
Bioinformatics team at the Barts Cancer Institute. This analysis produced a 
number of key findings that required further investigation and validation, 
including a significant pro-inflammatory cytokine gene expression profile 







The aims of this chapter were: 
 
1. To confirm that ADI-PEG20 causes cell death in ASS1 negative 
mesothelioma cell lines  
 
2. To validate the pro-inflammatory gene expression signature induced by 
ADI-PEG20 treatment and to ascertain whether these changes in gene 
expression are specific to ASS1 negative mesothelioma cells 
 
 
3. To evaluate whether a similar pro-inflammatory response is seen in 
ASS1 negative mesothelioma cells following culture in arginine- 
deficient media 
 
4. To determine how ADI-PEG20 provokes a pro-inflammatory cytokine 
response in ASS1 negative mesothelioma cells. 
 
 
5. To assess whether the in vitro pro-inflammatory cytokine response is 







3.3 ADI-PEG20 causes cell death in ASS1 negative 
mesothelioma cells 
 
First, I confirmed the ASS1 status of a panel of mesothelioma cell lines by 
western blot. This panel included three representative wild-type ASS1 
negative mesothelioma cell lines, 2591(epithelioid), MSTO (biphasic) and 
Ju77 (sarcomatoid), two representative wild-type ASS1 positive mesothelioma 
cell lines, H28 and H226, and one ASS1 over-expressing cell line, Ju77ASS1 
(Figure 3.1A).  
 
Having confirmed the ASS1 status of each mesothelioma cell line in my panel, 
I next assessed the effect of ADI-PEG20 treatment on cell viability. To do this, 
the three validated ASS1 negative cell lines, 2591, MSTO and Ju77, plus the 
three ASS1 positive controls, H28, H226 and Ju77ASS1, were treated with 
increasing concentrations of ADI-PEG20. As expected, after six days of 
treatment with ADI-PEG20, a significant reduction in ASS1 negative 
mesothelioma cell viability was observed using the MTS assay. In contrast, 






































































 A) ASS1 expression in a panel of malignant mesothelioma cell lines. Confirmation of 
loss of ASS1 expression in three wild-type ASS1 negative cell lines 2591, MSTO and Ju77, 
and of the presence of ASS1 protein in wild-type cell lines H226 and H28, and in the ASS1 
overexpressing cell line, Ju77 ASS1, as shown by western blot.  
 
B) Response of ASS1 negative cells to ADI-PEG20 treatment.  MTS assay demonstrating 
the effect of ADI-PEG20 on cell viability in the three ASS1 negative cell lines and the three 
positive controls at six days post ADI-PEG20 exposure. Viability decreases to less than 20% 
in the ASS1 negative cell lines, whereas the ASS1 positive cell lines are unaffected. 












































3.4 Validation of the pro-inflammatory gene expression 
signature induced by ADI-PEG20 treatment 
 
 
To elucidate mechanisms mediating tumoural resistance to arginine 
deprivation, I studied the gene expression profile of the three ASS1 negative 
wild-type mesothelioma cell lines treated with ADI-PEG20, generated using 
the Affymetrix Human Genome U133 plus 2.0 microarray platform. Ju77-
ASS1 overexpressing cells were also assessed in this Affymetrix analysis as 
controls. Raw Affymetrix data had already been analysed in detail by the 
bioinformatics team and differentially expressed genes were determined by 
applying a double threshold of false discovery rate (0.05) and fold change (at 
least 2). Following exposure to ADI-PEG20, over 7,000 genes are modulated 
in the three wild-type ASS1 negative mesothelioma cell lines by 24 hours. 
However, only 30 genes were found to be modulated greater than log 2-fold 
(as specified by the bioinformatics team) across all three ASS1 negative cell 
lines. Notably, among the most highly modulated genes identified in this group 
were up-regulation of the pro-inflammatory cytokines IL-8 (CXCL8), CXCL2, 
CXCL3, VEGFA and IL-1α, whereas JU77-ASS1 overexpressing cells were 


















4.03 4.17 3.33 0.37 
IL-1α 
 
4.29 4.44 2.22 0.26 
CXCL2 
 
7.77 2.58 7.45 0.51 
CXCL3 
 
3.38 5.00 4.47 0.52 
IL-8 
 
3.82 3.48 4.11 0.66 
 
 
Table 3.1. Table showing the significant up-regulation of pro-inflammatory cytokine 
gene expression in ASS1 negative mesothelioma cells following ADI-PEG20 treatment. 
The table illustrates the fold increases in expression of the most highly up-regulated genes 
(VEGFA, IL-1 alpha, CXCL2, CXCL3 and IL-8) across all three wild-type ASS1 negative 
mesothelioma cell lines (2591, MSTO and Ju77) at 24hours post ADI-PEG20 (750ng/ml) 
treatment. This pro-inflammatory gene expression signature was not seen in the Ju77 ASS1 




To validate this gene expression data, I analysed the induction of cytokine 
mRNA (Figure 3.2) following ADI-PEG20 exposure by qRT-PCR, in the three 
ASS1 negative and three ASS1 positive cell lines, and induction of cytokine 
protein (Figure 3.3) in the three ASS1 negative cell lines by ELISA. Results 
confirmed that the cytokine gene expression signature was specific to the 



















Figure 3.2. Validation of the pro-inflammatory gene expression by qRT-PCR. Three 
ASS1 negative and three ASS1 positive cell lines were analysed for induction of cytokine 
mRNA following ADI-PEG20 treatment at 0, 8, 24 and 48 hours. The no drug control for each 
cell line is normalised to one at every time point (not shown). All experiments were performed 
3 times in triplicate for each cell line, with values representing the mean (+/- SEM). Statistical 
significance (1 way ANOVA with Newman Keul’s multiple comparison post-test) * = p<0.05, ** 































Figure 3.3. Assessment of pro-inflammatory cytokines by ELISA (ASS1 negative MPM 
cells only). Graphs represent the concentration of each pro-inflammatory cytokine at 24 and 
48 hours following ADI-PEG20 treatment (750ng/ml) in the three ASS1 negative cell lines. 
ELISA-based assays to assess the concentrations of IL-8, IL-1α, CXCL2, CXCL3 and VEGFA 
were each performed twice in triplicate according to the manufacturer’s protocol, with values 
representing the mean (+/- SEM). Statistical significance: (1-way ANOVA with Newman 































3.5 Arginine-deficient media replicates the cytokine response 
in ASS1 negative mesothelioma cells 
 
 
The qRT-PCR and ELISA experiments described above were repeated with 
the wild-type ASS1 negative cell lines, 2591, MSTO and Ju77, substituting 
ADI-PEG20 with arginine-deficient media. Results revealed that arginine-
deficient media stimulates a similar cytokine response in ASS1 negative 
mesothelioma cells, highlighting that nutrient depletion is key to inducing the 
inflammatory reaction seen following ADI-PEG20 treatment (Figures 3.4 and 







































Figure 3.4. Pro-inflammatory gene expression signature induced by arginine-deficient 
media in ASS1 negative MPM cells lines. Three ASS1 negative cell lines 2591, MSTO and 
Ju77, were analysed for induction of cytokine mRNA following exposure to arginine deplete 
media at 0, 8, 24 and 48 hours. The graphs represent the relative increase in expression of 
individual genes in each cell line following substitution with arginine-deficient media, 
compared with control. The arginine control for each cell line is normalised to one at every 
time point (not shown). Experiments were performed twice in triplicate for each cell line, with 
values representing the mean (+/- SEM). Statistical significance (1 way ANOVA with Newman 










































Figure 3.5. Pro-inflammatory cytokine response induced by arginine-deficient media in 
ASS1 negative MPM cells.  Graphs represent the concentration of each pro-inflammatory 
cytokine at 24 and 48 hours following culture in arginine deficient media in the three ASS1 
negative cell lines. ELISA-based assays to assess the concentrations of IL-8, IL-1α, CXCL2, 
CXCL3 and VEGFA were each performed twice in triplicate according to the manufacturer’s 
protocol, with values representing the mean (+/- SEM). Statistical significance: (1-way 








Arginine Deplete media 
144 
 




Since nutrient deprivation is a known endoplasmic reticulum (ER) stress 
signal (302), I explored its homeostatic role in ADI-PEG20-induced cytokine 
secretion in the ASS1 negative cells. One of the early cellular responses to 
endoplasmic reticulum (ER) stress is the activation of the unfolded protein 
response (UPR) (reviewed in the discussion). This is accompanied by 
increases in several well-recognised ER stress related proteins: data 
generated from the Affymetrix U133 2.0 platform demonstrated robust up-
regulation of the ER stress-responsive genes, XBP1 and GADD34, at 24 
hours, in parallel with the ADI-PEG20-induced pro-inflammatory gene 
expression (Table 3.2), suggesting a possible role for ER stress in the 




GENE 2591 MSTO Ju77 
XBP1 1.6 2.39 3.37 
GADD34 2.25 3.66 4.20 
 
 
Table 3.2. Gene expression analysis using the Affymetrix U133 plus 2.0 microarray 
platform. The table illustrates the log-fold increase in expression of individual genes in the 
three wild-type ASS1 negative mesothelioma cell lines at 24hrs following exposure to ADI-




To validate this gene expression data, I analysed the induction of  XBP1 
mRNA (Figure 3.6A) and spliced XBP1 protein (Figure 3.6B) following ADI-
PEG20 exposure, by qRT-PCR and western blot, respectively, in the three 
wild-type ASS1 negative MPM cell lines and one ASS1 positive control cell 
line (H28). Results confirmed that XBP1 is significantly up-regulated by 24 
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hours following ADI-PEG20 treatment in the ASS1 negative MPM cell lines. 






































A) Validation of the up-regulation of ER stress marker, XBP1, by qRT-PCR. Three ASS1 
negative MPM cell lines (2591, MSTO and Ju77) and one ASS1 positive MPM cell line (H28) 
were analysed for induction of XBP1 mRNA following ADI-PEG20 treatment at 0, 8, 24 and 
48 hours. Graph shows relative increase in XBP1 gene expression in each cell line compared 
with no drug control. The no drug control for each cell line is normalised to 1 at every time 
point (not shown). Experiments were performed twice in triplicate for each cell line with values 
representing the mean (+/- SEM). Statistical analysis: (1 way ANOVA with Newman Keul’s 
multiple comparison post test analysis) * = p<0.05, *** = p<0.001. 
 
B) Western Blot validation of up-regulation of XBP1 (spliced). Three ASS1 negative MPM 
cell lines (2591, MSTO and Ju77) and one ASS1positive MPM cell line (H28) were analysed 
for expression of XBP1 (spliced) at 24 hours following ADI-PEG20 treatment by western blot. 
Results show an increase in XBP1 (s) protein in the ASS1 negative MPM cells. No expression 

































































































































XBP1 (s) 54kDa 
β actin 42kDa 
147 
 
To corroborate the role of ER stress in the inflammatory response, the three 
ASS1 negative and the two wild-type ASS1 positive mesothelioma cell lines 
were treated with Tunicamycin (TM), an established ER stress inducing agent 
that blocks all N-glycosylation of proteins and causes cell cycle arrest in G1 
phase (303). An increase in XBP1 mRNA expression was observed in all TM-
treated cells, including the ASS1 positive cell lines (as TM will induce ER 
stress regardless of ASS1 status), by 24 hours (Figure 3.7). Furthermore, the 
pro-inflammatory genes that were up-regulated following ADI-PEG20 
treatment, were also significantly up-regulated in the TM-treated cells (Figure 
3.8). Thus, ADI-PEG20 stimulates a gene expression profile in ASS1 negative 
MPM cell lines that corresponds with that elicited by the well-recognised ER 
























Figure 3.7. Up-regulation of XBP1 mRNA at 24 hours following TM treatment. Three 
wild-type ASS1 negative cell lines (2591, MSTO and Ju77) and two ASS1 positive cell lines 
(H28 and H226) were analysed to evaluate changes in expression of XBP1 at 24 hours 
following treatment with TM (5µg/ml). Graph represents the relative increase in XBP1 gene 
expression in each cell line after 24hrs of treatment with TM, compared with the no drug 
control. The no drug control is normalised to 1 (not shown). Experiments were repeated twice 
in triplicate for each cell line. Statistical analysis (unpaired two-tailed Student’s t test): * = 









































Figure 3.8. Pro-inflammatory cytokine gene expression in a panel of mesothelioma cell 
lines at 24hrs following TM treatment. Three ASS1 negative (2591, MSTO and Ju77) and 
two ASS1 positive cell lines (H28 and H226) were analysed for induction of cytokine mRNA at 
24 hours following TM treatment. Graphs represent the relative increase in gene expression 
of the individual cytokines IL-8, IL1α, CXCL2, CXCL3 and VEGFA, compared with the no drug 
control. The no drug control is normalised to 1 (not shown). Experiments were repeated twice 
in triplicate for each cell line. Statistical analysis (unpaired two-tailed T Test): * = p<0.05, ** 





Having demonstrated a link between ER stress, XBP1 up-regulation, and pro-
inflammatory cytokine secretion following ADI-PEG20-induced arginine 
depletion, I explored whether silencing of XBP1 would reduce the expression 
of pro-inflammatory genes following ADI-PEG20 treatment. To test this 
hypothesis, XBP1 knockdown was performed, using a SiRNA SMARTpool 
(Dharmacon). Good knockdown was achieved in two ASS1 negative cell 
lines, 2591 and MSTO; however, effective knockdown was not seen in Ju77, 




















Figure 3.9. Confirmation of XBP1 Silencing in ASS1 negative MPM cell lines 2591 and 
MSTO at 24hrs by qRT-PCR. ASS1 negative MPM cell lines (2591, MSTO and Ju77) were 
analysed to evaluate XBP1 knockdown at 24 hours following SiRNA transfection.  Graph 
represents the relative decrease in XBP1 gene expression compared with SiControl in 2591 
and MSTO. Knockdown was not achieved in Ju77. Experiments were performed twice in 
triplicate for 2591 and MSTO, and threes times for Ju77. Graph represents the mean (+/- 
SEM). Statistical analysis: (unpaired two-tailed Student’s t test) * =p<0.05. 
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Following confirmation of XBP1 knockdown by qRT-PCR, XBP1 silencing in 
the two ASS1 negative cell lines, 2591 and MSTO, was repeated and the cells 
were then treated with ADI-PEG20 for 24 hours. However, qRT-PCR results 
contradicted the hypothesis, revealing instead that XBP1 knockdown did not 
significantly dampen the pro-inflammatory cytokine response to ADI-PEG20. 
In fact, expression of IL-8 and CXCL3 actually increased significantly in both 






































Figure 3.10. ADI-PEG20-induced pro-inflammatory cytokine gene expression signature 
following XBP1 silencing in ASS1 negative cells (qRT-PCR). ASS1 negative cell lines 
2591 and MSTO, transfected with XBP1 SiRNA or SiControl, were analysed to evaluate 
changes in gene expression of individual cytokines at 24 hours following ADI-PEG20 
treatment. Graphs represent the relative increase or decrease in expression of individual 
genes in each cell line transfected with either SiControl or XBP1 SiRNA, following ADI-PEG20 
treatment, compared with no drug control. The no drug control for each cell line is normalised 
to one (not shown). Experiments were performed twice in triplicate for each cell line, with 
values representing the mean (+/- SEM). Statistical analysis (Unpaired two-tailed  Student’s t 
test) *=p<0.05, ** = p<0.01.  
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The UPR is a homeostatic signaling network that orchestrates the recovery of 
ER function (this will be reviewed in more detail in the discussion). Three 
separate UPR branches regulate ER homeostasis and the results here imply 
that the silencing of an ER-stress responsive gene from one UPR branch is 
insufficient to reduce the robust inflammatory response, as there is likely to be 
significant signaling crosstalk between branches which may provide 
compensatory regulation, whereby loss of one gene stimulates other 
pathways in order to maintain cell homeostasis. Thus, the inflammatory 
response is maintained, or, as seen here, heightened. 
 
However, although maintenance of the inflammatory cytokine response 
following XBP1 knockdown was observed, I saw a significant decrease in 
tumour cell viability in XBP1 knockdown cells, at 24hrs following ADI-PEG20 
treatment, highlighting the importance of the UPR pathways in maintaining 













Figure 3.11. Tumour cell viability in XBP1 silenced ASS1 negative cell lines at 24hrs 
following ADI-PEG20 treatment.  Two ASS1 negative cell lines, 2591 and MSTO, were 
transfected with XBP1 SiRNA or SiControl and analysed to assess cell viability at 24 hours 
following ADI-PEG20 treatment (750ng/ml). Cell viability was assessed by trypan blue 
exclusion assay using the Beckman Coulter ViCELL™ cell viability analyser. Graph shows the 
decrease in XBP1 knockdown tumour cell viability at 24hrs following ADI-PEG20 treatment. 
Typically treatment does not have an effect on tumour cell viability until 72 hours. 
Experiments were performed twice in triplicate for each cell line, with values representing the 
mean (+/- SEM). Statistical analysis (unpaired two-tailed Student’s t test) *** = p<0.001.  
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In view of the maintained pro-inflammatory response following XBP1 
knockdown, the next step was to look at factors regulated by more than one 
branch of the UPR. The transcription factor NF-κB is a key regulator of 
inflammation and is also reported to become activated by a number of cellular 
pathways during the UPR as a consequence of ER stress (304). Therefore, I 
sought to ascertain whether ADI-PEG20 treatment activated NF-κB in the 
ASS1 negative MPM cell lines. Western blot analysis confirmed 
phosphorylation (therefore activation) of NF-κB in the three ASS1 negative 
cell lines at 24 hours following ADI-PE20, with no evidence of phosphorylation 
in the ASS1 positive control, further supporting a link between ADI-PEG20, 


















Figure 3.12. NFкB phosphorylation following ADI-PEG20 treatment in ASS1 negative 
MPM cell lines. The three ASS1 negative MPM cell lines (2591, MSTO and Ju77) and an 
ASS1 positive control (H28) were analysed for NFкB phosphorylation at 24 hours following 
ADI-PEG20 treatment. Western blot demonstrates increased protein expression of 
phosphorylated NFкB (NFкB (p)) in the three ASS1 negative cell lines at 24 hours following 
ADI-PEG20. There was no evidence of NFкB phosphorylation following ADI-PEG20 in ASS1 























































































































To determine whether the in vitro ADI-PEG20-induced pro-inflammatory 
cytokine response is relevant in vivo, I analysed plasma samples from a 
cohort of patients with ASS1-deficient (‘ASS1 low’) mesothelioma treated with 
or without ADI-PEG20 as part of the Arginine Deiminase and Mesothelioma or 
ADAM trial (clinicaltrials.gov identifier NCT01279967). This recently 
completed phase II national clinical trial was the first randomised trial to 
explore the role of arginine deprivation using ADI-PEG20 in patients selected 
for an ASS1-deficient tumour. For a diagrammatic summary of the ADAM trial 


























Figure 3.13. Diagrammatic summary of ADAM trial design. ASS1-deficient (ASS1 ‘low’) 
patients were randomised (2:1 randomisation) to either best supportive care (BSC) (Arm A; 
24 patients) or ADI-PEG20 + BSC (Arm B; 44 patients). In Arm B, ADI-PEG20 was given 
weekly as an intramuscular injection. Radiological assessment of response was performed 











Patient plasma samples were analysed by ELISA for pro-inflammatory 
cytokines in response to ADI-PEG20 treatment. Results demonstrated that in 
patients with ‘ASS1 low’ tumours randomised to Arm B, the initial treatment 
dose of ADI-PEG20 induced an increase in all the cytokines analysed, with 
statistically significant increases seen in plasma IL-8 (p=0.002) CXCL2 
(p=0.02) and VEGFA concentrations (p=0.002) (Figure 3.14). Furthermore, IL-
8 and VEGFA remained significantly elevated at the two month assessment in 
the ADI-PEG20 treated group. No significant change from baseline was seen 
in IL-1α, CXCL2 or CXCL3 at the two month assessment in the ADI-PEG20 
group. IL1-α was in fact unrecordable in the majority of plasma samples 
analysed and therefore it is difficult to make any conclusions from the IL1-α 
data. The untreated control group showed no change in any plasma cytokine 
levels from baseline (Figure 3.15). In addition, patients in the ADI-PEG20 
group whose disease had progressed by the first assessment at two months, 
were found to have significantly higher levels of IL-8 (p=0.004), CXCL2 
(p=0.02) and VEGFA (p=0.04) compared with those who demonstrated 
disease control at two months (Figure 3.16). Collectively, the ADAM data 
validate the in vitro studies and support the hypothesis that pro-inflammatory 






















































Figure 3.14. Plasma concentrations of pro-inflammatory cytokines at baseline and 
following 1st administration of ADI-PEG20. Patients enrolled on the ADAM clinical trial 
consented to having blood taken for research. Patients in Arm B (n=44) had weekly blood 
samples taken. After centrifugation, plasma was removed from each sample of blood and 
stored at -80°C until ELISA analysis. For ELISA analysis, plasma samples from patients in 
arm B at baseline and week 2 (1 week post 1st dose of ADI-PEG20), were thawed on ice and 
centrifuged a 12,000 rpm to remove debris. ELISAs were performed according to the 
manufacturer’s instructions to assess plasma concentrations of each pro-inflammatory 
cytokine previously studied in vitro (1L-1α, IL-8, CXCL2, CXCL3, VEGFA). Graphs represent 
plasma concentrations of each pro-inflammatory cytokine at baseline and following 1st dose of 
ADI-PEG20. Plasma IL-1α was undetectable in the majority of samples; this has been shown 
























































Figure 3.15. Plasma concentrations of pro-inflammatory cytokines at baseline and the 9 
week follow-up for patients in both trial groups. Plasma samples taken at baseline and 9 
weeks from patients randomised to both Arm A and Arm B, were analysed by ELISA, 
according to the manufacturer’s protocol. Graphs represent the plasma concentrations of 
each pro-inflammatory cytokine at baseline and at 9 weeks following BSC or ADI-PEG20 plus 
BSC, in Arm A and Arm B, respectively. Graphs on the left hand side represent Arm A and 
graphs on the right represent Arm B. Statistical analysis (paired two-tailed T Test): * p=<0.05, 












































Figure 3.16 a. Difference in plasma concentrations of pro-inflammatory cytokines in 
patients receiving ADI-PEG20 (Arm B) whose disease progressed at 9 week follow up 
compared with those who showed stable disease or a partial response. Patients were 
assessed at 2 months (week 9) following initiation of ADI-PEG20. Patients whose disease 
had progressed (radiological assessment) whilst receiving ADI-PEG20 discontinued the drug, 
whilst patients with stable disease/partial response continued weekly treatment. Plasma 
samples from each week were analysed by ELISA, according to the manufacturer’s protocol. 
Week 1 is baseline, prior to administration of the initial dose of ADI-PEG20. Week 2 is the 1st 
blood sample following ADI-PEG20 treatment initiation. Graphs represent the difference in 
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plasma concentrations of each pro-inflammatory cytokine in patients whose disease 
progressed (black line) compared with patients who had stable disease/partial response (red 
line). Statistical analysis (unpaired two-tailed t test for each week) * p=<0.05, ** p<0.01. PD; 



















Figure 3.16 b: Graphs plotting the individual patient plasma concentrations of IL-8 and 
CXCL2 at baseline, following initial ADI-PEG20 treatment (week 2) and at 9 weeks. 
Individual patient plasma concentrations of IL-8 and CXCL2 were plotted to assess individual 
differences in these cytokine levels at baseline and following ADI-PEG20 exposure (week 2). 
Individual results were plotted for IL-8 and CXCL2 as these cytokines showed the most 
significant differences between patients who progressed at 9 weeks and patients who had 
stable disease/partial response. With IL-8, in particular, there were a number of individuals in 
the progressors group who had significantly higher concentrations of IL-8 than the majority of 
both progressors (black) and responders (red).  PD; progressive disease, SD; stable disease, 







A distinct pro-inflammatory gene expression signature was identified in ASS1 
negative mesothelioma cell lines following exposure to ADI-PEG20. 
Specifically, IL-8, CXCL2, CXCL3, IL-1α and VEGFA were all found to be 
significantly up-regulated in the Affymetrix data analysis, and this was 
validated by qRT-PCR and ELISA. Furthermore, the pro-inflammatory 
cytokine production was also clinically relevant and supports a link between 
inflammation and ADI-PEG20 resistance in ASS1 negative mesothelioma. 
  
Macrophages are key regulators of inflammation in cancer (305). Within a 
tumour, the cytokine network influencing these immune cells is intricate and 
extensive, and macrophage recruitment into tumours is mediated by multiple 
cytokines (230, 306), including the cytokines described above. Indeed, it is 
widely accepted that both VEGFA and IL-8 contribute to macrophage 
recruitment and activation (305, 307). Interestingly, IL-8 (CXCL8) belongs to 
the CXC family of chemokines, which also includes CXCL2 and CXCL3.This 
family is a chemotactic group of cytokines, characterized by the presence of 
four conserved cysteine amino acid residues in the amino terminus of the 
protein, in which the first two are separated by one non-conserved amino acid 
residue (hence the CXC designation). This family of molecules can be further 
subdivided based on the presence (+) or absence (-) of the amino acid 
sequence glutamic acid-leucine-arginine (ELR) immediately preceding the first 
cysteine. The ELR (+) family of CXC chemokines, to which IL-8, CXCL2 and 
CXCL3 belong, are potent pro-inflammatory agents and have increasingly 
been found to promote tumour growth, metastasis and angiogenesis as well 
as mediate tumour resistance to chemotherapeutic agents (308). CXCL2 and 
CXCL3 are better recognised for their role in neutrophil recruitment (309); 
however, all three of these ELR (+) chemokines bind to the CXC chemokine 
receptor 2 (CXCR2), a 7-transmembrane G-protein-coupled receptor that is 
also expressed on human blood monocytes and macrophages (211). Indeed, 
IL-4 and IL-13, cytokines that are typically increased within the TME (310, 
311), induce CXCR2 in monocytes, therefore rendering these cells extremely 
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sensitive to IL-8 and related molecules (i.e. CXCL2 and CXCL3), which may 
contribute to regulating the positioning and functioning of TAM (312). Through 
CXCR2, CXCL2 and CXCL3 are also able to mediate robust monocyte arrest, 
an important step in monocyte recruitment (313). Moreover, research into 
cardiovascular disease has demonstrated that CXCR2 has a major impact on 
macrophage recruitment and accumulation in advanced atherosclerotic 
lesions (314), further supporting a role for CXCL2 and CXCL3, in addition to 
IL-8 and VEGFA, in macrophage recruitment. Further discussion on CXCR2 
can be found in Chapter 5.  
 
Other well-recognised chemokines involved in macrophage recruitment into 
tumour sites are CCL2 (MCP-1) and CCL5 (RANTES) (218). Affymetrix data 
analysis revealed that CCL5 gene expression was increased in ASS1 
negative MPM cell lines following ADI-PEG20 treatment, but this increase did 
not meet the stringent criteria of greater than log 2-fold across all three ASS1 
negative cell lines. No change in CCL2 expression was seen. This finding is 
similar to a recent study investigating the molecular signals induced by 
androgen blockade therapy that could recruit and modulate the function of 
TAM in Myc-CaP prostate cancer cells. Investigators found that CCL2 was 
expressed at very low levels, with no change seen following treatment, 
despite evidence of increased TAM infiltration (315). Indeed, although CCL2 
is recognised to play a key role in macrophage recruitment, it has also been 
shown that in CCL2-deficient (CCL2 (-/-)) mice displaying abnormalities in 
wound repair, the number of macrophages within the wounded site was not 
affected by the absence of CCL2, suggesting that monocyte/macrophage 
recruitment can be independent of CCL2 (316).  
 
A similar pro-inflammatory cytokine signature to that identified following ADI-
PEG20 treatment was also seen in ASS1 negative mesothelioma cells 
following culture in arginine-deficient media. This result implies that the 
response is due to arginine depletion, rather than any off-target effects of ADI-
PEG20. Interestingly, an IL-8-dependent pro-inflammatory response was seen 
in U20S osteosarcoma cells following deprivation of the amino acid glutamine 
(317). Here, the authors demonstrated that short-term glutamine restriction 
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triggers an endoplasmic reticulum (ER) stress response that leads to 
production of IL-8. In view of this finding, and the fact that there is an 
established link between ER stress, inflammation and malignancy (318-320), I 
considered the role of ER stress in induction of the inflammatory response 
following ADI-PEG20 treatment.  
 
The endoplasmic reticulum (ER) is a multifunctional organelle essential for the 
synthesis, folding, and processing of secretory and transmembrane proteins. 
In order for proteins to fold properly, vital for normal cell function, a balance 
between the ER protein load and the folding capacity to process this load 
must be established (ER homeostasis). However, ER homeostasis can be 
disturbed by a number of different pathological processes, including hypoxia, 
nutrient overload or deprivation, infections, toxins and inflammatory cytokines 
(302), resulting in the accumulation of unfolded and misfolded proteins in the 
ER, a condition known as ‘ER stress’. ER stress then activates a complex 
signaling network referred to as the Unfolded Protein response (UPR) (319). 
The UPR is initiated by three ER transmembrane proteins: Inositol Requiring 
1 (IRE1), PKR-like ER kinase (PERK), and Activating Transcription Factor 6 
(ATF6). These three master regulators sense and interpret protein-folding 
conditions in the ER and translate this information across the ER membrane 
to regulate downstream effectors. All three activate specialised transcriptional 
programs mediated by distinct transducers: ATF4 (for PERK), cleaved ATF6 
(for ATF6), and spliced XBP1 (sXBP1) (for IRE1) (for a diagrammatic 
summary of the UPR and its role in inflammatory response, please see Figure 
3.17). Ultimately, the aim of the UPR is to restore normal ER homeostasis. If 
this fails, the UPR tends to mediate cell death (321). UPR signaling is 
emerging as a contributing factor to the pathology of several human diseases, 
including cancer. Indeed, it has been shown to contribute to the growth and 




Figure 3.17. ER stress and activation of the UPR: implication in the inflammatory 
response following ADI-PEG20 treatment. The figure represents a simplified diagram of the 
core elements of the UPR signaling network. In unstressed conditions, the BiP chaperone 
interacts with the luminal domain of the three ER transmembrane sensors, AF6, IRE1 and 
PERK (representing the three branches of he UPR), and maintains them in an inactive state. 
Upon ER stress, caused by several pathological processes, including hypoxia, nutrient 
depletion or overload, infection and toxins, BiP interacts with unfolded proteins, leading to the 
activation of the UPR transducers. Activation of each sensor produces a transcription factor 
(ATF6(N), XBP-1 and ATF4, respectively) that activates genes to increase the protein folding 
capacity in the ER. IRE1 and PERK also decrease the load of proteins entering the ER. Both 
the increase in protein folding capacity and the decrease in protein load act to mitigate ER 
stress. The UPR is associated with inflammation via a variety of mechanisms involving ROS, 
JNK and NFкB. PERK promotes ATF4 and NRF2, which then suppress ROS production by 
activating antioxidant pathway. Upon activation, IRE1/TRAF2 recruits IKK, leading to the 
phosphorylation of IкBα and subsequent activation of NFкB. IRE1/TRAF2 can also activate 
AP1, resulting in the activation of JNK. XBP-1 induced by IRE1/TRAF2 can further induce the 
expression of various genes implicated in inflammation. Furthermore, ATF6 can promote 
inflammation via activating NFкB. 
 
ATF, activating transcription factor; BiP, immunoglobulin heavy-chain-binding protein; IRE1, 
inositol-requiring enzyme-1; PERK, PKR-like ER kinase; XBP-1, X-box binding protein 1; 
ROS, reactive oxygen species; NRF2 nuclear factor-erythroid-derived 2-related factor 2; AP1, 
activator protein 1; JNK, c-Jun N-terminal kinase; IKK, IκB kinase; TRAF2, TNF receptor-
associated factor 2 







The Affymetrix data generated in our laboratory supports data from the 
glutamine study and also demonstrates an association between ER stress 
and the pro-inflammatory gene expression profile following ADI-PEG20-
induced arginine deprivation. A number of transcriptional changes associated 
with ER stress were noted, and increased expression of the critical 
transcription factor XBP1 was confirmed by qRT-PCR and western blot.  
 
XBP1 is activated by an IRE1-mediated splicing event, and the spliced form 
of XBP1 (XBP1s) encodes a protein with a novel C terminus that acts as a 
potent transcriptional activator of many genes involved in the UPR. The IRE1-
XBP1 pathway, the most conserved branch of the UPR, is required for ER 
biogenesis, as well as for efficient protein folding, maturation, and degradation 
in the ER (325). Furthermore, it has been shown to be an important 
component of tumour development and an essential survival factor (326). It is 
therefore not surprising that tumour cell viability was found to be significantly 
decreased after 24 hours of ADI-PEG20 treatment in XBP1 knockdown ASS1 
negative cells, compared with the wild-type ASS1 negative control cells. This 
finding supports results from other studies showing that loss of XBP1 severely 
inhibits tumour cell survival. Indeed, under hypoxia, another inducer of ER 
stress, cell death was also increased following loss of XBP1 in the 
fibrosarcoma cell line HT1080 (323). Additionally, in this study, the IRE1-
XBP1 pathway was also found to promote tumour growth in xenograft models. 
Depletion of XBP1 resulted in cell sensitization to ER stress–induced cell 
death and smaller tumours, and expression of XBP1(s) restored tumour 
growth under these conditions. Notably, investigators reported that although 
tumour cell death increased, loss of XBP1 had little influence on VEGFA 
expression in these cells (323). Likewise, I saw no significant decrease in pro-
inflammatory cytokine expression following XBP1 knockdown in ASS1 
negative cells, despite a decrease in cell viability. In fact, there was a 
compensatory increase. It is well recognized that all three main branches of 
the UPR have been shown to mediate pro-inflammatory gene expression 
(327, 328). This perhaps explains why the siRNA silencing of XBP1 
(representing one branch) in ASS1 negative cells did not significantly dampen 




In addition, XBP1 mRNA splicing is also reported to trigger the autophagic 
response through regulation of BECLIN-1 transcriptional activation. BECLIN-1 
plays a fundamental role in the initiation of autophagy (329). As autophagy is 
a recognized tumoural resistance mechanism following arginine depletion, 
providing a temporary supply of arginine, this may also explain why cell 
viability significantly decreased at 24hrs following ADI-PEG20 in the XBP1 
knockdown ASS1 negative cells, compared to wild-type ASS1 negative cells.   
 
Activation of the transcription factor NF-κB has been reported to be a 
consequence of ER stress (328). NF-κB is recognized as one of the key 
mediators of pro-inflammatory pathways, with genes transcribed by NF-κB 
including those that encode essential pro-inflammatory cytokines (330). 
Generally, NF-κB is kept in an inactive form within the cytoplasm; however, 
the UPR is able to activate NF-κB via different mechanisms (318). Therefore, 
in view of this, the next step was to evaluate whether NF-κB was activated 
following ADI-PEG20 treatment of ASS1 negative mesothelioma cells, to 
further validate the link between nutrient depletion, ER stress and 
inflammation. Western blot analysis confirmed phosphorylation (therefore 
activation) of NF-κB in these cells following treatment, with no evidence of 
phosphorylation in the ASS1 positive control. Further confirmation of NF-κB 
involvement would require inhibiting NF-κB activity in combination with ADI-
PEG20 to see whether this combination attenuates pro-inflammatory cytokine 
production. This may, however, still be insufficient because of the redundancy 
demonstrated earlier with XBP1 blockade. 
In cancer, ER stress has the capacity to activate cells of the adaptive immune 
system. Remarkably, it has also been suggested that ER stress may be 
transmissible from tumour cells to cells of the immune system. For example, 
when cultured in media conditioned by murine cancer cells experiencing ER 
stress, macrophages show activation of the UPR in a TLR-dependent manner 
(331). It is therefore possible that this acquired UPR in macrophages might 
influence their phenotype and result in the release of inflammatory mediators 
that further contribute to tumour inflammation and progression. 
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It is important to highlight here that the potential role of ER stress in 
modulating the pro-inflammatory cytokine response to ADI-PEG20 in ASS1 
negative mesothelioma cells has not been confirmed by the data presented in 
this chapter. This is preliminary work and requires further validation.  
To determine the clinical relevance of the pro-inflammatory gene signature, 
plasma samples obtained from the ADAM trial were analysed to look for 
changes in cytokine levels in response to ADI-PEG20. Results revealed that 
all the pro-inflammatory cytokines identified in the in vitro studies increased to 
some extent in patients one week following the initial dose of ADI-PEG20, 
with the increase in IL-8, VEGFA and CXCL2 being statistically significant at 
this time point. Furthermore, plasma IL-8 and VEGFA levels remained 
significantly higher than baseline at the two month follow up. In addition, IL-8, 
CXCL2 and VEGFA were significantly increased in patients whose 
mesothelioma progressed whilst on ADI-PEG20 therapy, compared with 
patients who demonstrated disease control to treatment, by two months. 
These findings validate the pre-clinical data and support a link between 
inflammation and ADI-PEG20 resistance. Moreover, they are in concordance 
with several independent reports showing a link between increased pro-
inflammatory cytokines and therapeutic resistance. For example, IL-8 serum 
levels were assessed in melanoma patients treated with both BRAF inhibitors 
and immunotherapy. Here, decreased IL-8 correlated with best clinical 
response and increased IL-8 correlated with progressive disease (332). A 
decrease in IL8 levels during treatment has also been associated with 
improved response to chemotherapy and radiotherapy (333, 334). In addition, 
IL-8 was found to mediate resistance to PI3K-mTOR inhibitors in breast 
cancer (335). Furthermore, it was recently reported that mouse mammary 
tumours that developed resistance to chemotherapy had high expression of 
CXCL2 (336) and it has been suggested that elevated VEGF levels may also 
contribute to increased resistance to chemotherapy or endocrine therapy in 
advanced breast cancer (337). Accordingly, VEGF status has been shown to 
be of value in predicting the effectiveness of radiotherapy, chemotherapy, and 
hormonal therapy, as well as the likelihood of relapse, in a variety of cancers 
(338, 339). My data show that the increase in plasma IL-8, CXCL2 and 
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VEGFA corresponds with disease progression at 2 months in patients 
receiving ADI-PEG20. These cytokines may therefore have utility as early 
resistance biomarkers to ADI-PEG20 in the future.   
 
However, plasma IL-8 could also be reflecting tumour burden in ADAM trial 
patients. It has been reported that in both melanoma and colorectal cancer 
xenografts, IL-8 concentrations precisely correlated with tumour burden, 
supporting the hypothesis that IL-8 output is a relatively constant parameter 
for a single tumour cell and that, as suggested by Sanmamed et al (332), IL-8 
levels may accurately reflect the amount of tumour cells. However, as the 
ADI-PEG20 treatment Arm (Arm B) showed an increase in PFS compared 
with the BSC Arm (Arm A) overall (3.3 months versus 1.9 months; p=0.02), 
this indicates that the pro-inflammatory cytokine signature involving IL-8, 
CXCL2 and VEGFA, is linked to resistance and disease progression on ADI-
PEG20.   
 
 
Finally, the pro-inflammatory gene expression signature identified by 
Affymetrix in response to ADI-PEG20 was specific to ASS1 negative 
mesothelioma cells. It was not seen in the ASS1 negative bladder cell line, 
253J. In fact, in 253J, the only cytokine that demonstrated a statistically 
significant increase compared with the no treatment control, was VEGFA, 
indicating that the response to ADI-PEG20 is not consistent across different 
tumour types. Further studies are required to assess the cytokine response to 
ADI-PEG20 in other ASS1 negative tumour types.  
 
Collectively, the pre-clinical and clinical data support a link between the pro-
inflammatory cytokine response and ADI-PEG20 resistance in malignant 
mesothelioma. Therefore, I sought to study further the relationship between 
these pro-inflammatory cytokines and resistance to arginine deprivation 





Chapter 4. Macrophages promote resistance to 





The pre-clinical and clinical data presented in Chapter 3 support a link 
between the pro-inflammatory cytokine response and ADI-PEG20 resistance 
in malignant pleural mesothelioma. Macrophages, well-recognised 
inflammatory cells, are recruited and activated by the pro-inflammatory 
cytokines identified in the previous chapter. Furthermore, they are reported to 
be abundant in mesothelioma, playing a central role in mesothelioma 
tumourigenesis (248, 279). Indeed, given the close relationship between 
macrophages and tumour cells within the mesothelioma tumour 
microenvironment, I sought to study further the link between the pro-
inflammatory cytokines, macrophages and resistance to arginine deprivation 






The aims of this chapter were: 
 
1. To confirm that macrophages resident within the mesothelioma 
microenvironment express ASS1 
 
2. To establish whether there is a difference in macrophage number 
between ASS1 ‘high’ and ASS1 ‘low’ expressing mesotheliomas using 
patient biopsies from the ADAM trial 
 
3. To evaluate the phenotype of co-cultured macrophages in the 
presence and absence of ADI-PEG20 
 
 
4. To investigate whether macrophages are able to modulate the 
therapeutic response of ASS1 negative mesothelioma cells to ADI-
PEG20 
 
5. To identify the mechanism behind macrophage-mediated tumoural 








First I assessed the expression of ASS1 in macrophages residing in the 
mesothelioma tumour microenvironment.  Analysis of human mesothelioma 
tissue confirmed co-localisation of ASS1 with the macrophage-marker CD68, 
indicating that macrophages are capable of synthesizing the arginine 































Figure 4.1 A+B. Human mesothelioma is enriched with ASS1 expressing macrophages. 
Human mesothelioma sections were assessed by immunofluorescence (IF). Each figure 
demonstrates representative examples of IF stains against CD68 (green) and ASS1 (red), 
clearly showing CD68 and ASS1 co-localisation (merged cells). DAPI (blue) was used as a 
counter-stain to identify cell nuclei. Co-localisation was identified by 63x magnification 
confocal microscopy. Figure A: the scale bar represents 20µm. Figure B: this image is 
zoomed in x2 and the scale bar represents 10µm.  
DAPI CD68 ASS1 MERGE 
DAPI CD68 ASS1 MERGE 
DAPI CD68 ASS1 MERGE 
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4.4 Quantification of macrophage number in ASS1 ‘high’ and 
ASS1 ‘low’ mesothelioma 
 
Biopsies obtained from ADAM clinical trial patients were used to create tissue 
microarrays (TMAs). These TMAs were stained for the macrophage marker 
CD68 by immunohistochemistry. CD68-positive macrophages were then 
quantified using a validated imaging analysis program on the Ariol Imaging 
System (300). Results showed that there was no significant difference in 























Figure 4.2. Percentage of CD68 positive macrophages in human mesothelioma tissue. 
Tissue microarrays (TMAs) from the ADAM clinical trial were stained with the macrophage 
marker CD68. Prior to calculation of the percentage area of CD68 positive staining, all TMA 
cores were first reviewed manually and only included in the analysis if the core was intact with 
minimal fibrotic or acellular areas. This was to standardise tumour area and cellularity and 
enable valid comparisons. Each reviewed core was then entered into the Ariol imaging 
analysis program, to quantify CD68 antibody staining of the TMAs. Graph represents the 
percentage of CD68 positive macrophages in both ASS1 ‘low’ and ASS1 ‘high’ biopsies. The 
black line represents the median.  
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  4.5 Macrophages mediate resistance to ADI-PEG20 in ASS1 
negative mesothelioma cells in vitro    
  
Having established that mesothelioma-associated macrophages are abundant 
in human mesothelioma tissue and express ASS1, I sought to evaluate the 
effect of ADI-PEG20 on the three ASS1 negative mesothelioma cell lines in 
the presence of macrophages using an in vitro co-culture model. Human 
PBMC-derived macrophages were co-cultured with the ASS1 negative cell 
lines 2591, MSTO and Ju77, both with and without direct cell contact (i.e. 
using a 0.4µM transwell insert), in the presence and absence of ADI-PEG20. 
Tumour cell viability was assessed at four days. Results revealed that 
macrophages partially protected the mesothelioma cells from arginine 
depletion (Figure 4.3 and 4.4). Indeed, while macrophage viability was 
unaffected by exposure to ADI-PEG20 (Figure 4.5), there was a significant 
increase in tumour cell viability of up to 30% when tumour cells were co-
cultured with macrophages, compared with tumour cells cultured alone, 
following ADI-PEG20. This increase in viability was apparent when cells were 
cultured with and without direct macrophage contact, implying a soluble factor 
in mediating resistance.  
 
Notably, similar increases in viability were seen across all three ASS1 
negative cell lines, but both 2591 and Ju77 were not as sensitive to ADI-
PEG20 at four days as MSTO. As MSTO was the more sensitive cell line (i.e. 
there was significantly more MSTO cell death (80%) than Ju77 and 2591 by 4 

















































Figure 4.3. Tumour cell viability at 4 days post ADI-PEG20 treatment. The three ASS1 
negative cell lines, 2591, MSTO and Ju77 were analysed. Each cell line was cultured alone 
and in co-culture with macrophages, either with or without direct cell contact (using a 0.4µM 
transwell insert), in the presence and absence of ADI-PEG20. The 2:1 macrophage:tumour 
cell ratio was chosen following extensive optimisation of the ratios, using 1:1, 2:1 and 5:1 
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initially. In addition, the 2:1 macrophage:tumour ratio has previously been used in a recent 
study evaluating the crosstalk between macrophages and colon cancer cells (340).Viability 
was assessed at 4 days by FACS. Apoptotic cells were taken to be the number of annexin V 
positive cells (see raw FACS data, Figure 4.4). Experiments were repeated three times for 
each cell line with values representing the mean (+/- SEM). Statistical analysis (1 way 
ANOVA with Newman Keuls post-test analysis using ‘live cells annexin V negative’): * = 

















































































Figure 4.4. 2591 tumour cell viability following ADI-PEG20 treatment. A) tumour cells 
cultured alone; B) tumour cells co-cultured with macrophages without direct cell contact; C) 
tumour cells co-cultured with macrophages with direct cell contact. Graphs represent one of 
three experiments analysed by FACS. Key: Q1=DAPI +ve dead cells, Q2=DAPI +ve and 
ADI-PEG20 -ve ADI-PEG20+ve 
ADI-PEG20 -ve ADI-PEG20 +ve 
ADI-PEG20 -ve ADI-PEG20 +ve 
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annexin V +ve dead cells (apoptosis), Q3=annexin V +ve live cells (undergoing apoptosis), 
Q4=live cells. 10,000 events were recorded for each condition. Prior to analysis of tumour cell 
viability, the macrophages from co-culture conditions were identified (using CD14 and CD11b 


























































Figure 4.5. MSTO tumour cell viability following ADI-PEG20 treatment. A) tumour cells 
cultured alone; B) tumour cells co-cultured with macrophages without direct cell contact; C) 
tumour cells co-cultured with macrophages with direct cell contact. Graphs represent one of 
ADI-PEG20 -ve ADI-PEG20 +ve 
ADI-PEG20 -ve ADI-PEG20+ve 
ADI-PEG20 -ve ADI-PEG20 +ve 
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three experiments analysed by FACS. Key: Q1=DAPI +ve dead cells, Q2=DAPI +ve and 
annexin V +ve dead cells (apoptosis), Q3=annexin V +ve live cells (undergoing apoptosis), 
Q4=live cells. 10,000 events were recorded for each condition. Prior to analysis of tumour cell 
viability, the macrophages from co-culture conditions were identified (using CD14 and CD11b 


























































Figure 4.6. Ju77 tumour cell viability following ADI-PEG20 treatment. A) tumour cells 
cultured alone; B) tumour cells co-cultured with macrophages without direct cell contact; C) 
tumour cells co-cultured with macrophages with direct cell contact. Graphs represent one of 
ADI-PEG20 -ve 
ADI-PEG20-ve ADI-PEG20 +ve 




three experiments analysed by FACS. Key: Q1=DAPI +ve dead cells, Q2=DAPI +ve and 
annexin V +ve dead cells (apoptosis), Q3=annexin V +ve live cells (undergoing apoptosis), 
Q4=live cells. 10,000 events were recorded for each condition. Prior to analysis of tumour cell 
viability, the macrophages from co-culture conditions were identified (using CD14 and CD11b 























Figure 4.7. Macrophage viability at 4 days post ADI-PEG20 treatment. Macrophages 
were cultured alone and in co-culture with each ASS1 negative tumour cell line (2591, MSTO 
and Ju77, either with or without direct cell contact (using a 0.4µM transwell insert), in the 
presence and absence of ADI-PEG20. Viability was assessed at 4 days by FACS. Annexin V 
positivity denoted apoptotic cells. Graph shows the percentage of viable macrophages 
cultured alone and with MSTO cells (both with and without direct contact) in the presence and 
absence of ADI-PEG20. Similar viability was observed when macrophages were co-cultured 
with the cell lines Ju77 and 2591. ADI-PEG20 does not appear to affect macrophage viability. 
Experiments were repeated three times for each tumour cell line, with values representing the 





4.6 ADI-PEG20 exposure leads to coordinate up-regulation of 
ASS1 in macrophages and ASL in tumour cells 
 
 
To explore the mechanism behind this observed resistance, I tested the effect 
of ADI-PEG20 on the key urea cycle enzymes, ASS1 and ASL, in 
macrophages and ASS1 negative mesothelioma cells. A significant increase 
in ASS1 expression was detected in macrophages co-cultured with tumour 
cells by 48 hours following ADI-PEG20 exposure, compared with 
macrophages cultured alone (Figure  4.8 A+B). In contrast, there was no 
corresponding increase in macrophage ASL (Figure 4.9 A+B). Notably, in the 
tumour cells, re-expression of ASS1, an important early mechanism of 
resistance to ADI-PEG20 in other tumour types (173), was not seen (Figure 
4.10 A+B). However, there was a significant increase in ASL expression in 
tumour cells co-cultured with macrophages, compared with tumour cells 
cultured alone (Figure 4.11 A+B). Taken together, these findings suggest that 
the macrophages are cooperating metabolically with ASS1 negative 
mesothelioma cells via a coordinate up-regulation of the urea cycle enzymes 




























































Figure 4.8. Increase in ASS1 expression in co-cultured macrophages at 48 hours 
following treatment with ADI-PEG20 
  
A) qRT-PCR . Macrophages were cultured alone and in co-culture with MSTO cells 
(without direct cell contact) at a ratio of 2:1 macrophages to tumour cells, in the 
presence and absence of ADI-PEG20. ASS1 gene expression was assessed at 48 
hours following ADI-PEG20 treatment. Graph represents the relative increase in 
ASS1 mRNA expression in co-cultured macrophages following treatment with ADI-
PEG20, compared with macrophages cultured alone in the absence of ADI-PEG20 
(normalised to 1).  Experiments were performed three times in triplicate with values 
representing the mean (+/- SEM). Statistical analysis (I way ANOVA with Newman 
Keuls post-test analysis) ** = p<0.01, *** = p<0.001. 
 
B) Western Blot. Blot shows the increase in expression of ASS1 protein in co-cultured 
macrophages at 48 hours following treatment with ADI-PEG20, with βactin as a 












































































































Figure 4.9. Macrophage ASL expression at 48 hours following ADI-PEG20 treatment. 
 
A) qRT-PCR. Graph shows no difference in ASL mRNA expression in macrophages 
cultured alone and with tumour cells at 48 hours following ADI-PEG20 treatment, 
compared with macrophages cultured alone in the absence of ADI-PEG20 
(normalised to 1). Experiments performed three times in triplicate with values 
representing the mean (+/- SEM). 
 
B) Western Blot. Following ASS1 analysis (see 4.8 B), the blot was stripped using 
stripping buffer for 5 minutes, washed three times for ten minutes in PBS-Tween20, 
and re-probed for ASL.  Western Blot shows expression of macrophage ASL protein 
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observed. βactin was used as a control protein. Experiment was performed three 
times in triplicate.  
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Figure 4.10. ASS1 expression in MSTO tumour cells cultured alone and with 
macrophages ± ADI-PEG20 treatment 
 
A) qRT-PCR. MSTO cells were cultured alone and with macrophages (without direct cell 
contact) in the presence and absence of ADI-PEG20. MSTO ASS1 gene expression 
was assessed at 48 hours following ADI-PEG20 treatment. There is no re- expression 
of tumoural ASS1 mRNA following ADI-PEG20 treatment in cells cultured alone or 
with macrophages. ASS1 expression in MSTO cells is shown relative to an ASS1 
positive control (H226), normalised to 1. Experiments were performed three times in 
triplicate, with the graph representing the mean (+/- SEM).  
 
B) Western blot assessing ASS1 protein expression in MSTO tumour cells, cultured 
alone and in co-culture with macrophages, in the presence and absence of ADI-
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macrophages, following ADI-PEG20 treatment. The ASS1 positive cell line, H226, 








































Figure 4.11. Tumoural ASL expression ± ADI-PEG20 treatment 
 
A) qRT-PCR. Graph shows the relative increase in expression of ASL mRNA in co-
cultured MSTO tumour cells at 48 hours following ADI-PEG20 treatment. 
Experiments were performed three times in triplicate with the values representing the 
mean (+/- SEM).Statistical analysis (1 way ANOVA with Newman Keuls post-test 
comparison analysis) * = p<0.05, ** = p<0.01.   
 
B) Western Blot. A significant increase in ASL protein expression is seen in MSTO cells 
co-cultured with macrophages at 48 hours post ADI-PEG20 treatment, supporting the 
increased expression in ASL mRNA seen by qRT-PCR. There is also an increase in 
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4.7 Tumour-derived pro-inflammatory cytokines induced by 
ADI-PEG20 modulate macrophage ASS1 expression 
 
 
Next, I studied whether the tumour-derived pro-inflammatory cytokines 
induced by ADI-PEG20 (IL-1α, IL-8, CXCL2, CXCL3 and VEGFA) and 
associated with ADI-PEG20 resistance in ADAM trial patients (IL-8, CXCL2 
and VEGFA; Chapter 3), modulated ASS1 and ASL expression. I found that 
macrophages stimulated with IL1α, CXCL2, CXCL3 and IL-8, but not VEGFA, 
increased ASS1 expression to levels comparable to that seen in co-culture. 
Moreover, the cytokine combination was the most potent inducer of ASS1 
(Figure 4.12 A+B), confirming a link between inflammatory and metabolic 
signalling pathways. 
 
In contrast, tumoural ASL expression was unaffected by cytokine stimulation 
(Figure 4.13), nor by the addition of the product of ASS1 activity, 
argininosuccinate, at lower concentrations (Figure 4.14). There was, however, 
a small decrease in tumoural ASL protein expression following addition of 












































Figure 4.12 A. Induction of ASS1 in macrophages by pro-inflammatory cytokines (qRT-
PCR). Macrophages were stimulated with pro-inflammatory cytokines for 48 hours. Graphs 
show the relative increase in expression of ASS1 mRNA following the addition of individual 
cytokines IL-8, IL-1α, CXCL2 and CXCL3, and a combination of all five. The concentration of 
individual cytokines added to the combination were: IL-8, 100ng/ml; IL-1α, 1ng/ml; CXCL2, 
CXCL3 and VEGFA, 10ng/ml. No change is seen in VEGFA expression. Experiments were 
repeated twice in triplicate with the values representing the mean (+/- SEM). Statistical 





















Figure 4.12 B. Induction of ASS1 in macrophages by pro-inflammatory cytokines 
(western blot). Blot shows the increase in macrophage ASS1 protein expression at 48 hours 
following stimulation with the individual cytokines IL-8 (100ng/ml), IL-1α (1ng/ml), CXCL2 
(10ng/ml) and CXCL3 (10ng/ml), and the cytokine combination. The combination results in 
the most significant increase. Expression of ASS1 protein following VEGFA (10ng/ml) 



















































































Figure 4.13. ASL expression in MSTO mesothelioma cells ± pro-inflammatory 
cytokines. Western blot shows the expression of ASL protein in tumour cells at 48 hours 
following stimulation with IL8 (100ng/ml), IL1α (1ng/ml), CXCL2 (10ng/ml), CXCL3 (10ng/ml), 
VEGFA (10ng/ml) and a combination of all five. There is no difference in expression of ASL, 
compared with the un-stimulated MSTO control. Experiments were performed twice, with β 






































































































Figure 4.14. ASL expression in MSTO mesothelioma cells ± ADI-PEG20 and 
argininosuccinic acid (ASA). Western blot shows tumour ASL protein expression at 48 
hours following treatment with ADI-PEG20 plus ASA at increasing concentrations, compared 
with the no drug control. There appears to be a decrease in ASL expression at the higher 
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4.8 Co-cultured macrophages secrete argininosuccinate 
following ADI-PEG20 
 
Given the coordinate increase in urea cycle enzymes in macrophages and 
tumour cells, it was hypothesised that the arginine precursor, 
argininosuccinate, may be critical to macrophage-mediated resistance to ADI-
PEG20. Therefore, I analysed the cell supernatant levels of arginine, citrulline 
and argininosuccinate from tumour cells and macrophages, alone and in co-
culture, by mass spectrometry. As expected, across all conditions, the 
arginine concentration decreased to negligible levels, with a doubling in 
citrulline, by 48 hours following ADI-PEG20 treatment (Figure 4.15 A and B). 
The argininosuccinate concentration in cell supernatant from macrophages 
cultured alone did not change following ADI-PEG20. Conversely, upon co-
culture with ASS1 negative tumour cells, a relative doubling in the 
argininosuccinate concentration was observed by 48 hours following ADI-
PEG20 treatment, indicating that macrophages secrete this amino acid 
precursor in response to pro-inflammatory signalling from arginine-deprived 




































Figure 4.15. Arginine and Citrulline in supernatant of co-cultured cells ± ADI-PEG20. 
Graphs show; A) the decrease in arginine levels by 48 hours following ADI-PEG20 treatment; 
B) Citrulline levels are almost double following ADI-PEG20 treatment in all conditions. 
Experiments performed three times in triplicate with the graphs representing the mean (+/- 
SEM). Cell preparation for mass spectrometry was performed by Melissa Phillips. Mass 
spectrometry was kindly performed by Dr Essam Ghazaly.     


















Figure 4.16. Argininosuccinate in supernatant of co-cultured cells ± ADI-PEG20. Graph 
shows the significant increase in argininosuccinate concentration in the supernatant from co-
cultured cells at 48 hours following ADI-PEG20 treatment. This is seen in conditions where 
there is both no direct cell contact and direct cell contact. Each condition with no ADI-PEG20 
treatment is normalised to 1 and the ADI-PEG20 treated conditions are shown relative to the 
no drug control for that condition. The graph is presented in this way due to differences in 
argininosuccinate baseline levels across the three experiments when analysed by mass 
spectrometry. Argininosuccinate concentration in the supernatant of tumour cells cultured 
alone was negligible and is therefore not shown on the graph. Experiments were performed 
three times in triplicate with values representing the mean (+/- SEM). Statistical analysis 
(unpaired two-tailed t test) *** = p<0.001. Cell preparation for mass spectrometry was 
performed by Melissa Phillips, mass spectrometry was kindly performed by Dr Essam 
Ghazaly.   
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4.9 Argininosuccinate rescues ASS1 negative mesothelioma 
cells from ADI-PEG20-induced cytoxicity 
 
 
The above results suggest that macrophages mediate resistance to ADI-
PEG20 in ASS1 negative mesothelioma cells via the delivery of 
argininosuccinate, in this way bypassing the ADI-PEG20-induced tumour 
cytotoxicity. To further explore the role of argininosuccinate, ASS1 negative 
tumour cells were treated with ADI-PEG20 and argininosuccinic acid (ASA; 
Sigma) was added at increasing concentrations. For consistency with 
previous co-culture experiments, tumour cell viability was assessed at 4 days. 
MTS assay results revealed that tumour cell viability increased with escalating 
concentrations of argininosuccinate, confirming that ASS1 negative tumour 
cells are able to uptake and utilise argininosuccinate (Figure 4.17). Therefore, 




















Figure 4.17. Effect of argininosuccinate on MSTO cell viability following treatment with 
ADI-PEG20. MSTO cells were treated with ADI-PEG20 plus argininosuccinic acid (ASA) at 
increasing concentrations. After four days, cell viability was assessed by MTS. Graph shows 
the increase in MSTO cell viability with the addition of argininosuccinate, following ADI-
PEG20 treatment. Experiment was repeated three times in triplicate with values representing 




4.10 Macrophage-mediated resistance to ADI-PEG20 is 
reversed by tumoural ASL knockdown 
 
 
Results from the previous section led to the hypothesis that cytokine-induced 
argininosuccinate is key to macrophage-mediated resistance. To confirm this, 
MSTO cells were transfected with SiRNA directed against ASL. Efficient 
knockdown of ASL mRNA expression knockdown was achieved in MSTO 
cells by 48 hours and remained below 50% of control levels by 96 hours, 
enabling the knockdown cells to be used in co-culture experiments (Figure 
4.18). I found that cell viability in ASL knockdown tumour cells co-cultured 
with macrophages was similar to tumour cells cultured alone following ADI-
PEG20 treatment. Therefore, macrophage-mediated resistance of ADI-
















Figure 4.18. SiRNA knockdown of tumoural ASL mRNA expression. Graph shows ASL 
knockdown in MSTO cells after 48 and 96 hours, compared with the SiControl (normalised to 




















Figure 4.19. MSTO cell viability following ASL mRNA knockdown and ADI-PEG20. 
MSTO tumour cells were transfected with ASL SiRNA or SiControl 50nM as in Figure 4.18.  
After 8 hours, media was removed and cells were washed three times with PBS. Using one 
control well, the tumour cells were counted. MSTO cells were then cultured alone and in co-
culture with macrophages (with and without direct cell contact at a ratio of 2:1 macrophages 
to MSTO tumour cells) in the presence and absence of ADI-PEG20. Cell viability was 
assessed at 4 days by FACS. The graph represents live cells only and shows that ASL mRNA 
knockdown abrogates the metabolic resistance conferred by macrophages. Experiments and 
FACS analysis were repeated three times with values representing the mean (+/- SEM). 






























Figure 4.20.  MSTO tumour cell viability following ASL mRNA knockdown and ADI-
PEG20. A) tumour cells cultured alone; B) tumour cells co-cultured with macrophages without 
direct cell contact; C) tumour cells co-cultured with macrophages with direct cell contact. 
Graphs represent one of three experiments analysed by FACS. Key: Q1=DAPI +ve dead 
cells, Q2=DAPI +ve and annexin V +ve dead cells (apoptosis), Q3=annexin V +ve live cells 
(undergoing apoptosis), Q4=live cells. 10,000 events were recorded for each condition. Prior 
to analysis of tumour cell viability, the macrophages from co-culture conditions were identified 
(using CD14 and CD11b stains) and excluded. Only tumour cells are shown in the graphs.  
ADI-PEG20 -ve ADI-PEG20 +ve ADI-PEG20 +ve 
SiControl 










4.11 Proteomic analysis of arginine-labelled peptides in ASS1 
negative tumour cells cultured alone and with macrophages 
 
 
To further validate the mechanism of resistance, proteomic analysis to identify 
the percentage of arginine-labelled peptides present in ASS1 negative tumour 
cells cultured alone and with macrophages, was performed. By replacing 
arginine in the media with 13C arginine, the label could be traced through the 
cells. Arginine-labelled peptides were then identified in tumour cells cultured 
with and without macrophages by 48 hours of ADI-PEG20 treatment. Results 
show a small increase in the percentage of arginine labelled peptides 
identified in the lysates of tumour cells co-cultured with macrophages, 
compared with tumour cells cultured alone. However, results are difficult to 
interpret due to the fact that the triplicate results for tumour cells cultured 
alone across two separate experiments were very different and, furthermore, 
it is surprising to observe any arginine-labelled peptide in these tumour cells, 
given that no ASS1 expression was identified. Further experiments are 






















Figure 4.21. Proteomic analysis identifying the percentage of arginine labelled peptides 
present in MSTO tumour cells following ADI-PEG20 treatment. MSTO tumour cells were 
cultured in SILAC media, ±13C arginine, alone and in co-culture with macrophages (with direct 
cell contact) in the presence and absence of ADI-PEG20. After 48 hours, cells were collected 
and the tumour cells were separated from the macrophages by live cell sorting, with 99% 
purity. Tumour cells were then washed with PBS, lysed in 8M urea lysis buffer and stored at -
80°C in preparation for proteomic analysis. For proteomics, cell preparation was performed by 
Dr Pedro-Maria Casado with Melissa Phillips observing. Proteomic analysis was performed by 
Dr Pedro Cutillas. Graph represents the percentage of arginine labelled peptides identified in 
tumour cells cultured alone and with macrophages at 48 hours following ADI-PEG20 
treatment. Graph is representative of two experiments performed in triplicate.  Error bars 





4.12 Analysis of macrophage phenotype in the presence and 
absence of ADI-PEG20 
 
Having demonstrated that macrophages are involved in mediating tumoural 
resistance to ADI-PEG20, I next wanted to study macrophage phenotype in 
co-culture in the presence and absence of ADI-PEG20. Macrophage 
phenotype was assessed by analysing expression of several recognised ‘M1’ 
and ‘M2’ specific cell surface markers (high expression of HLADR in 
M1skewed macrophages and high expression of CD163 and CD206 in 
M2skewed macrophages), in addition to expression of the ‘M2’ intracellular 
cytokine, IL10, and the enzyme arginase. FACS analysis revealed a cell 
surface phenotype typical of alternative activation, with increased expression 
of CD163 and CD206 and a significant decrease in HLA-DR in macrophages 
co-cultured with tumour cells, compared with macrophages cultured alone in 
the absence of ADI-PEG20 (Figure 4.22 and 4.23). Interestingly, treatment of 
co-cultured macrophages with ADI-PEG20 resulted in a decrease in the 
percentage staining for CD163 and CD206. However, there was also a 
significant decrease in HLA-DR expression in co-cultured macrophages 
following ADI-PEG20.  
qRT-PCR results showed a significant increase in macrophage expression of 
IL-10 in macrophages co-cultured  with tumour cells, compared with 
macrophages cultured alone in the absence of ADI-PEG20 (Figure 4.24). 
Gene expression of IL-10 did not change significantly in co-cultured 
macrophages following ADI-PEG20 treatment.  Conversely, macrophage 
expression of arginase significantly decreased following ADI-PEG20 
treatment (Figure 4.25). Therefore, taken together, results suggest that 
changes in co-cultured macrophage phenotype following ADI-PEG20 do not 
fit classic M1or M2 stereotypes, instead displaying heterogeneity.  More work 
























Figure 4.22. Cell surface marker expression in macrophages cultured alone and with 
MSTO tumour cells ±ADI-PEG20. Macrophages were cultured alone and in co-culture with 
MSTO tumour cells without direct cell contact at a ratio of 2:1 macrophages to tumour cells, in 
the presence and absence of ADI-PEG20. After three days macrophage cell surface marker 
expression was analysed by FACS. Graph shows the increase in expression of recognised 
M2 markers CD163 and CD206 in co-cultured macrophages. Expression of these markers 
decreases in co-cultured macrophages following ADI-PEG20 treatment. HLA-DR, recognised 
as being increased in M1 skewed macrophages, significantly decreases in co-cultured 
macrophages. There is a further decrease following ADI-PEG20 treatment. Experiments were 
performed three times, with values representing the mean (+/-SEM). Statistical analysis (1 
way ANOVA with Newman Keuls multiple comparison post test analysis for each stain; HLA-




























Figure 4.23. Macrophage cell surface marker expression ± ADI-PEG20. FACS data 
shown represents one of three experiments performed. Following 3 days of culture ± ADI-
PEG20, macrophages were analysed by FACS. A) HLADR expression, B) CD163/CD206 





































Figure 4.24. Induction of IL-10 mRNA expression in co-cultured macrophages ± ADI-
PEG20. Macrophages were cultured alone and in co-culture with MSTO tumour cells without 
direct cell contact at a ratio of 2:1 macrophages to tumour cells, ± ADI-PEG20. After 3 days, 
macrophages were collected for qRT-PCR analysis. Graph shows an increase in expression 
of IL-10 in macrophages co-cultured with tumour cells with and without ADI-PEG20, relative 
to macrophages cultured alone in the absence of ADI-PEG20 (normalised to 1). Experiments 
performed twice in triplicate with values representing the mean (+/- SEM). Statistical analysis 





















Figure 4.25. Co-cultured macrophage arginase expression following ADI-PEG20 
treatment. Graph shows the relative decrease in arginase expression in co-cultured 
macrophages at three days following ADI-PEG20 treatment, compared with co-cultured 
macrophages in the absence of ADI-PEG20 (normalised to 1). Experiment was repeated 
twice in triplicate with values representing the mean (+/- SEM). Statistical analysis (unpaired 





The metabolic role of macrophages, as abundant host cells within the MPM 
tumour microenvironment, was examined in ASS1-deficient mesothelioma 
cells exposed to ADI-PEG20. The results show that TAM have a key 
modulatory effect on the impact of ADI-PEG20 in the arginine auxotrophic 
cancer, mesothelioma. The data indicate that ASS1-deficient mesothelioma 
tumour cells co-opt macrophages to release argininosuccinate, which 
bypasses the anti-tumour effects of ADI-PEG20 (for a diagrammatic 
summary, please see Figure 4.26).  
 
Thus, there was a significant pro-inflammatory cytokine response by ASS1 
negative mesothelioma cells following ADI-PEG20 which plays a central role 
in the up-regulation of ASS1 in co-cultured macrophages. Previously, it has 
been shown that a number of pro-inflammatory cytokines can induce up-
regulation of ASS1 in endothelial and inflammatory cells, including TNF alpha, 
IL1 and TGF beta (112). Here, I have identified members of the ELR +ve CXC 
subgroup of pro-inflammatory chemokines, CXCL2, CXCL3 and IL-8, as novel 
regulators of ASS1 expression in macrophages. Furthermore, as this up-
regulation is coupled with an increased capacity to protect the tumour cells 
from ADI-PEG20 cytotoxicity via argininosuccinate secretion, it suggests a 
key mechanistic link between the inflammatory response and macrophage-
mediated resistance evident in co-culture. 
 
ASL expression, although not modulated in macrophages, was found to be 
significantly increased in co-cultured tumour cells following ADI-PEG20 
treatment. However, the stimulus for the increase in ASL expression is 
unclear, as neither the pro-inflammatory cytokines, nor the addition of 
argininosuccinate, induced expression. The metabolic crosstalk between 
ASS1 negative tumour cells and macrophages is likely to involve multiple 
signalling pathways and identifying signals that induce ASL expression 
requires further investigation. 
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It is interesting to note, however, that ASL has been shown to be 
transcriptionally induced by ER stress (138). In this study, ER stress was 
induced in vitro and in vivo using tunicamycin. Results revealed significant up-
regulation of ASL mRNA and protein in human hepatoma cell lines in vitro. 
Moreover, ASL was also induced in the livers of C57BL/6 mice following 
intraperitoneal tunicamycin administration, confirming that ASL expression 
was induced by ER stress.  Further study into the effect of tunicamycin-
induced ER stress on ASL expression in the ASS1 negative mesothelioma 
cell lines would be helpful to identify whether ER stress is a contributing factor 
in the modulation of ASL expression seen here.  
 
Less is known about the tumoural role of ASL. Recently, ASL has been found 
to be up-regulated in hepatocellular carcinoma (HCC), with increased 
expression linked to increased aggressiveness mediated by NO and cyclin A2 
signaling (138). In addition, in fumarate hydratase (FH) deficient renal cell 
cancer (RCC), where ASL is intact, the enzyme’s activity is reversed 
producing high levels of argininosuccinate from arginine and fumarate. (140). 
As seen with ASS1, the role of ASL in human cancer appears to be 
dependent on tumour type and further work is needed to gain a better 




























Figure 4.26. Proposed mechanism of macrophage-mediated resistance to ADI-PEG20 
in ASS1 negative mesothelioma.  It is hypothesised that ADI-PEG20-induced arginine 
deprivation leads to ER stress in ASS1 negative mesothelioma cells, activating the UPR and 
resulting in pro-inflammatory cytokine secretion. This pro-inflammatory cytokine response 
induces up-regulation of macrophage ASS1, associated with macrophage secretion of the 
arginine precursor, argininosuccinate. Via ASL, tumour cells are able to uptake and utilize 






This is the first time that metabolic cooperation resulting in the provision of 
arginine has been demonstrated between ASS1 negative tumour cells and 
macrophages in the context of arginine depletion.  However, previous 
research into childhood citrullinemia, an autosomal recessive urea cycle 
disorder caused by mutations in the ASS1 gene, found that metabolic 
cooperation also exists between co-cultured fibroblasts deficient in either 
ASS1 or ASL. Similar to my findings, the coordinate regulation of these urea 
cycle enzymes resulted in protection of both cell types from arginine depletion 
(341).  In this study, however, it was hypothesised that the delivery of 
argininosuccinate was primarily via intercellular junctions, and this resulted in 
almost 100% fibroblast viability. Results from the tumour/macrophage co-
cultures instead suggest that a soluble factor is mediating resistance, as 
tumour cells are not required to be in direct contact with macrophages, and 
this leads to a smaller increase in tumour cell viability. The protection provided 
by macrophage-secreted argininosuccinate is also substrate dependent, with 
tumour cell viability increasing with increasing amounts of argininosuccinate. 
As the concentration of argininosuccinate in co-culture supernatant was in µM 
range, this may explain why smaller increases in cell viability were observed. 
In support of this, a study examining arginine synthesis in cattle kidney cortex 
also reported that in similar in vitro experiments to assess arginine production 
by HPLC, synthesis of arginine from argininosuccinate was also strongly 
dependent on substrate concentration. Here, the synthesis of arginine from 
argininosuccinate was found to be very sensitive to concentrations up to 
1mmol/l, and maximum production of arginine was found at 15mmol/l (342). 
Importantly, this study also demonstrates that argininosuccinate can be 
utilised by cells to synthesise arginine.  
 
To validate the role of argininosuccinate in ADI-PEG20 resistance, siRNA 
knockdown of ASL was performed. Results showed that the observed 
resistance is abrogated following silencing of ASL in the tumour cells, 
demonstrating that a functioning ASL in ASS1 negative mesothelioma cells is 
critical for macrophage-mediated resistance to ADI-PEG20. Indeed, ASL is 
required for the conversion of argininosuccinate to arginine, key to this 
proposed resistance mechanism. This finding also supports results from a 
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recent study investigating arginine depletion in glioblastoma multiforme 
(GBM); Syed and colleagues reported that methylated ASL contributes to the 
arginine auxotrophy of GBM, with the loss of ASL as well as ASS1 conferring 
greater sensitivity to ADI-PEG20 (139).  
 
As an alternative method of validation of the described resistance mechanism, 
proteomic analysis of 13C arginine-labelled peptides present in tumour cells 
cultured alone or with macrophages following ADI-PEG20 treatment, was 
performed. It was hypothesised that treating the media containing 13C labelled 
arginine with ADI-PEG20 prior to adding it to the MSTO tumour cells ± 
macrophages, would result in the breakdown of labelled arginine to labelled 
citrulline before contact with cells. As ASS1 negative cells would be unable to 
synthesise this citrulline to arginine due to the loss of ASS1 expression, it was 
proposed that in tumour cells cultured alone, no 13C arginine labelled peptides 
would be identified. In contrast, it was postulated that in tumour cells co-
cultured with macrophages, the macrophages could convert the labelled 
citrulline to argininosuccinate via ASS1 and as shown in the previous 
experiments, MSTO cells could utilise available argininosuccinate secreted by 
the macrophages to synthesise arginine. In this way 13C arginine labelled 
peptides would be detectable in co-cultured tumour cells. However, there 
were technical issues with this experiment. The arginine labelled peptides 
identified in tumour cells cultured alone were unexpected. This may be 
because media was added to the cells immediately following the addition of 
ADI-PEG20, which may have not allowed enough time for the complete 
breakdown of the labelled arginine. Therefore, tumour cells would have 
readily taken up any available labelled arginine, altering the results. Future 
work would require confirmation of arginine depletion in the media prior to 
adding it to the cells. 
 
It is now widely recognised that cancer cells cooperate with stromal cells and 
optimise the resources present within their environment to promote tumour 
growth. Until recently, most research on the mechanisms by which the stromal 
cells promote tumour growth has focused on changes in the ECM and the 
increased secretion of tumour promoting cytokines, such as IL-6, IL-8 and 
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VEGFA (343, 344). Now, increasingly, investigators are considering the 
metabolic properties of the tumour stroma and the contribution that metabolic 
cooperation between tumour cells and stromal cells makes to tumour 
progression (197). Indeed, several independent studies have recently 
highlighted the importance of metabolic-coupling, where stromal cells serve 
as ‘food donors’ for cancer cells, thereby promoting proliferation and invasion 
(345). For example, CAFs have been shown to serve as a key source of high 
energy nutrients to fuel cancer cell mitochondrial activity (346). In the 
crosstalk between CAFs and tumour cells, production of ROS by the tumour 
cells leads to oxidative stress and activation of key transcription factor HIF1α. 
By inducing autophagy, HIF1α promotes degradation of Caveolin-1 (Cav-1) in 
CAFs, leading to dysfunctional mitochondria. As CAFs attempt to remove the 
dysfunctional mitochondria via mitophagy, they rely on enhanced glycolysis, 
leading to increased production of energy-rich nutrients. Thus, a ‘reversed 
Warburg’ effect occurs in these cells, which secrete the high energy nutrients, 
including lactate, ketone bodies and glutamine. These molecules are then 
used by anabolic cancer cells in more oxygenated areas to serve as a source 
of energy and/or intermediates to biosynthesis (347, 348). Via this metabolic-
coupling, CAFs therefore ‘feed’ cancer cells. The loss of Cav-1 as a result of 
this coupling is associated with poor clinical outcome in prostate and breast 
cancers (349, 350).  
 
Adipocytes have also been shown to fuel mitochondrial oxidation and promote 
tumour growth. Indeed, it was recently reported that in ovarian cancer, tumour 
cells reprogram the metabolism of adipocytes to become catabolic, leading to 
lipolysis in adipocytes, with the release of free fatty acids that can be used as 
a fuel for cancer cells. Ovarian cancer cells adjacent to these activated 
adipocytes show increased fatty acid uptake and utilisation via β-oxidation in 
mitochondria, demonstrating that metabolic-coupling also occurs between 
these two cellular compartments (351). 
 
Here, I have found that tumour cells co-opt macrophages to secrete 
argininosuccinate, critical to the survival of ASS1-deficient mesothelioma 
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cells, following arginine depletion. In this situation the argininosuccinate is 
therefore ‘feeding’ these cancer cells.  
 
Interestingly, macrophage plasticity has previously been shown to be 
modulated by metabolites and metabolic enzymes within the tumour 
microenvironment (TME) (352).  Both the increased production of lactate by 
tumour cells and the acidic TME have a profound impact on the secretory 
profile of TAM, promoting tumour angiogenesis (353, 354). This environment 
also promotes the development of MDSCs and immune suppression (355). 
Thus, a metabolic symbiosis is formed with innate immune cells to facilitate 
tumour growth. 
 
Importantly, tumour-stromal metabolic-coupling also induces drug resistance, 
as energy-rich metabolites derived from stromal cells are able to maintain 
mitochondrial ‘well-being’ in cancer cells. Indeed, it was recently discovered 
that the enhanced mitochondrial activity in epithelial cancer cells promotes 
tamoxifen resistance in breast cancer. Here, co-culture of oestrogen receptor 
positive (ER+) MCF7 breast cancer cells with fibroblasts resulted in a 4.4-fold 
reduction in tumour cell apoptosis following tamoxifen treatment, compared 
with tumour cells cultured alone. The authors found that combination 
treatment with a mitochondrial ‘poison’ such as metformin was able to re-
sensitise breast cancer cells to tamoxifen (356).  
 
Furthermore, following asparaginase- induced depletion of asparagine, 
mesenchymal-derived stromal cells are able to ‘feed’ this amino acid to 
asparagine-auxotrophic leukaemic cells in ALL, thereby protecting these cells 
from asparaginase cytotoxicity (described in the introduction)(357).  
 
The pro-tumoural effects of TAM, including drug resistance, are generally 
attributed to the M2-skewed phenotype. It was therefore of interest that 
macrophages co-cultured with ASS1 negative mesothelioma cells 
demonstrated cell surface marker expression typical of alternative activation, 
with increased expression of CD206 and CD163, recognised M2 markers. 
Furthermore, IL-10 mRNA was significantly increased in co-cultured 
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macrophages and HLA-DR significantly decreased, compared with 
macrophages cultured alone, both linked to alternative activation. These 
findings are consistent with a previous in vitro study that analysed ovarian 
cancer cells in co-culture with macrophages. Investigators here found that 
following co-culture there were dynamic changes in macrophage expression 
of IL-10 and development of a cell surface phenotype typical of alternative 
activation (358). Notably, they also found that one of the genes significantly 
up-regulated in co-cultured macrophages compared with macrophages 
cultured alone, was ASS1, which increased 5-fold (using semi-quantitative 
PCR). mRNA expression of macrophage ASS1 also increased following co-
culture with ASS1 negative mesothelioma cells, which may indicate another 
marker of alternative activation.  
 
However, the phenotype of macrophages following ADI-PEG20 is more 
difficult to understand. Findings suggest a more complex situation, resulting in 
functional polarisation towards a mixed M1/M2 phenotype. Indeed, the 
expression of M2 cell surface markers were decreased and were more 
comparable with the expression observed in macrophages cultured alone. 
However, HLR-DR significantly decreased following ADI-PEG20, suggesting 
an even more immunosuppressive phenotype. It is well-established that 
plasticity and diversity are hallmarks of macrophages and that these immune 
cells undergo intense functional re-programming in response to different 
signals from within the TME, including cytokines and metabolic products of 
cancer cells (e.g. lactate) (359). Therefore, perhaps exposure to ADI-PEG20, 
the cytokine response by the tumour to this arginine-depleting agent, and the 
modulation of metabolic pathways as a result of the loss of arginine, result in 
the dynamic changes observed in the co-cultured macrophages. Further 
investigation is required to establish the functional relevance of these 
changes. 
 
Another significant change in co-cultured macrophages following ADI-PEG20 
exposure is the decrease in mRNA expression of arginase. Indeed, arginase 
is another key marker of alternative activation. However, the decrease here 
may to be due to the sudden need to endogenously synthesise arginine 
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following ADI-PEG20-induced arginine depletion, and it has previously been 
shown that macrophages are able to effectively synthesise arginine (360). 
Arginine is either catabolised by iNOS to give NO and citrulline, or arginase, 
to give ornithine and urea. Therefore, as arginine synthesis is essential for 
macrophage survival in the context of arginine depletion, it is hypothesised 
that catabolism of arginine may become dominated by iNOS, and the citrulline 
produced re-cycled to synthesise arginine. This may explain the decrease in 
arginase expression in co-cultured macrophages following ADI-PEG20 
treatment.  
 
It is important to note that arginase expression in TAM has been shown to 
have a key role in tumour growth, possibly via an arginase-dependent 
pathway responsible for producing polyamines, substrates that play a critical 
role in cell proliferation (361). The functional change in arginase expression 
may therefore have a longer term effect on tumour growth under continued 
depletion of arginine. This requires further study.      
 
In addition to evaluating macrophage phenotype, macrophage number in 
human mesothelioma tissue was also assessed, to determine whether 
numbers differed between ASS1 ‘low’ and ASS1 ‘high’ expressing tumours. 
Results demonstrated that there was no significant difference in macrophage 
number between low and high expressing ASS1 mesotheliomas, although 
there was a trend towards an increase in ASS1 ‘low’ tumours. In view of this 
observed trend, a more significant difference may be seen with more biopsy 
analyses. Furthermore, for macrophage quantification, immunohistochemical 
staining against the pan-macrophage marker CD68 was used. This has a 
number of limitations, which may affect the results.  Firstly, in humans, 
although CD68 expression is predominantly found on macrophages, it can 
also be expressed on granulocytes, dendritic cells, fibroblasts, endothelial 
cells and some lymphoid subsets (236, 245). Secondly, CD68 is not a specific 
marker for determining macrophage phenotype. As it has previously been 
shown that high numbers of M2-skewed TAM predict poor prognosis in 
mesothelioma (283), and, indeed, in many other tumour types (244), perhaps 
immunohistochemical staining against the M2 cell surface marker CD163 may 
228 
 
be useful in identifying differences in ASS1 ‘low’ and ASS1 ‘high’ expressing 
mesotheliomas.   
 
In summary, results presented in this chapter clearly demonstrate that as a 
result of metabolic cooperation, macrophages are able to partially protect 
ASS1 negative mesothelioma cells from ADI-PEG20 cytotoxicity via provision 
of the arginine precursor, argininosuccinate. Furthermore, the crosstalk 
between inflammatory and metabolic signalling pathways is central to this 
resistance mechanism.  
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Chapter 5. Macrophage depletion potentiates the 





Results presented in the previous chapters have demonstrated that 
macrophages are able to mediate tumoural resistance to ADI-PEG20 in ASS1 
negative MPM, and that the crosstalk between inflammatory and metabolic 
signalling pathways is critical to this resistance. Therefore, having established 
a link between pro-inflammatory cytokine signalling, macrophage activation 
and ADI-PEG20 resistance, the next step was to consider methods to 
overcome this resistance. This chapter evaluates two methods to overcome 
macrophage-mediated resistance in MPM; blockade of the CXCL/CXCR2 
signalling pathway in vitro and in vivo, and depletion of macrophages in vivo. 
Ultimately, the aim was to establish whether targeting macrophages in 









The aims of this chapter were: 
 
 
1. To investigate the role of CXCR2 in macrophage-mediated resistance 
to ADI-PEG20 
 
2. To study the effect of CXCR2 blockade on macrophage-mediated 
resistance to ADI-PEG20 
 
 
3. To quantify macrophage number in murine tumours in the presence 
and absence of ADI-PEG20, to determine whether ADI-PEG20 induces 
macrophage recruitment into the tumour site. 
 
 
4. To evaluate whether macrophage depletion potentiates the cytotoxic 












5.3 CXCR2 expression is up-regulated in co-cultured 
macrophages following ADI-PEG20 treatment 
 
 
As discussed previously, three of the ADI-PEG20-induced chemokines found 
to up-regulate ASS1 expression in macrophages, IL-8, CXCL2 and CXCL3, 
promote tumour angiogenesis, proliferation and inflammatory cell recruitment 
via binding to the G protein-coupled receptor, CXCR2. This indicates that 
CXCR2 signalling may play a key role in macrophage-mediated resistance to 
ADI-PEG20. Macrophage CXCR2 expression was therefore evaluated to 
determine whether there was any modulation following ADI-PEG20 treatment. 
Results revealed a significant increase in CXCR2 mRNA expression in co-
cultured macrophages compared with macrophages cultured alone. A further 
increase in CXCR2 mRNA expression was seen in co-cultured macrophages 
following ADI-PEG20 treatment, suggesting that expression of this receptor 
increases in response to the inflammatory cytokines released by the tumour 




















Figure 5.1. Co-cultured macrophage CXCR2 expression following ADI-PEG20 
treatment. Macrophages were cultured alone and in co-culture with MSTO tumour cells 
without direct cell contact ±ADI-PEG20 for 24 hours. Graph shows the relative increase in 
CXCR2 mRNA expression in macrophages co-cultured with tumour cells, compared with 
macrophages cultured alone (normalised to 1). A further increase is seen following ADI-
PEG20 therapy. Experiments were performed twice in triplicate with values representing the 
mean (+/-SEM). Statistical analysis (unpaired two-tailed t test) * = p<0.05, ** = p<0.01. 
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5.4  CXCR2 blockade fails to prevent up-regulation of 
macrophage ASS1 in response to ADI-PEG20 
 
Having identified that CXCR2 is up-regulated in co-cultured macrophages 
following ADI-PEG20 treatment, it was hypothesised that the CXCR2-axis 
may be an important link between the inflammatory and metabolic signalling 
pathways leading to increased macrophage ASS1 expression and 
subsequently ADI-PEG20 resistance. To investigate this, a small molecule 
inhibitor of CXCR2, SB225002, was used in combination with ADI-PEG20 in 
macrophages co-cultured with tumour cells, to determine whether CXCR2 
blockade attenuates the increase in expression of macrophage ASS1 
following ADI-PEG20 treatment. Results revealed that CXCR2 blockade had 
no effect on co-cultured macrophage ASS1 expression following ADI-PEG20 
treatment, with the increased expression identified on western blot analysis 
comparable to that seen following ADI-PEG20 alone (Figure 5.2). This implies 
that blocking CXCR2 alone is not sufficient to dampen the macrophage 
metabolic response to ADI-PEG20 treatment, indicating that other signalling 


















Figure 5.2. Co-cultured macrophage ASS1 expression following ADI-PEG20 treatment 
and CXCR2 blockade. Macrophages were co-cultured with MSTO tumour cells without direct 
cell contact ±ADI-PEG20 and SB225002 for 48 hours. Blot shows an increase in co-cultured 
macrophage ASS1 expression following ADI-PEG20 treatment. ASS1 expression also 
increases with ADI-PEG20 in combination withSB225002.Experiment repeated twice with 















































5.5  CXCR2 blockade has no effect on the anti-tumour efficacy 
of ADI-PEG20 in vivo.   
 
In parallel with evaluating the effect of CXCR2 blockade on macrophage 
ASS1 expression in vitro, a pilot xenograft study was set up to look at the 
influence of CXCR2 blockade on ADI-PEG20-induced tumour cytotoxicity in 
vivo. Nude mice bearing subcutaneous xenografts of MSTO were treated with 
SB225002, ADI-PEG20, or a combination of both. Results revealed that ADI-
PEG20 suppressed tumour growth (p=0.07 with n=5) compared with vehicle 
control. However, although there was a small reduction in tumour volume in 
mice receiving SB225002 compared with vehicle control (p=0.28 with n=5), 
there was no additive effect in supressing mesothelioma growth when 
combined with ADI-PEG20, compared with ADI-PEG20 alone (Figure 5.3). In 
view of the results from this pilot study, no further in vivo studies evaluating 























Figure 5.3. CXCR2 blockade plus ADI-PEG20 in vivo.  In this pilot study 5 mice were used 
in each of the four conditions (n=20). Tumours were measured twice weekly for the duration 
of the study. Dosing schedule for both agents is explained in detail in the methods section. 
Graph shows the difference in tumour volume following ADI-PEG20, SB225002, or a 
combination of both, compared with vehicle control. Pilot experiment performed once. 
Statistical analysis (unpaired two-tailed t test at final time point comparing ADI-PEG20 (red) 





5.6  Liposomal Clodronate (CLIP) does not affect tumour cell 
viability in vitro  
 
 
Given that CXCR2 blockade did not demonstrate any additive effect in 
combination with ADI-PEG20, I next sought to evaluate the effect of depleting 
macrophages in combination with arginine deprivation in vivo. Clodronate-
containing liposomes (Liposomal Clodronate; CLIP) were used to deplete 
macrophages in vivo. Previous studies have shown that CLIP is cytotoxic to 
phagocytic cells of the monocyte/macrophage lineage (282). However, in 
order to determine the effect of macrophage depletion on tumour growth in 
vivo, it was first necessary to investigate any direct effect of CLIP on ASS1 
negative mesothelioma cells. MTS results demonstrate that CLIP has no 
effect on tumour cell viability in vitro, implying that any observed effect of CLIP 





















Figure 5.4. MSTO cell viability at 6 days following treatment with CLIP. MSTO tumour 
cells were treated with increasing volumes of CLIP. After 6 days, cell viability was determined 
by MTS. Graph shows that CLIP has no significant effect on tumour cell viability. Experiments 
were performed three times in triplicate with values representing the mean (+/- SEM).  
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5.7  Macrophage depletion enhances the cytotoxic effect of 
ADI-PEG20 in vivo 
 
To evaluate the effect of macrophage depletion on ADI-PEG20 cytotoxicity in 
ASS1 negative mesothelioma cells, nude mice bearing subcutaneous 
xenografts of MSTO were treated with PBS, CLIP, ADI-PEG20, or a 
combination of ADI-PEG20 and CLIP. Both ADI-PEG20 and CLIP therapy 
individually demonstrated similar tumour suppression effects in the mice, 
compared with vehicle control. Furthermore, the combination of ADI-PEG20 
and CLIP therapy had an additive effect in suppressing tumour growth 























Figure 5.5. ADI-PEG20 combined with macrophage depletion suppression in the MSTO 
xenograft model. For this study nude mice bearing subcutaneous xenografts of MSTO were 
randomised to the following five groups: PBS, CLIP, PLIP (PBS-containing liposomes as the 
CLIP control), ADI-PEG20, or a combination of ADI-PEG20 and CLIP, with 12 mice in each 
group (n=60).  The treatment schedule is described in detail in Chapter 2. Tumour volumes 
for each group were measured twice weekly over a 5 week period. Graph represents the 
difference in tumour volume between the groups and shows that ADI-PEG20, CLIP, and the 
combination of ADI-PEG20 and CLIP, all significantly suppress tumour growth, compared with 
the vehicle control. Furthermore, the combination of ADI-PEG20 with CLIP significantly 
enhances the tumour suppression effect of ADI-PEG20. Values represent the mean (+/- 
SEM) tumour volume for each group at specific time points. No difference was seen between 
PLIP and PBS (data not shown). Two other mouse studies were also completed; one was a 
pilot with 5 mice per group, and one compared the difference between ADI-PEG20 and ADI-
PEG20/CLIP combination with 10 mice per group (without the controls). Similar results were 
observed (data not shown). Statistical analysis (1 way ANOVA of all 5 groups at the last time 




5.8 ADI-PEG20 stimulates recruitment of macrophages into 
ASS1 negative xenografts 
 
 
Having observed that in vivo, macrophage depletion in combination with ADI-
PEG20 potentiates ADI-PEG20-induced tumour cytotoxicity, I sought to study 
whether ADI-PEG20 treatment had an effect on macrophage number in 
tumours. Immunohistochemical staining and analysis of formulin fixed, 
paraffin embedded (FFPE) tumour sections using the murine macrophage 
marker, F4/80, demonstrated a significant increase in the number of 
macrophages present in the tumours of mice treated with ADI-PEG20 therapy 
compared with vehicle control. CLIP therapy alone effectively depleted 
macrophages, with a significant decrease in macrophage number also 
observed in tumours from mice treated with ADI-PEG20/CLIP combination 
therapy. These results imply that ADI-PEG20 therapy stimulates macrophage 
recruitment and activation in tumours, which then contributes to ADI-PEG20 























Figure 5.6. Difference in macrophage number in xenograft tumours following ADI-
PEG20 treatment. The tumours of five mice from each group were analysed for comparison 
of macrophage number. Graph represents the percentage of F4/80 stained macrophages in 
each of the five mice from the different experimental conditions. Statistical analysis (1 way 
































Figure 5.7. F4/80 expression in 
mouse xenografts. Representative 
examples of tumours treated with A) 
PBS (vehicle control), B) ADI-
PEG20, C) CLIP, D) ADI-
PEG20/CLIP combination 
(magnification x200. Scale bars 
represent 20µm). Tumours were 
stained with F4/80, an adhesion 
protein expressed on the surface of 
murine macrophages, and 
counterstained with haemotoxylin. 
Macrophages are conspicuous as 
large, brown staining cells with 
branching cytoplasmic processes. 
ADI-PEG20 therapy results in a 





5.9  Discussion 
 
 
The aim of this chapter was to find a method to overcome the macrophage-
mediated ADI-PEG20 resistance and in this way enhance the anti-tumour 
efficacy of ADI-PEG20 in vivo. Given that in vitro studies had identified 
abundant secretion of several CXC chemokines by ASS1 negative cells 
following ADI-PEG20 treatment, all signaling through the G protein-coupled 
receptor, CXCR2, it was hypothesized that this signaling axis might be playing 
a role in ADI-PEG20 resistance.   
 
The ELR+ CXC chemokines were originally considered to be 
chemoattractants for neutrophils via the chemokine receptor CXCR2, but 
more recently CXCR2 expression has been also identified on other stromal 
cells, including endothelial cells, mast cells, monocytes and macrophages, as 
well as on multiple tumour cells (362, 363). Indeed, CXCR2 has become the 
subject of much interest recently because of a number of studies indicating its 
involvement in cancer. It has recently been reported that CXCR2 and its 
ligands are intimately involved in tumour regulation, growth and metastasis of 
various cancers, including colorectal cancer, melanoma, lung cancer, 
pancreatic cancer, HCC and head and neck cancers, with blockade of the 
CXCL/CXCR2 axis reducing tumourigenesis/angiogenesis (364-369). 
 
In addition, the CXCR2 axis has also been linked to therapeutic resistance. 
For example, an increase in the transcription and secretion of IL-8 and 
CXCL1, in parallel with increased CXCR2 expression, was observed after 
oxaliplatin treatment in androgen-independent prostate cancer, and this 
autocrine signaling was implicated in the attenuation of chemotherapy 
induced apoptosis (370). More recently, Sharma and colleagues reported a 
novel role of CXCR2 and its ligands in maintaining chemotherapy resistance 





Importantly, in addition to autocrine signaling, there have been several 
interesting reports regarding the relationship between the CXCL/CXCR2 
paracrine network and tumour development. Indeed, Ijichi and co-workers 
reported that in a Kras+ TGF-beta receptor type II knockout 
(Kras+TGFbr2KO) mouse model of pancreatic cancer, the PDAC cells 
secreted much higher levels of several CXC chemokines compared with 
mouse pancreatic intraepithelial neoplasia cells, which are preinvasive. The 
CXC chemokines induced connective tissue growth factor (CTGF) expression 
in the pancreatic stromal fibroblasts, not in the PDAC cells themselves. 
Subcutaneous grafting studies revealed that the fibroblasts enhanced growth 
of PDAC cell allografts, which was attenuated by CXCR2 inhibition. Moreover, 
treating the Kras+Tgfbr2KO mice with the CXCR2 inhibitor reduced tumour 
progression. The authors concluded that  pancreatic cancer-stromal 
interactions via a CXCR2-dependent chemokine and connective tissue growth 
factor axis regulate the progression of pancreatic cancer (372). Moreover, 
another study has demonstrated a network of endothelial-cancer cells-myeloid 
signaling mediated by CXCL/CXCR2. Here, overexpression of CXCL1 and 
CXCL2 (both CXCR2 ligands) in breast cancer cells was found to attract 
CXCR2-expressing myeloid cells to the tumour. These cells produced 
S100A8/9 chemokines which enhanced cancer cell survival (336). In line with 
this study, I found that macrophage CXCR2 expression was significantly 
increased when macrophages were co-cultured with ASS1 negative 
mesothelioma cells, with a further increase in expression seen following ADI-
PEG20 treatment. This suggested that overexpression and secretion of the 
CXCR2 ligands by ASS1 negative mesothelioma cells following ADI-PEG20 
treatment is attracting and activating CXCR2-expressing macrophages, 
resulting in ADI-PEG20 resistance. Therefore, it was proposed that these 
molecules driving the inflammatory response to ADI-PEG20 could have 
considerable potential as therapeutic targets to overcome macrophage-
mediated resistance to ADI-PEG20 in mesothelioma.  
 
However, results showed that CXCR2 blockade was insufficient to attenuate 
the increase in macrophage ASS1 expression following treatment with ADI-
PEG20, implying that there is redundancy, with other pro-inflammatory 
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signaling pathways able to compensate for the loss of CXCR2. Furthermore, 
findings from the small pilot xenograft study using CXCR2 blockade in 
combination with ADI-PEG20 demonstrated no additive effect in suppressing 
mesothelioma growth in vivo, supporting the view that other factors are 
involved in the signaling crossalk between cell types.   
 
Several limitations which need to be considered when interpreting my results. 
Firstly, CXCR2 blockade was performed using SB225002, a potent 
nonpeptide inhibitor of CXCR2. Although this has been validated as an 
effective inhibitor, with a number of independent studies using this as a 
method for CXCR2 blockade (373, 374), it would have been helpful to have 
performed CXCR2 knockdown studies in vitro, in addition to using SB225002, 
to confirm the results observed. Furthermore, due to unforseen circumstances 
in the animal unit housing the mice, the study had to be terminated early; 
differences between groups may only have been identified at later time points.  
 
Nevertheless, CXCR2 blockade in combination with ADI-PEG20 does not 
appear to increase the anti-tumour efficacy of ADI-PEG20.   
 
Given that there was no apparent effect in suppressing mesothelioma growth 
in vivo by blocking CXCR2, the next step was to evaluate the effect of 
macrophage depletion on ADI-PEG20 cytotoxicity. Macrophages were 
depleted in vivo using Liposomal Clodronate (CLIP). Liposomes are artificially 
prepared lipid vessels consisting of concentric phospholipid bilayers. They 
can be used to encapsulate strongly hydrophilic molecules such as 
clodronate, a non-toxic bisphosphonate. Clodronate will not cross liposomal or 
cellular phospholipid membranes. After injection, liposomes are ingested and 
digested by macrophages, followed by intracellular release and accumulation 
of clodronate. Clodronate then induces apoptosis of the macrophage.  
 
Results revealed that CLIP as a single agent significantly suppressed tumour 
growth compared with vehicle control, emphasizing the critical role 
macrophages play in mesothelioma growth. Furthermore, this finding supports 
results from a previous study demonstrating that macrophage depletion 
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following CLIP therapy significantly reduced the number of tumours, the area 
of tumour burden and the percentage of liver and lung metastasis in an 
orthotopic murine model of mesothelioma (282).  
 
Similarly, ADI-PEG20 has been shown to suppress tumour growth in various 
ASS1 negative xenograft models (130, 133, 145). In this study, ADI-PEG20 
treatment resulted in a small but significant stabilisation of mesothelioma 
growth in vivo; however, it did not prevent subsequent tumour outgrowth. In 
contrast, a similar study using a xenograft model of ASS1 negative bladder 
cancer demonstrated superior anti-tumour efficacy using ADI-PEG20 as a 
single –agent, compared with mesothelioma, by effectively halting tumour 
growth (133).It is interesting to note again here that results from our lab’s 
Affymetrix analysis revealed that the ASS1negative bladder cell line 253J did 
not demonstrate the same robust pro-inflammatory gene expression signature 
as the ASS1 negative mesothelioma cell lines in response to ADI-PEG20 
treatment . Given that I have demonstrated a link between pro-inflammatory 
cytokines and ADI-PEG20 resistance in ASS1 negative MPM, this difference 
may explain in part the difference in response to ADI-PEG20. Further studies 
are required to validate this Affymetrix data.  
 
Macrophage number also increased significantly in the MSTO xenografts, to 
an average of almost 6% of the mesothelioma tumour area, following ADI-
PEG20 treatment, implying an increase in TAM infiltration in response to 
treatment. As described above, the use of CLIP effectively depleted the 
macrophages and in parallel suppressed tumour growth as efficiently as ADI-
PEG20. Furthermore, there was an additive effect when using CLIP in 
combination with ADI-PEG20, suppressing mesothelioma growth significantly 
more than ADI-PEG20 or CLIP alone, further supporting a role for 
macrophages in mediating mesothelioma resistance to ADI-PEG20. 
 
Increased TAM infiltration causing drug resistance has recently been 
demonstrated in prostate cancer. Similar to my findings, macrophages 
comprised a significant component of the TME in implanted Myc-CaP murine 
prostate tumours, as well as in the parental transgenic Hi-Myc spontaneous 
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prostate cancer model, constituting 2-5% of viable cells within the tumour. 
Furthermore, there was a significant increase in TAM infiltration following 
androgen blockade therapy (ABT) (315), associated with drug resistance. 
Investigators found that inhibition of macrophage recruitment using a CSF-1 
receptor inhibitor re-sensitised the tumour cells to ABT and reversed 
macrophage-mediated resistance.  For this study, two murine models were 
used; a xenograft and a spontaneous prostate cancer model. I used only a 
xenograft model for studying macrophage infiltration following ADI-PEG20 
therapy in mesothelioma. This has its limitations: although the CD1 nu/nu 
mice do have macrophages, they lack a functioning thymus and therefore 
have an altered immune system due to the absence of B cells and T cells. 
When studying the role of immune cells and immune response, the optimal 
model would be an immunocompetent orthotopic murine model. However, an 
ASS1 negative orthotopic model was not available. Perhaps creating a stable 
murine mesothelioma ASS1 knockdown cell line using the CRISPR-Cas9 
system may help with future studies investigating ASS1 negative 
mesothelioma and immune response.  Nevertheless, my results provide 
evidence which suggests that targeting macrophages in combination with 
ADI-PEG20 in mesothelioma may be a rational combination for increasing its 
anti-tumour efficacy. 
 
A number of methods can be used to target macrophages. The Liposomal 
Clodronate used in this study, although well validated in mice, is not used in 
humans due to the concern over systemic toxicities caused by pan-
macrophage depletion. It is interesting to note, however, that it was recently 
demonstrated for the first time that targeting TAM plays a central role in the 
anti-tumour activity of the clinically approved agent, Trabectedin. This natural 
product, derived from the marine organism Ecteinascidia turbinate, is 
specifically cytotoxic for human and murine macrophages and inhibits the 
production of CCL2 and IL-6 (375). The selective monocyte/macrophage 
cytotoxicity has now been shown to be a major component of its potent anti-
tumour activity. This finding provides proof-of-principle for macrophage 
depletion in humans and therefore has implications for the future design of 
combination therapies. Indeed, a single arm phase 2 study evaluating 
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Trabectedin as second line therapy in epithelioid MPM and as first/second line 
therapy  in biphasic/sarcomatoid MPM, was recently presented at ASCO 2015 
(NCT02194231). Results from the completed cohort of biphasic/sarcomatoid 
patients demonstrated Trabectedin activity in terms of PFS (29.4% of patients 
had a PFS >18weeks), and reported that it was well tolerated in this 
population of patients with advanced disease, concluding that these results 
merit further investigation with a larger cohort (376).  
 
In addition, there is increasing interest in the development of novel methods 
for targeting macrophages in human cancers in an effort to eliminate their pro-
tumorigenic properties. This is based on pre-clinical data from a number of 
independent laboratories indicating that macrophage presence and/or activity 
are malleable in vivo (212). Key strategies under investigation include 
targeting macrophage recruitment, blocking pro-tumour polarisation, or 
directly promoting macrophage activation. A number of agents are being 
evaluated in clinical trial in several solid tumour types in an effort to augment 
the response to cytotoxic therapy (please refer to Table 5.1). To date, the 
major strategy for inhibiting macrophage recruitment has been to target CSF-
1 or the CSF-1 receptor (CSF-1R). Several clinical trials are underway 
targeting CSF-1R signalling, and a recently completed trial using an anti-CSF-
1R antibody reported objective clinical responses in diffuse-type giant cell 
tumours (377). Alternatively, re-polarising macrophages toward an anti-
tumour phenotypic state, either by blocking signals that drive pro-tumour 
polarisation or by delivering signals that enhance anti-tumour polarisation, 
could perhaps provide a more efficacious approach. Indeed, a phase I clinical 
trial of the fully human CD40 agonist antibody CP-870,893 in combination with 
gemcitabine chemotherapy in patients with advanced pancreatic cancer, 
demonstrated efficacy via the anti-tumour activities of macrophages (378). 
Using this agent, investigators identified a modified macrophage phenotype 
displaying upregulated MHC Class II and CD86 (M1-skewed) expression 
(379). Importantly, the two studies described here are among the first clinical 
studies to demonstrate the potential efficacy of macrophage- targeted agents 
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Table 5.1.  Macrophage Therapeutic Targeting. Table shows macrophage targets currently 




When considering targeting macrophages in combination with other anti-
cancer therapies, the question still remains which of these approaches will be 
the most efficacious? With regards to ADI-PEG20, my in vitro work suggests a 
mixed M1/M2 macrophage phenotype. The functional relevance of the 
changes seen in co-cultured macrophages in response to ADI-PEG20 
remains unclear, which may make re-polarisation more difficult in combination 
with ADI-PEG20. However, as the phenotype was immunosuppressive, with a 
significant decrease in MHC Class II expression observed following ADI-
PEG20, perhaps directly promoting M1-skewed macrophage activation and 
increasing the antigen presentation, as seen with the anti-CD40 antibody, 
may prove an effective combination. Certainly, going forward, it will be critical 
to understand the best therapeutic approach to accompany combination 
therapy, as this is likely to vary for different tumour types and at different 
stages of tumour progression. Toxicity also remains a key concern for 
combinatorial studies. Nevertheless, data presented in this thesis suggests 
that, with the right agent, targeting macrophages in combination with ADI-
PEG20 in the clinical setting may increase its anti-tumour efficacy in 
mesothelioma. Ultimately, with further research, this combination may improve 
the treatment efficacy of many cancers that depend on arginine for survival.   
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An investigation into mechanisms of tumoural resistance to ADI-PEG20 in the 
arginine-auxotrophic cancer, MPM, led to the discovery that macrophages 
within the mesothelioma tumour microenvironment have a key modulatory 
effect on the impact of ADI-PEG20 therapy in this disease. Thus, ASS1-
deficient malignant mesothelioma cells co-opt macrophages to release 
argininosuccinate, which bypasses the anti-tumour effects of ADI-PEG20.  
 
The main findings of the work presented in this thesis are: 
 
Identification and validation of a robust pro-inflammatory gene expression 
signature specific to ASS1-negative mesothelioma cells and patients in 
response to ADI-PEG20 treatment (chapter 3). 
 
 Discovery of a role for ER stress in modulating the inflammatory 
response to ADI-PEG20-induced arginine depletion. 
 
 
Macrophages promote resistance to ADI-PEG20 therapy in ASS1 negative 
MPM (chapter 4). 
 
 Macrophages are able to partially protect ASS1 negative MPM cells 
from ADI-PEG20 cytotoxicity. 
 ADI-PEG20 causes coordinate up-regulation of ASS1 and ASL in 
macrophages and tumour cells, respectively. Pro-inflammatory 




 Co-cultured macrophages secrete argininosuccinate in response to 
ADI-PEG20 treatment. 




Macrophage depletion potentiates ADI-PEG20 cytotoxicity in vivo (chapter 5).  
 
 ADI-PEG20 in combination with macrophage depletion has an additive 







In recent years, medical oncology has placed significant focus on 
personalizing therapeutic approaches, with the aim of identifying patient 
subpopulations that would benefit from specific targeted therapies. The use of 
the arginine-depleting agent ADI-PEG20 in patients with ASS1-deficient 
malignancies, including MPM, is an example of a promising novel single 
target therapeutic approach. However, resistance to targeted therapies 
remains the major obstacle to their effective use in the clinical setting. A better 
understanding of tumoural resistance mechanisms is therefore critical to 
improving outcome. The exploration of therapeutic resistance has largely 
focused on the tumour cell; however, increasingly, the influence of the local 
tumour microenvironment is being identified as an important contributor to 
drug resistance (380) . Macrophages are recognised as abundant cells within 
the tumour microenvironment, with evidence indicating that they promote 
tumour growth and metastasis in a wide range of solid tumours. However, 
despite advances in our understanding of the pro-tumourigenic function of 
TAM, less is known about the microenvironmental and metabolic factors 
which enable tumour cells to co-opt macrophages to promote tumour growth 
and drug resistance  (381) . The work presented here shows for the first time 
254 
 
that macrophages within the mesothelioma tumour microenvironment are able 
to mediate tumoural resistance to ADI-PEG20, and that it is the cross-talk 
between inflammatory and metabolic signaling pathways that is critical to this 
resistance mechanism. This data highlights the importance of the dynamic 
and adaptive dialogue that exists between tumour cells and their surrounding 
microenvironment in promoting tumour growth and drug resistance and raises 
the question; in the clinical setting, can durable responses result from 
combination therapies that target both the ASS1 negative mesothelioma 
tumour cells and the tumour stroma? 
 
6.3 Future work 
 
6.3.1 Alternative methods of targeting macrophages 
 
6.3.1.1 Inhibition of macrophage recruitment 
 
For this thesis, macrophage depletion was achieved in vivo using liposomal 
clodronate. It would be interesting to use an alternative method of targeting 
macrophages, such as targeting macrophage recruitment via CSF-1/CSF-1R 
blockade, to evaluate whether this has the same additive effect in combination 
with ADI-PEG20. Furthermore, if an additive effect in combination with ADI-
PEG20 is observed, this agent could also potentially be used in the clinical 
setting. Indeed, trials of novel CSF-1R antagonists have commenced in other 
solid tumours and results are awaited (please see table 5.1 for details).  
 
6.3.1.2 Targeting ER Stress 
 
ER stress and the UPR function as a ‘double-edge sword’,  by supporting or 
repressing cancer initiation and progression under different circumstances 
(382). Data presented in chapter 3 demonstrates that in ASS1 negative 
mesothelioma cells, activation of the UPR following ADI-PEG20-induced 
arginine depletion supports mesothelioma cell survival by leading to induction 
of the pro-inflammatory cytokine response that is critical to the macrophage-
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mediated resistance to ADI-PEG20. Furthermore, as mentioned previously, 
ER stress has been reported to trigger tumour cells to modulate macrophage 
phenotype (331) via the release of soluble factors, resulting in both the 
induction of an ER stress response and a robust pro-inflammatory phenotype 
in macrophages, further supporting tumour cell survival. Therefore, as the 
UPR can promote tumour cell adaptation and drug resistance, and activate 
macrophages within the tumour cell microenvironment, combination therapies 
that include drugs targeting ER stress and the UPR with ADI-PEG20 in ASS1-
deficient MPM may enhance the sensitivity of mesothelioma cells to ADI-
PEG20. Indeed, in other examples, an IRE1α inhibitor sensitized resistant 
human glioblastoma cells to oncolytic virus therapy both in vitro and in vivo 
(383). Inhibition of PERK was also shown to kill hypoxic tumour cells that are 
radioresistant in vivo (384).  Following on from work presented in this thesis, a 
potential target of UPR signalling to consider investigating further is NFкB. I 
have shown in chapter 3 that NFкB is induced in ASS1 negative cell lines 
following ADI-PEG20. NFкB is activated by the UPR signalling pathways and 
is well-recognised as a master transcriptional regulator of pro-inflammatory 
pathways. Therefore, it would be interesting to evaluate whether blocking 
NFкB would dampen the inflammatory response to ADI-PEG20 therapy and in 
this way attenuate macrophage-mediated resistance. 
 
 
6.3.2 Assessment of ADI-PEG20 in combination with chemotherapy 
 
When considering rational drug combinations to enhance the efficacy of ADI-
PEG20, it is also important to evaluate the effect of ADI-PEG20 in 
combination with chemotherapy. Chemotherapy can promote an inflammatory 
microenvironment (385). On the other hand, chemotherapy has been shown 
to stimulate antigen presentation on infiltrating immune cells, leading to 
enhanced adaptive anti-tumour immune response (386, 387). Chemotherapy 
in combination with ADI-PEG20 may therefore affect macrophage phenotype 
and in this way modulate macrophage-mediated resistance. Furthermore, 
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dexamethasone is used in chemotherapy regimes, and this anti-inflammatory 
agent may suppress the pro-inflammatory cytokine response to ADI-PEG20, 
in this way enhancing ADI-PEG20 cytotoxicity. There is currently a clinical trial 
assessing ADI-PEG20 in combination with chemotherapy and recruitment will 
be completed by the end of 2016.  
 
6.3.2.1 ADI-PEG20 with pemetrexed and cisplatin for lung cancer and 
mesothelioma (TRAP) study.  
 
 
The TRAP study is a phase 1 study that is currently recruiting patients with 
mesothelioma and other ASS1-deficient tumours, to assess ADI-PEG20 in 
combination with pemetrexed and cisplatin chemotherapy.  Plasma samples 
are being collected from this cohort of patients with ASS1 ‘low’ disease each 
week, and these samples will be analysed by ELISA for the pro-inflammatory 
cytokines identified previously (IL-1α, IL-8, CXCL2, CXCL3 and VEGFA) in 
response to ADI-PEG20 plus pemetrexed and cisplatin.   The objective is to 
assess whether the addition of chemotherapeutic agents in combination with 
ADI-PEG20 modulates the pro-inflammatory cytokine response, and the 
impact this may have on macrophage-mediated resistance.   
 
In parallel with this analysis, it would be interesting to set up in vitro co-culture 
experiments using ASS1 negative tumour cells and macrophages, to evaluate 
the effect of ADI-PEG20 in combination with pemetrexed and cisplatin on 
macrophage phenotype (analysed by FACS as in Chapter 4) and 
macrophage-mediated resistance.      
 
6.3.3 Further assessment of the regulation of ASL 
 
 
Results presented in Chapter 4 demonstrated that ASL expression was 
significantly increased in co-cultured ASS1 negative tumour cells following 
ADI-PEG20 treatment. However, the stimulus for the increase in ASL 
expression was not clear, as neither the pro-inflammatory cytokines, nor the 
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addition of argininosuccinate, induced expression. Identifying signals that 
induce ASL expression in ASS1 negative tumour cells therefore requires 
further investigation. Indeed, a better understanding of the regulation of ASL 
expression may allow therapeutic intervention here, in this way abrogating 
macrophage-mediated resistance. As previously discussed, ASL has been 
shown to be transcriptionally induced by ER stress (138). Assessment of ASL 
expression in ASS1 negative mesothelioma cells following exposure to 
tunicamycin would therefore be interesting. 
 




Proteomic analysis of ASS1 negative tumour cell lysates was performed to 
identify the percentage of 13C arginine-labelled peptides in tumour cells co-
cultured with macrophages, compared with tumour cells cultured alone, as an 
alternative method of validating the macrophage-mediated resistance 
pathway. However, results were difficult to interpret due to technical issues 
with the experiment. It would therefore be helpful to confirm depletion of the 
13C arginine by ADI-PEG20 prior to adding this media to the cells, in this way 
reducing the risk of false positives.  
 
6.3.5 Assessment of the effect of arginine depletion on other 
stromal cells within the MPM tumour microenvironment 
 
 
For this thesis, macrophages were considered to be the optimal stromal cell 
type to evaluate for a number of reasons. Firstly, macrophages are abundant 
and important host-derived cells within the MPM tumour microenvironment. 
Secondly, they are recruited and activated by the pro-inflammatory cytokines 
initially identified at the beginning of the project. However, many other cell 
types make up this microenvironment and a key cell type requiring further 
investigation is the fibroblast. Indeed, as discussed in the introduction, 
fibroblasts are also found in abundance in MPM. Moreover, previous co-
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culture studies using fibroblasts and mesothelioma cells demonstrated that 
fibroblasts promoted MPM tumour progression via a malignant cytokine 
network (196). Can fibroblasts partially protect ASS1 negative MPM cells from 
ADI-PEG20 cytotoxicity? Certainly, previous research into citrullinaemia 
demonstrated that fibroblasts deficient in ASS1 and ASL, when cultured 
together, were able to ‘feed’ each other the required amino acid, highlighting 
their ability to cooperate metabolically with each other (341). Perhaps 
metabolic cooperation also exists between fibroblasts and ASS1 negative 
MPM tumour cells as well? This requires further investigation, initially by 
evaluating whether the pro-inflammatory cytokines identified induce up-
regulation of ASS1 in fibroblasts, a key step in macrophage-mediated 
resistance.   
 
Ultimately, a better understanding of the cross-talk between cells of the 
tumour microenvironment and potential resistance pathways will help lead to 
new therapeutic targets, with the aim of overcoming this microenvironment-
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